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Abstract 
Poor quality medicines are a global problem affecting both developed and developing 
countries. Governments and the health authorities are focusing on the spread of counterfeit 
medicines, as it is a threat to patients and funds criminal activities. 
Recently questions have been raised about using generic substitutes, especially for Narrow 
Therapeutic Index Drugs (NTIDs), such as ciclosporin. In-vitro dissolution testing was 
undertaken to identify differences in dissolution performance between branded and generic 
ciclosporin capsules. Dissolution testing of the capsules was carried out according to the 
USP guidelines. According to the USP not less than 80% of the labelled amount of 
ciclosporin should dissolve in 90 min. The samples were analysed using a HPLC method. 
Two ciclosporin generic products showed less than the minimum percentage of labelled 
amount < 80%. Statistical analysis showed significant differences (p<0.0001) of the mean 
percentage content between brand and generic. Investigations were carried out to detect 
impurities in ciclosporin capsules using LC-MS. Concentrations of inactive ingredients 
such as sorbitol were variable between capsules. One from South America, manufactured 
in central Asia, showed contamination with a plant product (Zizyphine A). the synthetic 
intermediate (Delcorine) was found to be more than 1000 fold higher in the generic product 
compared to reference capsules (p<0.001). 
In 2013, the FDA warned of the possible fatal effect of azithromycin. LC-MS 
quantification for azithromycin tablets were carried out in order to quantify azithromycin 
content in different products. A bioequivalence study in man, confirmed that generic 
(Mazit) capsules were bioequivalent with brand (Zithromax™) capsules. 
Based on the results presented in this thesis, HPLC and LC-MS proved suitable approaches 
for analysis of drugs and their unknown impurities in brand, generic and counterfeit 
medicines. Some ciclosporin preparations did not contain the mass labelled. Therefore, 
switching between branded and generic ciclosporin may lead to undesirable effect. 
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Chapter 1. Introduction 
1.1 The nature of the problem 
Substandard and counterfeit medicines are considered to be a worldwide problem, affecting 
both developed and developing countries. The toughest realization is that there are many 
cases where counterfeit drugs have caused serious harm to consumers, including death. 
These are serious consequences and add a real urgency in the fight against counterfeit 
drugs. The consequences are well known, as the Department of Homeland Security (DHS) 
advised, counterfeit and substandard medicines could cause a serious threat to America’s 
economic vitality, the health and safety of American consumers, and our critical 
infrastructure and national security (U.S. Customs and Border Protection Office of 
International Trade, 2012). 
Many incidents as a result of using such drugs, have been reported. In Nigeria, 2500 deaths 
were reported in 1995 because of fake vaccines. In 1995 and 1998, 89 deaths in Haiti and 
30 deaths in India occurred because of using a paracetamol preparation that contained di-
ethylene glycol. In 1999, 30 people died in Cambodia after using a counterfeit antimalarial 
preparation prepared with sulphadoxine-pyrimethamine (World Health Organization, 
2006). Developing countries are a clear target for counterfeiters, because of the high prices 
for genuine medications and weak supervision from the authorities, but developed 
countries could be a target too. In 2006, UK authorities detained around £500,000 worth 
of anti-flu medication that was counterfeit (Mukhopadhyay, 2007). In 2012, the Food and 
Drug Administration (FDA) announced that a fake anti-cancer drug had been found in US 
clinics (Figure 1.1). It was confirmed that the fake intravenous 400 mg/16 mL Altuzan® 
(bevacizumab) had no active ingredients (Food and Drug Administration, 2012a). In 2002 
Amgen pharmaceuticals issued a warning about counterfeit Epogen® (an anti-anaemic 
drug) which had been intentionally relabelled with a higher dosage to sell it at a higher 
price (Amgen Inc., 2002, C. and Tigue, 2006). Another example of critical medication 
being counterfeited is a case in which heparin, an anticoagulant drug had its active 
ingredient substituted for a cheaper alternative. This unfortunately resulted in the suspected 
deaths of 81 patients. A nationwide recall of heparin was announced (Food and Drug 
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Administration, 2008c). Further investigation carried out by the FDA confirmed that the 
active ingredient, which was the main contaminant, originated out of 12 Chinese 
companies and had made its way into 11 countries (Food and Drug Administration, 2008b). 
 
Figure 1.1: Fake anti-cancer drug found in a clinic, USA 
Counterfeit drugs in the United States are growing rapidly, in particularly due to ever 
increasing suppliers from around the world (Blackstone et al., 2014). In 2006, the World 
Health Organization estimated that the business in counterfeit drugs could be worth US 
$75 billion globally by 2010. The size of the problem today is likely to be even greater than 
these estimates. Dr Lee Jong-wook, General Director of WHO said "Combating low 
quality or illegal medicines is now more important than ever" (Pincock, 2003). 
In 2011, a TV report on the Al-Arabiya News Channel highlighted the problem of the 
smugglers and counterfeiters of medicines in Yemen. Millions of patients seeking a cure 
fell victims of expired smuggled, forged and substandard medications. Health authorities 
discovered that some lifesaving medications, e.g.: anti-D (Rho) immunoglobulin and 
vaccines, were only water. Health professionals in Yemen blamed the government, agents 
and health authorities for lack of supervision. They called it “Trade of Death”. Many 
reasons for smuggling and faking include drug availability, no alternative, and high prices. 
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By the year 2000, 80% of medications in the market were smuggled with the majority 
containing low or no active ingredients (Al Arabiya News Channel, 2011b). Another TV 
report focused on fake medicines in West Africa. Fake medicines were manufactured in 
Pakistan, India and China and imported to developing countries. This resulted in deaths 
and blindness in patients. Reasons for the increase of the fake and substandard medicines 
were, lack of government supervision and poor storage conditions. Some medications were 
sold on the street with half price for expired medications (Al Arabiya News Channel, 
2014). 
In May 2014, Interpol reported that during a single week, police/customs in 111 countries 
seized 9.4 million doses (2.4 million in 2011) of fake medicines including cancer 
medication, erectile dysfunction pills, anti-malarial and cholesterol medications, worth 
nearly USD 36 million (Al Arabiya News Channel, 2011a, Interpol, 2014). 
Recently, the WHO announced a drug alert for counterfeit meningitis vaccines circulating 
in West Africa (Figures 1.2 and 1.3). WHO advised increased supervision of the 
medications, further verification and checks with drug manufacturers should be made 
before administration (World Health Organization, 2015). 
 
Figure 1.2: Falsified version of meningitis vaccines, West Africa 
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Figure 1.3: Another falsified version of meningitis vaccines, West Africa 
Innovators, whose key activities are to create or obtain the rights or exclusivity to their 
work, make use of intellectual property rights and registration. These rights are appointed 
in the form of trademarks, copyrights and in the case of the pharmaceutical industry, 
patents. These ensure that all innovations and efforts are protected to a certain degree 
within the legitimate marketplace. As sufficient as these measures are within the 
pharmaceutical industry, it is undermined by theft associated with counterfeiting and 
trafficking of pharmaceuticals products (Blackstone et al., 2014). 
Counterfeiting may be related to organised crime across the world, assisting the likes of 
money laundering and terrorism (Pfizer Inc., 2007). Profits made could well exceed those 
compared with narcotics. Drug companies are investing their efforts to fight these criminal 
acts by applying new technologies, such as short message service (SMS) authentication 
code systems on packaging. They are working in co-operation with health authorities 
across the world like the British Medicines and Healthcare products Regulatory Agency 
(MHRA), the Australian Therapeutic Goods Administration (TGA), and the FDA to fight 
against these crimes. 
Distribution channels for pharmaceuticals in the European Union is going through a major 
regulatory update. A new directive was adopted in July 2011 to protect patients and to 
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prevent the distribution of fake medicines (European Medicine Agency, 2012). These new 
directives applied from January 2013. However, for effective implementation for the new 
directives, it may take up to 3 years (Williams, 2011). 
1.2 Substandard and counterfeit medicines 
Substandard medicines do not contain the correct amount of active ingredients or meet the 
standard (innovator's) preparation requirements for quality, safety and efficacy (European 
Medicine Agency, 2012, Food and Drug Administration, 2012b). 
According to the FDA, counterfeit medicine is “fake medicine. It may be contaminated or 
contain the wrong or no active ingredient. They could have the right active ingredient but 
at the wrong dose”. They may have the wrong manufacturer’s name or the country of 
origin. Counterfeits may include both branded and generic products. Using such drugs may 
cause harmful effects to patients (Figure 1.4). 
Substandard and counterfeit drugs can make their way into the market place. This can occur 
in both branded and generic drugs. Higher or lower levels of the active ingredient which 
differ from the required formulation are regarded as a substandard drug (Johnston and Holt, 
2014). 
 
Figure 1.4: Definitions of brand, generic, substandard and counterfeit medicines 
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There are several effects that consumers could experience when using substandard and 
counterfeit drugs. This all varies on which element of the drug fails to meet the required 
quality levels. With low quality antibiotics, the patient’s treatment plan can be highly 
unsuccessful and face additional risk of adverse effects. With substandard and counterfeit 
antibiotics, this can increase the level of antibiotic resistance and there is loss of confidence 
in the treatment method by both physicians and patients. Some other scenarios include 
where the non-active ingredients do not meet the required limits and/or contamination of 
the drug (Kelesidis et al., 2007, Kelesidis and Falagas, 2015). 
1.3 Factors affecting the spread of counterfeit and substandard 
medicines  
There are many factors encouraging the spread of counterfeit and substandard medicines. 
These factors include poor regulation in countries that do not establish or have good 
regulatory mechanisms and weak supervision from authorities. The profit that can be made 
by selling fake medicines is one of the reasons. According to Blackstone et al., counterfeit 
medicines are more profitable than selling narcotics (Blackstone et al., 2014). Drug 
availability is an important reason as well, because if the drug is not available on the market 
patients will search for other available resources. Low supply levels are a reason why 
counterfeit drugs enter the supply chain in the United States. Some drugs, which are 
considered lifesaving, such as anti-cancer drugs, are in high demand and offer opportunist 
counterfeiters the chance to supply a high demand drug at higher than normal prices. But 
as these counterfeit lifesaving drugs are sold to consumers, there is greater risk of suffering 
and even death to patients. 
The lack of regulation, especially in free trade zones, is considered an important reason for 
the prevalence of fake medications.  In addition, the packaging and storage conditions may 
affect the quality of the drug if it is not stored under proper conditions. A study of generic 
ramipril tablets showed that 24% out of 17 samples failed to meet the drug quality 
requirements because of improper storage conditions (Khan et al., 2013, Johnston and Holt, 
2014). These problems are present in all global regions, but particularly affect most 
developing countries. According to the FDA, 10% of medications in both industrialised 
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and developing countries are counterfeit. In rich countries, expensive medicines used for 
body building, such as hormones and steroids, are subject to higher levels of counterfeiting 
(World Health Organization, 2006). 
Even in a country such as the United Kingdom with strict regulations, there is infiltration 
of counterfeit drugs because of loopholes in transit and supply chains. The common 
vulnerabilities in the supply chain are due to the many handling levels associated in 
reaching the end consumer. Because of the many points of entry into the supply chain, 
detecting substandard or counterfeit products poses a much bigger challenge.  
Unfortunately, substandard and counterfeit drugs make their way into legitimate supply 
chains and these also include reputable online pharmacies. There are many points of entry 
for counterfeiters to enter during the supply chain from key ingredients to manufacturers, 
to storage vulnerabilities, transportation and several points at the final distribution 
channels. 90% of drugs distributed in the United States are handled by national wholesalers 
who deliver direct to pharmacies, hospitals, clinics and physicians. The remaining 10% 
unfortunately have a more complicated and indirect method of distribution and due to flaws 
in their practices, give a greater chance for counterfeits to enter the supply chain. Further 
regulation and monitoring need to be successfully put in place to avoid such vulnerabilities. 
The wholesale market comprises of three types, the primary wholesalers which typically 
deal directly with the manufacturers and pose the least risk for substandard and 
counterfeiting to occur. Secondary wholesalers are comprised of large regional wholesalers 
which can package and repackage. The third comprises of thousands of smaller wholesaler 
(Yadav, 2014). 
The internet is the main source of purchasing medications in most of Europe and it was 
recently revealed that out of a survey of 3,100 online pharmacies, only four were certified 
through the verified Internet Pharmacy Practice (American Enterprise Institute For Public 
Policy Research, 2012). Many online pharmacies are considered a real threat to consumers 
because they offer potentially harmful medications. High profits can be made selling 
substandard and counterfeit medications, especially without the need for a prescription. 
Some patients may prefer an online pharmacy as it can provide an additional level of 
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privacy as some conditions they may find embarrassing, such as impotence. For disabled 
patients it is also more convenient as they may be home bound (Orizio et al., 2010). 
Ordering online medications consisted more of lifestyle drugs such as Viagra but there is 
an increase in the use of prescribed medications via the Internet for more serious diseases, 
such as cardiovascular, diabetes and cancer. A higher threat of using online pharmacies for 
purchasing NTID such as ciclosporin, patients could be at risk of either toxicity at higher 
doses or treatment failure with lower doses. Examples of NTIDs which have been found 
to be available from online pharmacies (Liang et al., 2013): 
 Aminoglycosides 
 Amikacin 
 Gentamicin 
 Rifampicin 
 Warfarin 
 Ciclosporin 
 Carbamazepine 
 Lithium 
 Phenytoin 
 Theophylline 
 Phenobarbital 
 Valproic acid 
 Digoxin  
A death was reported due to consumption of a drug which was ordered online. A teenager 
took one pill to treat his anxiety disorder and this resulted in his death (Broomhead, 2014). 
Many counterfeit online pharmacies are falsely stating that they are based and operate from 
Canada, as Canada is considered the 9th largest country in pharmaceutical sales, with a 
global share of 2.5% (Jackson, 2015). In 2005, a study revealed that out of 11,000 online 
pharmacies registered to be based in Canada, only 214 were legitimate (Blackstone et al., 
2014). 
Chapter 1 Introduction 
    Page 44 of 296 
1.4 Methods for detecting counterfeit medicines 
The war against counterfeit medicines should be united worldwide. There should be a 
common definition for counterfeit medicines and a universal law against it. The UK 
government takes many actions against counterfeit drugs. Supplying or sale of counterfeit 
medicines is considered a criminal offence. 
There are many tests carried out to check for counterfeit drugs. Package and general 
characteristics (size, shape and colour of the drug) analysis is a key step for detecting 
counterfeits. If there are any changes or doubts raised from these initial examinations, they 
should be investigated by the pharmacist and reported so that appropriate action can be 
taken. For further investigation chemical analysis is considered. Spectroscopy analysis 
such as Fourier-transform infrared, near infrared and Raman spectroscopy can establish the 
identity of most drugs and discriminate from closely related or structurally similar 
compounds (Moffat, 2008). Other detection methods use microscopy techniques, such as 
light microscopy and the scanning electron microscope. Separation techniques are used to 
detect counterfeits such as liquid chromatography, capillary electrophoresis, and mass 
spectrometry (Moffat, 2008). HPLC methods with separation are generally an acceptable 
technique. This is because HPLC methods can generally provide the required specificity. 
All drug products should have a specific assay to determine the content of the drug. 
In 2011, Pfizer Inc. started implementing their SMS authentication code system on 
packaging. Patients and consumers can send an SMS containing the pack code to the 
company and receive verification of the product’s authenticity (Marsh, 2011). 
On November 28, 2013, President Obama signed the Drug Quality and Security Act into 
law, which provides for a national track-and-trace system that would allow a specific drug 
to be followed from the manufacturer to the pharmacy. This should make it more difficult 
for counterfeiters to enter the supply chain in the United States. This law is expected to be 
implemented in 2015 (Food and Drug Administration, 2013a). 
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Specific tests should be developed on an individual product basis. The dissolution test gives 
an idea of the release of the drug substance from the drug product when taken orally. 
Although one time point measurement is enough for immediate release drugs, suitable test 
conditions and sampling procedures should be established and reported for non-immediate 
release drugs. If a drug is not available in the required time after it has been taken orally, 
it will significantly affect the bioavailability (rate and extent of the drug inside the body). 
Drug disintegration, tablet hardness, water content and microbial limits should be 
thoroughly investigated, reported, and documented to identify counterfeit and substandard 
medicines. 
1.5 Safety of drug use: branded versus generic 
The branded drug is a new medication that is found to improve or treat a certain disease or 
medical problem. This new medication passes through many phases of developmental and 
research processes. The phases include the preclinical testing in animals for 
pharmacokinetic and pharmacodynamics of the tested drug, phase I studies which are 
conducted on 20 – 80 healthy volunteers for safety screening, phase II studies to ensure the 
effectiveness of the drug, phase III studies to get more information about the safety and 
effectiveness (subjects range from 200 – 3000 people) and phase IV which consists of the 
post approval studies (Figure 1.5). These phases can happen over many years. The product 
can only be in the market once it has been approved by a regulatory health body such as 
the FDA. The manufacturer  usually gets a patent for the new drug for a period of up to 20 
years (Pipeline patent intelligence, 2011). Patenting the product prevents other companies 
from making and selling the new product. When the patent period has expired, other 
companies can start making and selling a generic version, but it must be evaluated and 
approved by the FDA or other regulatory health authorities. Over the last few years, the 
production of generic medications has increased rapidly due to competition after expiry of 
the originator drug company’s patent (Food and Drug Administration, 2009c). 
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Figure 1.5: General phases for new drug development. Adapted from innovation.org 
The FDA approved an average of 101 new generic drugs each year from 2001 until 2014 
into the market place (Figure 1.6). These included many drug classes: hormones, 
antibiotics, analgesics, cardiovascular, respiratory, antimetabolite and many other classes 
(Food and Drug Administration, 2015a). 
 
Figure 1.6: FDA generic drug approvals from year 2001 until 2014 
Due to competitive market demands, many generic drug companies place their products on 
the market as soon as the patent period of the brand medicine has expired bringing concerns 
for patients safety because in some cases they are not safe and effective like their reference 
counterpart. Some tentative applications may even be approved before the patency has 
even expired. There have been many reported clinical studies highlighting the adverse 
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effects of generic products (Gautam et al., 2009, Newton et al., 2010, Perks, 2011). During 
recent years, the production of generic medications has increased due to demand for 
cheaper medicines especially in developing countries. The generic medications may have 
lower therapeutic effects and/or toxic effects (Newton et al., 2010).  Due to the lack of 
good manufacturing practice, insufficient bioequivalence and toxicological studies 
(Gautam et al., 2009), and even deliberate forgery of the drug, there are an increasing 
number of patient safety concerns. Small differences in plasma concentrations, less than 
4%, may exist in some cases between a brand and its generic equivalent. However, this 
minor difference is no greater than the difference that may exist between two different 
manufactured batches of the brand drug manufactured by the same pharmaceutical 
company. Safety and efficacy trials are only required for new drugs (Nation and Sansom, 
1994). Therefore the average cost for the production of generic drugs is lower than the 
brand by approximately 45% (Canadian Health Services Research Foundation, 2007). 
Bioequivalence is the equivalence of the action of brand and generic medicines. Birkett, 
described bioequivalence as: "Two pharmaceutical products are bioequivalent if they are 
pharmaceutically equivalent and their bioavailabilities (rate and extent of availability) after 
administration in the same molar dose are similar to such a degree that their effects, with 
respect to both efficacy and safety, can be expected to be essentially the same. 
Pharmaceutical equivalence implies the same amount of the same active substance(s), in 
the same dosage form, for the same route of administration and meeting the same 
standards" (Birkett, 2003). 
A generic drug is bioequivalent when the active ingredients or the active metabolites are 
absorbed into the body after administration at the same rate and amount as the brand drug. 
Thus, the need for bioequivalence is evident by the fact that the generic products deliver 
the same therapeutic effect as the branded counterpart and can safely substitute the brand 
product. Before a generic drug can be marketed, the manufacturer must prove that it has 
the same potency and efficacy as the brand medication.  If a generic passes these tests, it is 
said to be bioequivalent to the original drug. The generic drug application goes through 
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several stages before approval by the FDA. Key areas being monitored are chemicals, 
manufacturing processes, bioequivalence tests, dissolution tests, labelling, etc. 
Bioequivalence gives health professionals and patients the confidence that the generic 
medicines provide the same therapeutic effect, clinical results and safety profile as their 
branded counterparts. Bioequivalence studies play an important role during  drug 
development to observe the optimum therapeutic effect and ensure no additional toxicities 
(Birkett, 2003). 
According to the FDA guidelines, bioequivalence is accepted when 90% confidence 
intervals (CI) for the ratio of target pharmacokinetic parameters of area under the curve 
(AUC) and maximum concentration (Cmax) fall in the range between 0.8-1.25 (80-125%) 
(Food and Drug Administration, 2003a). The time to maximum plasma concentration (tmax) 
should also be similar. Bioequivalence studies are an important part of drug development 
for the production of new drug formulations and for generic equivalents. Such studies are 
important after the approval phase if there are any manufacturing changes (European 
Medicines Agency, 2010). Many countries have established guidelines for the approval of 
generic drugs. Generic manufacturers are not required to submit data of clinical trials or 
preclinical tests which are long and expensive procedures, but they must submit proof of 
bioequivalence tests, in addition to other pharmaceutical information (European Medicines 
Agency, 2008). During bioequivalence studies, some minor differences between brand and 
generic drugs are allowed. For example, a generic drug may have differences in shape, size 
or colour compared to the branded product (Kesselheim et al., 2008). 
Since generic and therapeutic substitution might impact on the clinical outcomes, it could 
create a conflict between the interests of patients, clinicians and those of payers/providers 
(AlAmeri et al., 2010). Patients who are uncertain are warned that substitution that is done 
only for financial reasons might compromise their quality of care. They believe that a 
cheaper medicine must be inferior to the more expensive branded medicines (Meredith, 
2003). 
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Many healthcare providers have been promoting generic and therapeutic substitution in an 
attempt to contain their costs (Duerden and Hughes, 2010). In 2013, it was reported that 
generic prescribing had reached 83.9% of all prescribed items in community pharmacies 
in England (Health and Social Care Information Centre, 2014). Furthermore, the 
Department of Health (DOH) in England considered and then abandoned the idea of 
automatic generic substitution of medicines by pharmacists (Baker et al., 2009, The 
Pharmaceutical Journal News team, 2010). Accordingly, pharmacists and other dispensers 
who receive a prescription containing a branded medicine would be obliged to dispense an 
equivalent generic version of the medicine instead. 
The FDA and the European Medicines Agency (EMA) have set out guidelines to establish 
the requirement range for bioequivalence for generic drugs, which should be between 80-
125% of the original innovator drug’s bioavailability (European Medicine Agency, 2001, 
Food and Drug Administration, 2015b). On the other hand, many authors question the 
approval of such range limits for NTIDs such as ciclosporin (Bartucci, 1999, Cattaneo et 
al., 2005, Johnston and Holt, 1999a, Kahan, 1999, Kamerow, 2011, Sabatini et al., 1999). 
A small dose difference in NTIDs could have  serious side effects which could lead to 
treatment failure and/or toxicity (Johnston and Holt, 2001). 
1.6 Excipients in medicines 
Excipients are the inactive ingredients in a drug that include binders, fillers, lubricants, 
sweeteners, preservatives, flavours, colouring, printing inks, etc. (Wandel et al., 2003, 
Iheanacho and Blythe, 2009). Although excipients are considered to be inactive ingredients 
that do not have a therapeutic effect, some studies have shown that excipients can cause 
many side effects (Wandel et al., 2003). Figure 1.7 shows the differences in sizes, shapes 
and colours of the same medicine. 
Excipients do not need to match the innovator’s drug formulation. Some evidence shows 
that different excipients are metabolised differently in the body such as polyoxyethylated 
castor oil and polysorbate 80 (Johnston and Holt, 2014). 
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Figure 1.7: Different generics of the same medicine (lisinopril 20mg) showing 
differences in sizes, shapes and colours 
Another example of phenytoin (antiepileptic agent) toxicity happened in Australia because 
of changing the excipient in phenytoin to lactose instead of calcium sulphate. That change 
affected the solubility of phenytoin and made it more soluble which increased its systemic 
availability, which led to an increased incidence of toxicity (Tyrer et al., 1970). 
Another example is of a drug company decreasing the particle size of digoxin powder from 
20 μm to 3 μm to formulate digoxin tablets. That caused an increase in the drug absorption 
up to twofold. Consequently, many patients had signs of toxicity (Johnston et al., 1997). 
Therefore, many authors have highlighted the importance of the bioavailability of 
pharmaceutical products especially for critical dose and NTID (Johnston et al., 2004, Holt, 
1978). 
1.7 Impurities in drug products 
Impurities may be defined as any ingredients, substances or contaminations which do not 
belong to the active or non-active ingredients of the drug.  
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FDA guidelines classify impurities in new drug substances into organic, inorganic or from 
residual solvent. These impurities may affect the drug product quality and lead to serious 
adverse effects affecting patients’ safety. The origin of these impurities can be from the 
synthetic procedures for the active ingredient or from the degradation of the inactive 
ingredients in the drug product (Basak et al., 2007, Roy, 2002). 
Organic impurities may arise from degradation of the new drug substance or the 
manufacturing process. The acceptance limits of these impurities should be well specified. 
If an impurity in a drug product is coming from different sources such as a synthetic 
product and also a degradation product, it should be monitored and included in the impurity 
limits. The medication properties can be changed or could result in toxicity by impurities. 
1.8 Organic impurities 
Organic impurities can occur through the manufacturing procedures or during the storage 
of the drug substances and they include the following: 
1.8.1 Starting or intermediate materials 
Most common impurities come from this source, and are found in each active ingredient 
unless specific considerations and care are taken through the production. For example in 
paracetamol bulk, the para-aminophenol content is limited by specific tests, which could 
be a starting material for one manufacturer or an intermediate for another (Figure 1.8). 
1.8.2 By-products 
During the production of organic chemicals, it is very uncommon to get a finished product 
with 100% yield. It is common to have impurities from this source, for example in 
paracetamol bulk, diacetylated paracetamol (paracetamol with an attached butane-2,3-
dione group) may be formed as a by-product (Roy, 2002). 
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Figure 1.8: By product impurity formation during production of paracetamol from p-
aminophenol. Adapted from Roy (2002) 
1.8.3 Degradation products 
Degradation products are yet another source of impurities, which can affect drug quality 
level during the synthesis. Impurities can also be formed by degradation of the finished 
product. However, the degradation of the product can occur with storage and/or ageing. 
The degradation of penicillins and cephalosporins is a well-known example of degradation 
products. The presence of a ß-lactam ring as well as that of an α-amino group in the side 
chain plays an important role in their degradation (Figure 1.9 and Figure 1.10). 
 
Figure 1.9: General structure of penicillins (National Center for Biotechnology 
Information, 2004) 
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Figure 1.10: General structure of cephalosporins (National Center for Biotechnology 
Information, 2011) 
1.8.4 Reagents, ligands and catalysts 
These sources of impurities are rare in active ingredients. However they still should be 
considered. In general, some active ingredients may contain several sources of organic 
impurities mentioned above at levels varying from insignificant to critical. 
1.9 Inorganic impurities 
Inorganic impurities usually come from the production and the manufacturing procedures. 
They are normally known and identified and include the following: 
1.9.1 Reagents, ligands and catalysts 
There are limited possibilities for these kinds of impurities to happen. However care must 
take place during the production otherwise it may result in a product that exceeds permitted 
limits. 
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1.9.2 Heavy metals 
During the production, the two main sources for heavy metals are water and chemical 
reactors. They may cause acidification or hydrolysis of acid during manufacturing. 
These impurities of heavy metals can be prevented by using demineralised water and glass 
lined instruments. 
1.9.3 Other materials 
During the manufacturing process many types of filters may be used. Activated charcoal 
may be used for filtration. These impurities could be avoided by regular monitoring of 
fibres and black particles in the product (ICH Harmonised Tripartite Guideline, 2002, Roy, 
2002, Food and Drug Administration, 2003c). 
1.10  Residual solvent 
According to FDA guidelines residual solvents can be defined as organic volatile chemicals 
that are used or produced in the manufacture of drug substances or excipients, or in the 
preparation of drug products. 
The solvent is one of the important factors during the manufacturing procedures as residues 
may be harmful. If it cannot be removed completely during the synthetic process, then the 
product might not meet specifications, affect good manufacturing practices, or interfere 
with other quality based requirements. Based on these facts, there should be suitable 
selection of the solvent for the production of a drug as it may increase the yield, or modify 
characteristics such as crystal form, purity, and solubility (Roy, 2002, Food and Drug 
Administration, 2003b). 
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1.10.1 Solvent classification 
According to ICH guidelines, residual solvents are evaluated according to their possible 
hazard effect to human health and classified under three classes (European Medicines 
Agency, 2009) 
Class 1 solvents: Solvents to be avoided. 
Known human carcinogens, strongly suspected human carcinogens, and environmental 
hazards (Table 1.1). 
Table 1.1: Class I: Solvents to be avoided in medications 
Solvent Concentration limit 
(ppm) 
Concern 
Benzene 2 Carcinogen 
Carbon tetrachloride 4 Toxic and environmental hazard
1,2-Dichloroethane 5 Toxic
1,1-Dichloroethane 8 Toxic
1,1,1-Trichloroethane 1500 Environmental hazard 
*Source: (Food and Drug Administration, 2003b, European Medicine Agency, 2009) 
 
Class 2 solvents: Solvents to be limited. 
Non genotoxic animal carcinogens or possible causative agents of other irreversible 
toxicity such as neurotoxicity or teratogenicity. Solvents suspected of other significant but 
reversible toxicities (Table 1.2). 
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Table 1.2: Solvents to be limited in medications 
Solvent Permitted Daily 
Exposure PDE (mg/day) 
Concentration Limit 
(ppm) 
Acetonitrile  4.1 410 
Chlorobenzene 3.6 360 
Chloroform 0.6 60 
Cyclohexane 38.8 3880 
1,2-Dichloroethene 18.7 1870 
Dichloromethane 6.0 600 
1,2-Dimethoxyethane 1.0 100 
N,N-Dimethylacetamide 10.9 1090 
N,N-Dimethylformamide 8.8 880 
1,4-Dioxane 3.8 380 
2-Ethoxyethanol 1.6 160 
Ethylene glycol 6.2 620 
Formamide 2.2 220 
Hexane 2.9 290 
Methanol 30.0 3000 
2-Methoxyethanol 0.5 50 
Methylbutylketone 0.5 50 
Methylcyclohexane 11.8 1180 
N-Methylpyrrolidone 48.4 4840 
Nitromethane 0.5 50 
Pyridine 2.0 200 
Sulfolane 1.6 160 
Tetralin 1.0 100 
Toluene 8.9 890 
1,1,2-Trichloroethene 0.8 80 
Xylene 21.7 2170 
*Source: (Food and Drug Administration, 2003b, European Medicine Agency, 2009) 
Class 3 solvents: Solvents with low toxic potential. 
Solvents with low toxic potential to man where no health-based exposure limit is needed. 
Class 3 solvents have permitted daily exposure of 50 mg or more per day (Table 1.3). 
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Table 1.3: Solvents with low toxic potential* 
Acetic acid Heptane 
Acetone Isobutyl acetate 
Anisole Isopropyl acetate 
1-Butanol Methyl acetate 
2-Butanol 3-Methyl-1-butanol 
Butyl acetate Methyl-ethyl ketone 
Tert-Butylmethyl ether Methyl-isobutyl ketone 
Cumene 2-Methyl-1-propanol 
Dimethylsulfoxide Pentane 
Ethanol 1-Pentanol 
Ethyl acetate 1-Propanol 
Ethyl ether 2-Propanol 
Ethyl formate Propyl acetate 
Formic acid Tetrahydrofuran 
*Source: (Food and Drug Administration, 2003b, European Medicine Agency, 2009) 
1.11  Other sources of impurities 
Impurities in the drugs can also occur as a result of exposure to the heat, light, change in 
pH, interaction with the package component or with other active ingredients if it is a 
combination drug (Kovaleski et al., 2007). 
1.12  Aims and objectives 
In this thesis, the growing issue of substandard and counterfeit medicines and how methods 
used to reduce these challenges are reviewed. The challenges highlighted clearly affect all 
developed and developing nations on many levels. 
Using generic substitutions has the advantage of a reduced cost to the healthcare system 
and patients. Generic drugs must pass a bioequivalence test to ensure they have the same 
therapeutic effects as the innovator counterpart and offer the same quality and safety. 
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However, there are some critical differences between the generics and their branded 
counterparts. Randomly switching between brand and generic drugs could lead to 
undesirable effects especially with NTIDs. 
The aim of this thesis is to: 
1. Investigate the use of in-vitro dissolution test of ciclosporin capsules to generate 
information about capsule rupture and drug release of brand versus generic products. 
2. Develop, validate and apply a high performance liquid chromatography (HPLC) method 
for detecting the amount of ciclosporin in generic versus brand capsules. 
3. Modify an ultra-performance liquid chromatography/mass spectrometry (UHPLC-MS) 
method in order that ciclosporin and its impurities could be detected simultaneously. 
4. Investigate the use of in-vitro dissolution test of azithromycin tablets to generate 
information about tablet dissolution and drug release of brand versus generic products. 
5. Validate a modified UHPLC-MS/MS method for quantification of azithromycin tablets. 
6. Highlight any potential variations between the generic and branded innovator using an in-
vivo bioequivalence test in man. This study will give an example of the clinical trial 
required to approve generic medications. 
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Chapter 2. Materials and final methods 
2.1 Introduction 
This chapter explains in detail the materials used for all experiments and the final methods 
used for each test. 
The three main analysis systems used were a PT-DT 70 dissolution tester, HPLC and 
UHPLC-MS. 
A dissolution test is important for quality assurance of the drug (Dressman et al., 1998). 
An in-vitro dissolution test gives the information about the capsule rupture time and drug 
release. The dissolved sample can be used to measure the actual mass of a drug. 
HPLC is an excellent technique for measuring average drug content in tablets and capsules. 
It can be used for therapeutic drug monitoring (TDM) when suitable detectors such as a 
mass spectrometer are used. The advantages of HPLC-mass spectrometry are high 
sensitivity, specificity, small sample requirements, minimal sample preparation, rapid 
throughput, and simultaneous measurement for the drug and the possible impurities. 
However, HPLC with ultraviolet/fluorescent detection is also a good method to quantify 
and analyse the impurities in the analysis of medicines. 
The UHPLC-MS method is one of the new techniques in liquid chromatography. It has the 
advantage of using columns with smaller particle size e.g. 1.7 µm, which result in 
decreasing analysis time, increasing the sensitivity, good resolution and higher efficiency 
(Lu et al., 2015). UHPLC-MS is required when the samples are minimal such as biopsies 
and blood samples (Whitman et al., 1993). 
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2.2 General chemicals 
All general chemicals were purchased either from Sigma-Aldrich Company Ltd. (Fancy 
Rd., Poole, Dorset, BH12 4QH, UK) or from VWR International (Hunter Boulevard, 
Magna Park, Lutterworth, Leicestershire LE17 4XN, UK) unless otherwise stated. 
 Ciclosporin A, lot number: BCBD2418V, catalogue number: 30024-100 mg, purity > 
98.5%.  
  Acetonitrile, HPLC grade, catalogue number: RH1015, batch number 12A17CA.  
 Trifluoroacetic acid, catalogue number: PTS6045, batch number: PD241459. 
 Azithromycin dehydrate, lot number: 020M4703V, catalogue number: PZ0007-25 mg, 
purity > 98%. 
 Di-sodium hydrogen orthophosphate, lot number: K27313279010, product number: 
10383G 500 g. 
 Sodium dihydrogen orthophosphate 1-hydrate, lot number: A581121-425, product 
number: 102454R 500 g. 
 Phosphoric acid, lot number: 59H3638, catalogue number: P-6560 500 g. 
 Deionised water at purity of 18.2 MΩ.cm was obtained from ultra-water system 
(PURELAB® ULTRA), Windsor Court, Kingsmead Business Park, High Wycombe, HP11 
1JU, UK. 
 Acetonitrile, Optima™ LC/MS grade, product code: 10055454, Fisher Scientific UK Ltd, 
Bishop Meadow Road, Loughborough, LE11 5RG, UK. 
 Methanol, Optima™ LC/MS grade, product code: 10636545, Fisher Scientific UK Ltd, 
Bishop Meadow Road, Loughborough, LE11 5RG, UK. 
2.3 General equipment 
 PT-DT 70 dissolution tester from PharmaTest, Hainburg, Germany (Figure 2.1). 
 High quality electronic instrument: Sartorius (R 160 P) Electronic Semi-Microbalance, 
Sartorius Stedim, Surrey, UK. 
 20 µm Poroplast Filter Element from PharmaTest, Hainburg, Germany. 
 Ultra-water system (PURELAB®ULTRA) for deionised water, ELGA, UK. 
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 HPLC system Jasco UV- 975 intelligent UV-VIS with Jasco AS-950 intelligent sampler 
injector, two Jasco PU-980 intelligent HPLC pumps and Jasco DG-2080-53 3 lines 
degasser. 
  Jones Chromatography (Column Heater) Model 7990. 
 The HPLC control data acquisition was by Chromatography Data System version 1.8.6.1 
from JASCO Chrom Pass. 
 HPLC used for ciclosporin separation was carried out using a reversed phase C18 column 
(5 µm, 125 x 4.6 mm, ACE 5) obtained from Advanced Chromatography Technologies, 
Aberdeen, AB25 1HF, UK. 
 JENWAY spectrophotometer, Ultra-Violet/Visible, Model 6715 UV/Vis. 
 UHPLC/MS used for the detection of ciclosporin impurities was carried out using a 
reversed phase ACQUITY UHPLC HSS T3 Column (1.8 µm, 1 mm X 150 mm), obtained 
from Waters Limited, 730-740 Centennial Court, Centennial Park, Elstree, Hertfordshire, 
WD6 3SZ, UK. 
 Waters Nanoacquity UHPLC system with Waters Micromass Q-ToF Premier (Waters, UK). 
 Accela UHPLC system with triple-stage-quadrupole mass spectrometry (TSQ) Vantage 
system (Thermo Scientific, Hemel Hempstead, UK). 
 UHPLC-MS/MS azithromycin quantitation was carried out using a reversed phase Synergi 
HydroRP, LC Column (4 µm, 150 x 0.3 mm), obtained from Phenomenex, Queens Avenue, 
Hurdsfield Ind. Est., Macclesfield, Cheshire SK10 2BN, UK. 
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2.4 Methods used 
2.4.1 HPLC experimental method for ciclosporin capsules (Test A) 
 
Figure 2.1: PT –DT 70 dissolution tester used for dissolution test 
2.4.1.1 Application of the assay 
A HPLC method was applied to detect the amount of ciclosporin in generic versus brand 
capsules. 
2.4.1.2 Method details 
The extraction of active ingredients was done by a dissolution test. PT-DT 70 is the low 
head flip-back dissolution tester, which is (according to the manufacturer) the optimal 
tester for all US Pharmacopeia and European Pharmacopeia applications. It contains seven 
test stations with paddle stirrer adapters, fully adjustable and regulated speed from 25 to 
250 rpm. Seven ciclosporin products were included in the study. Each capsule was weighed 
and the average weight for the capsules calculated (n = 4). Dissolution tests were done to 
check if all capsules met with the US Pharmacopeia 2008, (USP-31) requirements such as 
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rupturing time within 15 min. All capsules were stored according to the conditions labelled 
on the package. Dissolution medium was prepared according to USP guidelines which is 
deionised water (500 mL). The samples were filtered using a 20 µm Filter. The HPLC 
experiment was carried out with a UV detection wavelength of 210 nm. The separation 
was carried out using a C18 column (as described in section 2.3). The column temperature 
was maintained at 50°C and the injection volume was 20 µL. The analytes were eluted by 
isocratic elution at a flow rate of 0.7 mL/min with acetonitrile and water (70:30%, v/v) and 
0.03%, v/v trifluoroacetic acid, over 25 min. The data acquisition and chromatography 
analysis were carried out using Chromatography Data System version 1.8.6.1 from Jasco 
Chrom Pass. Statistical analyses and graphical presentation were carried out using Minitab-
16 and Microsoft Excel 2010. 
2.4.2 HPLC experimental method for ciclosporin capsules (Test B) 
Same method (Test A) was applied to obtain more precise results with the following 
modifications: 
 Eight ciclosporin products were included in this study. 
 Increase the tested capsules to (n = 5). 
 New calibration line. 
 Peak area measurement adjustment of HPLC system, area calculated as (mV.s) instead of 
(mV.min)  
 Sampling times increased up to 120 min and included two additional time points. 
2.4.2.1 Application of the assay 
A HPLC method was applied to detect the amount of ciclosporin amount in generic versus 
brand capsules. 
2.4.2.2 Method details 
Eight ciclosporin products were included in the study. Each capsule was weighed and the 
average weight for the capsules calculated (n = 5). Dissolution tests were done to check if 
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all capsules met with the US Pharmacopeia 2008, (USP-31) requirements such as rupturing 
time within 15 min. All capsules were stored according to the conditions labelled on the 
package. Dissolution medium was prepared according to USP guidelines, which is 
deionised water (500 mL). The samples were filtered using a 20 µm Filter. The HPLC 
experiment was carried out with a UV detection wavelength of 210 nm. The separation 
was carried out using a C18 column (as described in section 2.3). The column temperature 
was maintained at 50°C and the injection volume was 20 µL. The analytes were eluted by 
isocratic elution at a flow rate of 0.7 mL/min with acetonitrile and water (70:30%, v/v) and 
0.03%, v/v trifluoroacetic acid, over 25 min. The data acquisition and chromatography 
analysis were carried out using Chromatography Data System version 1.8.6.1 from Jasco 
Chrom Pass. 
Statistical analyses and graphical presentation were carried out using Minitab-16 and 
Microsoft Excel 2010. 
2.4.3 UHPLC-MS detection of impurities in ciclosporin capsules 
The method used was slightly modified after Pandher et al. (2009) under the following 
conditions: UHPLC performed on Waters Nanoaquity UHPLC system. Separation of 
ciclosporin impurities was achieved on Waters Acquity UHPLC HSS T3 column (see 
details in section 2.3) with the following solvent system: solvent A = 0.1% formic acid in 
water, solvent B = 0.1% formic acid in acetonitrile. The flow rate was 40 µL/min. The 
analytical run starts by 100% of solvent A for 2 min, then a gradient 100% A to 100% B 
over 10 min, then 100% of solvent B for 3 min, then back to 100% A over 1 min and 
maintain 100% of A for 4 min (Pandher et al., 2009). 
Mass spectrometry conditions were as follows: mass spectrometry was performed on 
Waters Q-ToF Premier in positive and negative electrospray ionization modes (ESI). ESI 
voltages were 2.9 V in negative mode and 3.1 V in positive mode. Cone voltage was 38 V. 
Source temperature was 80 °C and desolvation temperature was 250 °C. Desolvation and 
cone gases were nitrogen with flow of 400 L/min and 30 L/min, respectively. The MS scan 
was adjusted to acquire between 40-1500 m/z range with scan time of 0.18 s and inter-scan 
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delay of 0.02 s. Data were acquired in centroid mode with online lock mass correction 
using leucine enkephaline (MW = 556.2771) as lock mass. Instrument calibration was done 
by 50 mM sodium formate. A quality control ciclosporin standard was injected regularly 
to monitor the stability of the UHPLC system. 
Data acquisition was done using Water Masslynx software (V 4.1) from Waters, UK. Data 
analysis of the mass detection, chromatographic peak detection, peak deconvolution, 
deisotoping, retention time normalisation and peak alignment were all done using MZmine 
software (version 2.2). Peak lists including retention, m/z and peak intensities were 
exported from MZmine and imported into MetaboAnalyst software (version 2.0, 
www.metaboanalyst.ca). Fold change, and p values were generated. Ciclosporin impurities 
were detected using three different online data base searches: 
 PubChem Compound Database  
http://www.ncbi.nlm.nih.gov/pccompound 
 KEGG Compound Database 
http://www.genome.jp/kegg/compound/ 
 Human Metabolome Database (HMDB) 
http://www.hmdb.ca/ 
2.4.4 UHPLC-MS/MS quantification for azithromycin tablets 
Quantification of azithromycin was carried using a modified UHPLC-MS/MS method, 
modified after Rossmann et al. (2014). Azithromycin was separated on an Accela UHPLC 
system equipped with a Synergi HydroRP, LC column (4 µm, 150 x 0.3 mm). The column 
temperature was maintained at 37 °C using an Accela column oven. Gradient elution was 
employed using a mobile phase of 0.1% formic acid (FA) in water (A) and 0.1% FA in 
acetonitrile (B) as follows: A = 90% from 0-0.2 min, from 90% A to 5% over 4 min, held 
at 5% A for 1.4 min, from 5% to 90% A over 0.2 min, ending with 90% A for 2.7 min, all 
at a flow rate of 30 µL/min. (Rossmann et al., 2014) A Triple Stage Quadrupole mass 
spectrometry (TSQ) Vantage system equipped with an electrospray ion source was used 
for mass detection. Samples were analysed in Multiple Reaction Monitoring (MRM), 
positive mode at a spray voltage of 3500 V. Nitrogen was used as sheath at a flow rate of 
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20 arbitrary units. Argon was used as the collision gas with a pressure of 1.5 mTorr. The 
optimum transitional daughter ion mass and collision energy for azithromycin was: m/z 
749.5  591.4 (Collision energy 20V) and internal standard roxithromycin was: m/z 837.5 
 679.4 (Collision energy 20V). Data acquisition and chromatography analysis were 
carried out using Xcalibur software version 2.2.
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Chapter 3. Development and validation of a HPLC 
method for ciclosporin 
3.1 Introduction 
In the last few years, many questions have been raised about using generic substitutes, 
especially those for NTIDs. New drug safety advice announced by the Medicines & 
Healthcare product Regulatory Agency states that ciclosporin is such a NTID. If the patient 
is using one brand of ciclosporin then the same brand should be maintained for the rest of 
the treatment, unless change is unpreventable. This patient should be closely monitored 
(Medicines and Healthcare products Regulatory Agency, 2009). 
Ciclosporin has significantly improved the graft survival rate in many transplantations 
from 60 to 80% (Opelz, 1995, Traynor et al., 2012). Ciclosporin in whole blood is routinely 
measured by an immunoassay supplied by some companies like Abbott (Sanghvi et al., 
1989, Hamwi et al., 2000). The limit of detection for such assays is 25 ng/mL. 
Bioequivalence studies of ciclosporin capsules require the measurement of the drug and 
also the concentrations of other impurities that can lead to serious problems. 
HPLC is an excellent technique for measuring average drug content in tablets and capsules. 
It can be used for TDM when suitable detectors such as a mass spectrometer are used. The 
advantages of HPLC-MS are high sensitivity, specificity, small sample requirements, 
minimal sample preparation, rapid throughput, and simultaneous measurement for the drug 
and the possible impurities. However, HPLC with ultraviolet/fluorescent detection is also 
a good method to quantify and analyse the impurities in the analysis of ciclosporin 
capsules. Like other peptides, ciclosporin can be measured by HPLC at relatively low UV 
absorbance wavelengths and this is considered as a gold standard for its measurement. 
(Burckart et al., 1990, Shaw et al., 1999, Chimalakonda et al., 2002). The HPLC-MS 
method is required when the samples are minimal such as biopsies and blood samples 
(Whitman et al., 1993). There have been various methods to measure the content of the 
drug in ciclosporin capsules. Some of the studies were done by cutting the capsules and 
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dissolving them before subjecting them to an analytical HPLC system (Aziz et al., 2010). 
Some suggest to cut the capsule and obtain the contents and dissolve a known volume in 
the mobile phase before quantifying using HPLC. According to the United States 
Pharmacopeia, 2007, it is advised to cut about 20 capsules and extract the contents with 
the aid of alcohol and make up a known solution in a volumetric flask with ethanol. Then 
this stock is diluted to obtain a concentration of 1 mg/mL. This can then be used for the 
determination of ciclosporin in capsules. The other method to obtain the contents of a 
capsule is to aspirate using a syringe and prepare a dilution from the obtained stock. Both 
of these methods lack accuracy and have the possibility of producing variable results, 
because we cannot make sure all the contents are extracted. 
A dissolution method of rupturing the capsule in the medium and then measuring the 
content of ciclosporin in this medium would give rise to more reproducible results. 
3.2 Ciclosporin 
Ciclosporin (cyclosporine A, ciclosporin A, cyclosporin A, CyA) is a lipophilic cyclic 
undecapeptide compound formed by a soil fungus called Tolypocladiuminflatum Gams 
(Golabi et al., 2003). It was discovered by Sandoz of Basel, Switzerland  in the 1970s 
(Tribe, 1998). Ciclosporin can be prepared by synthetic or semi-synthetic ways (Hauer et 
al., 1994). Ciclosporin capsules contain the following inactive ingredients: Corn oil-mono-
di-triglycerides, polyoxyl 40 hydrogenated castor oil NF, DL-α-tocopherol USP, gelatine 
NF, glycerol, iron oxide black, propylene glycol USP, titanium dioxide USP, carmine, and 
other ingredients (Novartis Pharmaceuticals Corporation, 2011). 
Chemically, ciclosporin is described  as [R-[R*,R*-(E)]]-cyclic(L-alanyl-D-alanyl-N-
methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-
amino-6-octenoyl-L-α-amino-butyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-
methyl-L-leucyl) (Figure 3.1). 
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Figure 3.1: The chemical structure of ciclosporin (ChemSpider, 2015) 
3.3 Applications and mode of action 
Ciclosporin is an immunosuppressant agent with a narrow therapeutic index. It has been 
widely used since 1978 after organ or tissue transplant to prevent rejection (Allison and 
Eugui, 2000, Thomas et al., 2005). For auto-immune diseases such as severe rheumatoid 
arthritis and psoriasis, ciclosporin can also be used (Food and Drug Administration, 
2011b). The donor cells used in the transplantation should be compatible with the recipient 
but not identical. However the response of the immune system can lead to the attack and 
rejection of the transplanted organ or tissue. Ciclosporin suppresses the activity of the cells 
of the immune system preventing such attacks or rejection of the transplanted organ or 
tissue (Postolache et al., 2002). 
Ciclosporin binds to cyclophilin A (CycA), an intracellular protein found in the cytosol  
(Ryffel et al., 1991).  This compound inhibits the production of lymphokines from the 
white blood cells via calcineurin inhibition. Lymphokines are the protein mediators 
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responsible for T and B lymphocyte stimulation, which function against infections and 
foreign cells (Amor et al., 2010). 
According to Johnston and Holt (2011), ciclosporin is a narrow therapeutic index drug 
(NTID). Irreversible kidney damage occurs at high doses. As a result, therapeutic drug 
monitoring is essential during ciclosporin therapy. With immunosuppressant agents, low 
therapeutic doses may lead to acute organ rejection. In contrast, a high dose may cause 
nephrotoxicity and infections. Switching among and between brands and generics (same 
as brand product in dosage form and route of administration, with respect to quality and 
safety) of these drugs can lead to undesirable effects. A study compared the biopsy-proven 
rate of acute rejection (BPAR) at six months after kidney transplantation between the 
branded immunosuppressant Neoral® and the branded-generic Gengraf™. BPAR was found 
to be significantly higher in patients who received Gengraf™ compared to Neoral®, 39% to 
25%, respectively (Taber et al., 2005). Yet, the Food and Drug Administration considers 
Gengraf™ to be bioequivalent and interchangeable with Neoral® (Roza et al., 2002, Food 
and Drug Administration, 2009a). Another study compared the physiochemical properties 
of another generic immunosuppressant, tacrolimus with its counterpart brand Prograf®. It 
revealed that the dissolution, solubility and content uniformity profiles of generic 
formulations were different from that of Prograf® (Petan et al., 2008). 
3.4 Pharmacokinetics and drug interactions 
3.4.1 Absorption 
After oral administration in man, the absorption of ciclosporin is variable. Peak plasma 
concentrations (Cmax) are obtained in about 1.5-3.5 h (Novartis Pharmaceuticals 
Corporation, 2011). Compared to an intravenous infusion, the bioavailability of the oral 
dose is approximately 30-40% (Bennett and Brown, 2003). 
3.4.1.1 Factors affecting ciclosporin absorption 
Absorption of ciclosporin can be affected by many factors such as the physiochemical 
properties of the drug such as pH, dosage form and physiological factors (Burckart et al., 
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1986b). These physiological factors include gastric emptying rate, gastrointestinal (GI) 
motility, GI blood flow rate, GI pH, and first-pass metabolism. The changes in blood flow, 
particularly after liver transplant, may change the first-pass metabolism of the drug. Bile 
secretion may alter the solubilisation of ciclosporin (Postolache et al., 2002, Howland et 
al., 2006). 
Drug-drug interactions and drug-food interactions are known to affect the GI physiological 
state, which can modify drug absorption. Ageing and GI disease states often lead to 
alterations in GI physiology and physiological reaction, resulting in further changes in the 
extent and rate of ciclosporin absorption. These conditions are the sources of inter- and 
intra-patient variability in ciclosporin absorption (Howland et al., 2006). 
The oral bioavailability of ciclosporin is affected by the presence of food in the GI tract 
because of changes in the rate and extent of absorption. These changes occur due to gastric 
and bile secretion, changes in gastric motility and changes in the blood flow to the GI tract 
(Drewe et al., 1992). All these changes lead to alteration in the efficacy and the toxicity 
profile of the drug (Karalis et al., 2008). 
3.4.2 Distribution 
When ciclosporin enters the body’s circulation, it distributes into the organs and tissues. 
Ciclosporin distribution is unequal due to differences in blood flow to the organs, lipid 
solubility, capillary permeability and accumulation at other sites. The process of 
distribution is reversible (Ruiz-Garcia et al., 2008). The distribution rate of the drug in the 
tissues is determined by perfusion. Some tissues are poorly perfused, like muscles and fat, 
and the distribution in such tissues is very slow especially if the tissue has a high affinity 
for the drug (Le, 2009). Because of the lipophilicity of ciclosporin, only a small amount is 
distributed in blood. The distribution within the blood is lower in lymphocytes 4-9%, and 
granulocytes 5-12%, and higher in plasma 33-47% and erythrocytes 41-58%. 
Approximately 90% of the drug undergoes plasma protein binding, mainly to lipoproteins 
(Novartis Pharmaceuticals Corporation, 2011). 
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3.4.3 Metabolism  
The liver is one of the major organs responsible for drug metabolism. When the drug is 
absorbed into the systemic circulation it undergoes biotransformation. Most of the drug 
metabolism occurs in the liver, although some occurs elsewhere like the intestine. Drug 
metabolism is by two broad categories of enzymatic reactions, known as Phase I 
(oxidation, reduction, and hydrolysis) and Phase II (sulfation, glucuronidation, glutathione 
conjugation, acetylation, amino acid conjugation and methylation) (Neber and Roe, 2001). 
The products of metabolism are usually more water soluble than the original compound. 
The elimination of a compound means that its biological half-life is reduced and hence its 
potential toxicity is minimized. Metabolism has an effect on the biological activity of the 
drug. However, in some cases like in liver dysfunction, metabolism may increase the 
toxicity of the drug. Metabolism plays a central role during drug disposition as it may have 
a major effect on it, generally by increasing polarity and therefore water solubility 
facilitating excretion but it may not change the half-life (t1/2) (period of time required for 
the concentration or amount of drug in the body to be reduced by one-half) (Timbrell, 2002, 
Verbeeck, 2008). 
Ciclosporin metabolism takes place in the liver and GI tract by cytochrome CYP3A (Food 
and Drug Administration, 2009b), mainly by the hepatic CYP3A4 family (Howland et al., 
2006, Rang et al., 2007). The metabolism includes primarily hydroxylation, demethylation, 
and cyclization. Thus, enzyme inducers or inhibitors of CYP3A4 alter the ciclosporin 
metabolism (Akhlaghi et al., 2001, Howland et al., 2006, Afshar and Nafar, 2011). 
Many factors affect ciclosporin metabolism, including: species, enzyme inhibition, 
genetics, enzyme induction, age, dose, gender, diseases, diet, physiochemical 
characteristics (Craig and Stitzel, 2004, Kees et al., 2004). 
3.4.4 Elimination 
Once absorbed, elimination of a drug or its metabolites occurs either by liver metabolism, 
and/or by kidney excretion. Hepatic elimination occurs primarily by the cytochrome P450 
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(CYP450) family of enzymes located in the hepatic endoplasmic reticulum but may also 
occur by non-P450 enzyme systems, such as N-acetyl and glucuronosyl transferases. P450 
enzyme systems located in gut mucosa can also significantly affect the amount of drug 
absorbed into the systemic circulation. Many factors alter hepatic and intestinal drug 
metabolism; most of these factors are usually relatively stable over time (Martindale, 
1996). Most of the elimination occurs in the liver and small intestine (Burckart et al., 1986a, 
Novartis Pharmaceuticals Corporation, 2011) with a t1/2 around 24 h (Rang et al., 2007). 
Small amounts of oral ciclosporin are eliminated by the kidney. 
3.5 Uses, doses and adverse effects of ciclosporin 
The FDA-labelled use of ciclosporin is for prophylaxis to prevent organ rejection in kidney, 
liver and heart transplantation. It is also indicated for use in severe rheumatoid arthritis and 
psoriasis (Food and Drug Administration, 2011b). Other uses include atopic dermatitis, 
severe autoimmune disease, lupus nephritis, and severe ulcerative colitis. 
The initial oral dose of ciclosporin should be 4-12 h post-transplant. The total daily dose 
should be divided twice daily. For renal transplant patients: 9 ± 3 mg/kg/day, liver 
transplant patients: 8 ± 4 mg/kg/day, heart transplant patients: 7 ± 3 mg/kg/day. For 
rheumatoid arthritis, starting dose: 2.5 mg/kg/day and may be increased by 0.5-0.75 
mg/kg/day up to maximum 4 mg/kg/day. The dose for psoriasis starts at 2.5 mg/kg/day, 
and may be increased by 0.5 mg/kg/day up to a maximum 4 mg/kg/day. Adverse reactions 
include: hypertension, hirsutism, renal dysfunction, and hypomagnesaemia (UpToDate, 
2011). 
3.6 Therapeutic drug monitoring of ciclosporin 
Therapeutic drug monitoring (TDM) is required to enhance drug therapy in patients and it 
differs from one drug to another. Therapeutically monitored drugs should have a clear 
relationship between the drug concentration and the effect (Johnston and Holt, 1999b). 
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Clinical findings have shown that the therapeutic window for ciclosporin is narrow. For 
example, in kidney transplant patients ciclosporin therapeutic range during the first month 
should be from 1600 – 2000 ng/mL (Table 3.1), (Schiff et al., 2007). Therefore, monitoring 
of the blood concentrations of the drug and drug metabolites is considered essential in dose 
adjustment for high efficacy and lower toxicity (Yatscoff, 1991). In addition to having 
narrow therapeutic index (NTI), oral ciclosporin has a large intra- and inter-individual 
variability in absorption and metabolism (Holt et al., 2000, Keown, 2002).  
The best way to monitor ciclosporin remains debatable (Yatscoff, 1991, Andrews and 
Cramb, 2002, Einollahi et al., 2011). Data suggested that single-point measurement of 
plasma ciclosporin after 2 h (C2) post dose can be a fast and effective method (Keown, 
2002). C2 monitoring is considered to be one of the ways to measure ciclosporin 
concentration in kidney and liver transplant patients (Johnston and Holt, 2001, Einollahi et 
al., 2011, Rostami and Einollahi, 2011). The target C2 level in early treatment for kidney 
and liver transplant are 1500 ng/mL and 1700 ng/mL respectively (Brunet et al., 2004, 
Schuetz et al., 2005). 
Table 3.1: Target range of ciclosporin for kidney transplant patients (Adopted from 
(Schiff et al., 2007) 
Time Therapeutic range 
From 0 to 3 months C2 > 1700 ng/mL by day 5, 1600 – 2000 ng/mL month 1, 1400 
– 1600 ng/mL month 2, 1200 – 1400 ng/mL month 3  
From 3 to 12 months C2 from 800 – 1000 g/mL, months 4 to 6 
C2 from 600 – 800 ng/mL, months 7 to 12 
More than 12 months C2 800 ng/mL 
3.7 Experimental method development for ciclosporin analysis 
3.7.1 Material and methods 
3.7.1.1 General chemicals 
 Please see chapter 2 (section 2.2) 
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3.7.1.2 General equipment 
 Please see chapter 2 (section 2.3) 
3.7.1.3 Collection of drug samples 
All brand samples were manufactured by Novartis in Switzerland (T, S, E, J, and P) and 
then repackaged in the imported country. Both generics (C and I) were manufactured in 
India (Table 3.2). 
Table 3.2: Doses and sources of ciclosporin soft gelatine capsules 
Drug, dose and code Obtained from 
Ciclosporin 100 mg (S)* Government hospital, Jeddah, Saudi Arabia 
Ciclosporin 100 mg (T)* Commercial pharmacy, Istanbul, Turkey 
Ciclosporin 100 mg (P)* Commercial pharmacy, Karachi, Pakistan 
Ciclosporin 100 mg (C) Commercial pharmacy, Colombia 
Ciclosporin 100 mg (I) Commercial pharmacy, India 
Ciclosporin 50 mg (J)* Commercial pharmacy, Amman, Jordan 
Ciclosporin 50 mg (E)* Commercial pharmacy, Cairo, Egypt 
(* = branded) 
3.7.2 Extraction by dissolution 
A dissolution method in-vitro gives the information about the capsule rupture and drug 
release. The dissolved sample can be used to measure the actual mass of ciclosporin in 
branded versus generic ciclosporin capsules. 
A dissolution method to analyse ciclosporin capsules was obtained from the US 
Pharmacopeia. Seven ciclosporin capsules were included in this study. Each capsule was 
weighed to check the dosage uniformity. The dissolution test was carried out under the 
following conditions: Temp: 37.5°C ± 0.5, 500 mL deionized water used as a medium, the 
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paddle apparatus (Apparatus 2): 50 rpm, sampling time at (5, 10, 15, 30, 60, and 90 min), 
with 5 mL volume for each sample. The samples were filtered using 20 µm filters. 
3.7.3 HPLC experimental method development 
3.7.3.1 Identification of the Lambda max (λmax) for ciclosporin measurement 
A standard ciclosporin solution of 2 mg/mL was used to detect the λmax. λmax is the 
wavelength at which the maximum fraction of light is absorbed by a solution. The spectrum 
was compared to an acetonitrile blank, which was used as a baseline. The scan range of the 
spectrophotometer was set from 190 nm to 400 nm to detect maximum absorbance for 
ciclosporin throughout this range. 
In order to determine the best absorbance wavelength for detection. Ciclosporin (2 mg/mL) 
in methanol was scanned using a spectrophotometer (Jenway 6715 UV/Vis). The spectrum 
generated showed that absorbance of ciclosporin starts at 180 nm and ends at about 250 
nm (Figure 3.2). The highest absorbance was between 205 and 215 nm. Based on this 
result, the absorbance at 210 nm was used to detect ciclosporin in all subsequent 
experiments. 
Figure 3.2: UV absorbance wavelength for 2 mg/mL ciclosporin in methanol 
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3.7.3.2 Selection of columns  
The hydrocarbon chain forming the hydrophobic phase is usually a hydrocarbon of 
eighteen (C18), eight (C8) or four (C4) carbons. Peptides need longer hydrophobic chain 
lengths to be resolved (Carr, 2002). Various C18 columns were tested to get a good 
separation of ciclosporin by the HPLC method. The ACE 5 column showed the best results. 
All subsequent development was undertaken on this column. 
3.7.3.3 Optimisation of column temperature for separation of ciclosporin 
Based on literature review and the US Pharmacopeia the effect of different column 
temperatures on ciclosporin retention were investigated. Temperatures studied were 25 °C 
(Figure 3.3), 75 °C (Figure 3.4), and 50 °C (Figure 3.5). The best retention was obtained 
at 50 °C. 
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Figure 3.3: Chromatogram showing ciclosporin standard, column temperature at 25 °C 
 
Figure 3.4: Chromatogram showing ciclosporin standard, column temperature at 75 °C 
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Figure 3.5: Typical chromatograms showing ciclosporin standards using the HPLC 
method, flow rate 0.7 mL/min, column temperature 50 °C 
3.7.3.4 Optimisation of flow rate 
In order to optimise the flow rate, different flow rates were studied to obtain the best 
resolution and peak shape, mL/min (Figure 3.6), 1.2 mL/min (Figure 3.7), and 0.7 mL/min 
(Figure 3.10). The best resolution was found at 0.7 mL/min. 
 
Figure 3.6: Chromatogram showing ciclosporin standard at 1 mL/min flow rate 
Ciclosporin (1 mg/mL) 
Ciclosporin (0.8 mg/mL) 
Ciclosporin (0.6 mg/mL) 
Ciclosporin (0.4 mg/mL) 
Ciclosporin (0.2 mg/mL) 
Ciclosporin (0.1 mg/mL) 
Ciclosporin (1.5 mg/mL) 
Ciclosporin (2 mg/mL) 
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Figure 3.7: Chromatogram showing ciclosporin standard at 1.2 mL/min flow rate 
3.7.3.5 Preparation of stock, calibration solutions and control samples 
Ciclosporin stock solution (2 mg/mL) was prepared in the mobile phase and stored at 
−20ºC. The ciclosporin calibration standards were freshly prepared at the time of the 
experiment. Eight concentrations of ciclosporin (0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5 and 2 mg/mL) 
were prepared in the mobile phase. 
3.7.4 Calibration and linearity 
Calibration standards (0.1–2 mg/mL) were injected into the HPLC system. The integrated 
peak areas of the ciclosporin were recorded. Linear regression of the standards was done 
using Microsoft Excel 2010, by plotting the peak area of ciclosporin against the ciclosporin 
concentration of the standards. The linearity was checked by calculating R-squared (R2) 
which is a statistical measure used to calculate how close the data are to the fitted regression 
line values using least-square linear regression analysis. 
UV detection at 210 nm was used to determine for the linearity of ciclosporin in the HPLC 
system. The retention of ciclosporin was achieved using the method and a typical 
ciclosporin chromatogram is shown in figure 3.10. A symmetrical peak shape with 
retention time of 13.8 min corresponded to ciclosporin retention time. The peak areas of 
the ciclosporin standards were 46, 92.3, 183, 275, 367, 459, 688, 916 mV.min for 0.1, 0.2, 
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0.4, 0.6, 0.8, 1.0, 1.5, and 2 mg/mL respectively (Figure 3.8). The linear regression (R2) 
was 1.00, regression residuals less than ±5 % (Figures 3.9). 
 
Figure 3.8: Standard curve for ciclosporin standards in mobile phase showing linear 
calibration line r2 = 1 using the HPLC system (Test A) 
 
Figure 3.9: Linear regression residuals for ciclosporin standards, less than 5% 
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3.7.5 Method sensitivity 
The detection limit of ciclosporin is the lowest concentration that can be detected using 
this method. The upper limit of detection is given by the point where the detector response 
deviates by 1% from the expected linear response. 
On seven different days, the mean concentration measured of the lowest standard (0.1 
mg/mL) (Figure 3.10) was 0.09 ± 0.01 mg/mL with (CV) of 11.84 %. The highest standard 
was 2.01 ± 0.08 mg/mL with a (CV) of 4.22 % (Table 3.3). 
 
Figure 3.10: Chromatogram for the lowest ciclosporin concentration (0.1 mg/mL) at 50 
°C, flow rate 0.7 mL/min 
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Table 3.3: Sensitivity test of ciclosporin standard showing the concentration of low and 
high standards on different days 
3.7.6 Method specificity 
The method specificity was investigated by injecting blank mobile phase before the start 
of each run. The blank standards were used to control for any interfering peaks that elute 
at the same retention time as ciclosporin. The interfering peaks might arise from the mobile 
phase or the extraction process. 
The method for measuring ciclosporin was specific. Blank mobile phase samples were used 
before, between and after each run. No significant interfering peaks and no presence of any 
carried over ciclosporin at the migration time of ciclosporin samples (Figure 3.11). 
Days Measured concentration of lowest 
standard (0.1 mg/mL) 
Measured concentration of highest 
standard (2 mg/mL) 
1 0.07 2.21 
2 0.10 1.97 
3 0.10 1.99 
4 0.10 2.00 
5 0.10 1.99 
6 0.10 2.00 
7 0.10 1.97 
Average 0.09 2.01 
±SD 0.01 0.08 
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Figure 3.11: Example chromatogram to show there is no interfering peak before running 
ciclosporin samples. Between and after samples chromatograms also showed no interfering 
peaks 
3.7.7 Coefficient of variation 
Each ciclosporin calibration standard peak area was divided by its concentration in order 
to calculate the slope of the standard curve. The average and the standard deviation of the 
slope of all calibration standards were then calculated. Then the intra-day co-efficient of 
variation (CV) of this calibration line was calculated. 
Chapter 3 Development and validation of a HPLC method for ciclosporin 
    Page 85 of 296 
100
slope  theof average
slope ofdeviation  standardCV% 
 
Equation 1: Calculation of coefficient of variation for ciclosporin calibration peak 
3.7.8 Precision 
3.7.8.1 Intra-day variability 
Ciclosporin standards at 0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, and 2 mg were injected into the HPLC 
system on the same day. Table 3.4 shows the actual and measured concentrations for these 
samples, average, standard deviation, and the correlation of variation percentage. 
Table 3.4: The mean, standard deviation (±SD) and the coefficient of variation (CV) for 
the intra-day variability for ciclosporin assay standard at 0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, and 
2 mg/mL 
Concentration 
(mg/mL) 
Concentration 
(mg/mL) 
Concentration 
(mg/mL) 
Mean ±SD CV% 
intra-day 
0.1 0.09 0.10 0.10 0.002 2.22 
0.2 0.20 0.21 0.20 0.007 3.64 
0.4 0.39 0.40 0.40 0.009 2.30 
0.6 0.61 0.57 0.59 0.024 4.05 
0.8 0.81 0.82 0.82 0.004 0.51 
1 1.01 1.02 1.02 0.009 0.89 
1.5 1.49 1.46 1.48 0.016 1.08 
2 1.98 2.00 1.99 0.010 0.51 
Intra-day variability was acceptable for ciclosporin across the standard range (<4%). 
3.7.8.2 Inter-day variability 
Ciclosporin standards at 0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, and 2 mg were injected into the HPLC 
system. Table 3.5 shows the hypothetical and measured concentrations by HPLC analysis 
for these samples over six different days along with the average, standard deviation, and 
the coefficient of variation percentage. 
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Table 3.5: The mean, standard deviation (±SD) and the coefficient of variation (CV) for 
the inter-day variability for ciclosporin assay standards at 0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, 
and 2 mg/mL 
Conc. 
(mg/mL) 
Day1 
 
Day2 
 
Day3 
 
Day4 
 
Day5 
 
Day6 
 
Mean ±SD CV% 
0.1 0.10 0.09 0.10 0.09 0.10 0.10 0.10 0.001 1.41 
0.2 0.20 0.20 0.21 0.20 0.21 0.20 0.20 0.005 2.45 
0.4 0.38 0.39 0.40 0.39 0.40 0.38 0.39 0.013 3.18 
0.6 0.62 0.61 0.57 0.61 0.57 0.62 0.60 0.020 3.35 
0.8 0.82 0.81 0.82 0.81 0.82 0.82 0.82 0.003 0.33 
1 1.01 1.01 1.02 1.01 1.02 1.01 1.02 0.006 0.59 
1.5 1.51 1.49 1.46 1.49 1.46 1.51 1.49 0.018 1.23 
2 1.97 1.98 2.00 1.98 2.00 1.97 1.98 0.014 0.68 
Inter-day variability was acceptable for ciclosporin across the standard range (< 5%). 
3.7.9 Inaccuracy 
The inaccuracy of the assay was determined by measuring the difference between actual 
(hypothetical) and measured concentration of each ciclosporin calibration standard. The 
concentration difference was then divided by the actual concentration and multiplied by 
100 (Equation 2). 
100
ionconcentrat Actual
ionconcentrat measured-ion concentrat ActualInaccuracy   
Equation 2: Inaccuracy percentage calculations of hypothetical and measured ciclosporin 
concentrations 
The inaccuracy of the method was measured by calculating the difference between actual 
and measured concentration of each ciclosporin calibration standard (Table 3.6). 
  
Chapter 3 Development and validation of a HPLC method for ciclosporin 
    Page 87 of 296 
Table 3.6: Inaccuracy of the assay was < 4% of the true value at standard curve 
concentrations range from 0.1 to 2 mg/mL of ciclosporin 
Conc. 
(mg/mL) 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Average ±SD 
0.1 -32.69 0.19 2.98 0.19 2.98 1.70 -4.10 14 
0.2 -29.27 0.12 5.41 0.12 5.41 1.15 -2.83 13 
0.4 -23.97 0.90 2.38 0.90 2.38 4.66 -2.12 11 
0.6 11.65 1.93 3.75 1.93 3.75 3.38 4.40 4 
0.8 2.24 2.26 3.01 2.26 3.01 2.52 2.55 0 
1 -1.96 1.64 2.94 1.64 2.94 1.96 1.52 2 
1.5 -18.14 0.53 2.05 0.53 2.05 0.69 -2.04 8 
2 10.62 0.61 0.11 0.61 0.11 1.41 2.24 4 
On the first day the inaccuracy of the 3 lowest concentrations was above the acceptable 
level due to an unknown reason. However in the subsequent 6 experiments the inaccuracies 
were within the acceptable range (less than 15%). 
3.7.10 HPLC system carryover 
The system carryover was checked by running blank samples between actual samples. The 
blank sample was checked for the presence of any carried over ciclosporin. Calibration 
standards were also randomised and the calibration curve linearity was then checked in 
order to detect any carryover. 
3.7.11 Statistical analysis and graphic presentation 
Graphic presentations and the statistical analyses were done using Excel 2010 for Windows 
version, 14.0.6112.500 (32-bit) and Minitab version, 16. 
3.7.12 Dissolution extraction recovery 
The recovery was calculated by dividing the actual volume over the total volume and then 
multiplied by the concentration (Equation 3). 
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ionConcentrat
 volumeTotal
 volumeActualRecovery 
 
Equation 3: Recovery calculation of ciclosporin standards 
3.7.13 Stability 
Freeze thaw stability was done for three ciclosporin calibration standards stored at −20C, 
thawed and re-frozen weekly for three weeks. 
This test was to check the stability of ciclosporin standards in stock solutions. Ciclosporin 
standards were stable for the whole period of the experiment. Two different concentrations 
of 0.4 and 0.6 mg from day 2, 4, and 6 were measured (Table 3.7). 
Table 3.7: The average concentration (±SD) and coefficient of variation (CV) of 
ciclosporin stability in stock solution for day 2, 4 and 6 
Conc. (mg/mL) Day 2  Day 4  Day 6  Average ±SD CV% 
0.4 0.39 0.39 0.38 0.39 0.009 2.22 
0.6 0.61 0.61 0.62 0.61 0.005 0.82 
 
Table 3.8: The inaccuracy of ciclosporin stability in stock solution for day 2, 4 and 6 
Inaccuracy 
(mg/mL) 
Day 2 Day 4 Day 6 Average ±SD 
0.4 0.90 0.90 4.66 2.15 2.17 
0.6 1.93 1.93 3.38 2.41 0.84 
The ciclosporin standards were stable for freeze-thaw cycles. Average measured 
concentration for 3 cycles of 0.4 and 0.6 mg of ciclosporin was 0.39 and 0.61 respectively 
(Table 3.7). The CV% of 0.4 and 0.6 mg of ciclosporin standards were less than 3%. 
Inaccuracy of measured concentration was less than ± 3% (Table 3.8). 
 
Chapter 4 Application of the HPLC method  
    Page 89 of 296 
Chapter 4. Application of the HPLC method to the 
measurement of ciclosporin from different countries 
4.1 Overall description of the method 
This study describes the development, validation and application of a simple HPLC method 
for the determination of ciclosporin. Seven ciclosporin products were obtained from 
commercial pharmacies and hospitals for inclusion in this study. 
Ciclosporin capsules were dissolved in dissolution tester. Samples were obtained at 
different time intervals. The contents of the dissolved sample were separated by injecting 
20 µL of the samples into the HPLC system. The column was held at 50 ± 0.3°C. The λmax 
for ciclosporin at 210 nm.  
4.2 Results of HPLC method for ciclosporin capsules (Test A) 
4.2.1 Dissolution test for ciclosporin 
The capsule rupture was determined by visual observation of the capsule shell and/or by 
the release of capsule content. Rupturing time was determined for each capsule by using a 
stopwatch. The results from the dissolution test showed that the average rupture times for 
ciclosporin capsules of generic C, brand T, brand J, brand E, generic I, brand P and brand 
S were (mean ± SD) 1.56 ± 0.02, 5.07 ± 0.02, 5.11 ± 0.01, 5.29 ± 0.02, 5.34 ± 0.03, 5.37 ± 
0.02 and 5.43 ± 0.02 min, respectively, (n = 4). A sample of medium was tested using 
HPLC before putting the capsule into the vessel to insure no ciclosporin contamination of 
the medium. The chromatogram shows that there was no ciclosporin peak (Figure 4.1) and 
confirms the absence of ciclosporin in the medium. In this study all the capsules met the 
USP requirements, rupturing within 15 min (Table 4.1). 
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Figure 4.1: Chromatogram of medium sample showing no ciclosporin contamination of 
the dissolution tester  
Table 4.1: Average rupture time for ciclosporin capsules (n = 4) 
 
Figure 4.2, shows a typical chromatogram of ciclosporin concentrations in 5 different 
capsules (Brands S, T, and P, Generics I, and C) which were detected at the same 
retention time. Although, standard ciclosporin gives one peak, while in some tested 
capsules more peaks can be seen. 
Ciclosporin capsule  Average rupture time (min) ± SD 
Generic C 1.56 ± 0.02 
Brand T 5.07 ± 0.02 
Brand J 5.11 ± 0.01 
Brand E 5.29 ± 0.02 
Generic I 5.34 ± 0.03 
Brand P 5.37 ± 0.02 
Brand S 5.43 ± 0.02 
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Figure 4.2: A typical overlaid chromatogram showing the varying ciclosporin concentration in 5 different capsules (Brands S, T, and P, 
Generics I, and C) 
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4.2.2 Drug recovery (from capsules) 
This was done in order to confirm that the dissolution test successfully recovered all the 
capsule content after 60 and 90 min. 
Maximal recovery (99 ± 0.4%) was after 60 min. Recovery after 90 min was 100 ± 0.5% 
(Table 4.2). 
Table 4.2: The average recovery percentage of ciclosporin mass amount after 60 and 90 
min of the dissolution test (n = 4) 
Recovery Average 
Ciclosporin 60 min 90 min 
Brand T 99 ± 0.04 % 100 ± 0.05 % 
Brand P 91 ± 0.03 % 90 ± 0.03 % 
Brand S 88 ± 0.04 % 90 ± 0.07 % 
Generic C 86 ± 0.05 % 91 ± 0.01 % 
Brand J 84 ± 0.02 % 83 ± 0.05 % 
Brand E 76 ± 0.05 % 81 ± 0.04 % 
Generic I 69 ± 0.04 % 69 ± 0.08% 
4.2.3 Final results of Test A  
This method was successfully applied to measure the actual concentration in each 
ciclosporin product using HPLC analysis. Sampling time was done on six different 
intervals in order to check for ciclosporin release from capsules. All brands (T, S, E, J, P) 
and one generic (C) showed more than 80% of labelled amount in ciclosporin capsules 
after 90 min of the dissolution test giving 100 ± 0.05, 90 ± 0.07, 81 ± 0.04, 83 ± 0.05, 90 
± 0.03, and 91 ± 0.01 % (±SD), respectively. One generic (I), showed less than the 
minimum percentage of labelled amount 69 ± 0.08% (Figure 4.3). Relative to the brand 
(T), statistical analysis showed significant differences (p<0.0001) of the mean percentage 
content between brand and generic, the 95% confidence interval (CI) range for the brands 
(S, E, J, P) were (80.1-101.8), (72.2-91.8), (73.4-93.3), (80.2-101.9), respectively, and 
(80.3-102.1), (61.3-77.9), for the generic (C) and (I), respectively (Table 4.4). 
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Table 4.3: Average percentage content of ciclosporin in capsules (Test A) 
Drug 
Name 
Country of 
Origin 
Average 
weight 
(g), n = 4 
Sampling time (min) and Average content %, n = 4 
5 min 10 min 15min 30 min 60 min 90 min 
Neoral®* Turkey 1.50 6.7% 55.8% 98.3% 98.6% 98.8% 100.0% 
Neoral®* Saudi 1.51 0.4% 57.8% 85.0% 91.9% 88.4% 90.4% 
Neoral® Jordan 1.67 3.2% 65.3% 77.6% 80.5% 84.2% 82.8% 
Neoral® Egypt 1.69 3.1% 13.5% 55.7% 74.8% 76.2% 81.4% 
Neoral®* Pakistan 1.50 6.9% 79.2% 93.3% 89.3% 91.3% 90.4% 
Generic C* Colombia 1.32 85.0% 94.7% 88.0% 89.5% 86.1% 90.5% 
Generic I* India 1.60 4.6% 47.8% 72.0% 65.7% 68.9% 69.3% 
*Ciclosporin 100 mg capsules. Jordan and Egypt capsules contain 50 mg 
 
Table 4.3 shows the average percentage of ciclosporin mass amount at different time 
intervals, reference capsule (Turkey) showed 100% mass amount after 90 min, (n = 4) 
Figure 4.3: Percentage of dissolved ciclosporin in brands and generics 
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Table 4.4: The average percentage of ciclosporin mass amount, standard deviation, 
coefficient of variation and 95% CI based on reference capsule (T) 100% mass amount, 
(n = 4) 
Ciclosporin 
capsule 
N % of mass amount 
at 90 min (mg/mL) 
± SD CV (%) 95% confidence 
interval 
Generic I (100 mg) 4 69.3 7.6 11 (61.3-77.9) 
Brand E (50 mg) 4 81.4 3.6 4 (72.2- 91.8) 
Brand J (50 mg) 4 82.8 4.7 6 (73.4-93.3) 
Brand S (100 mg) 4 90.4 6.9 8 (80.1-101.8) 
Brand P (100 mg) 4 90.4 3.3 4 (80.2-101.9) 
Generic C (100 mg) 4 90.5 1.2 1 (80.3-102.1) 
Table 4.4 shows that ciclosporin has variable mass labelled amount compared to the 
reference capsule. Even with brand capsules, ciclosporin showed variability. One generic 
failed to meet the minimum requirement, indicating availability of substandard and/or 
counterfeit ciclosporin in the market. 
4.3 Dissolution test for ciclosporin Test B 
Same method (Test A) was applied to obtain more precise results with the following 
modifications: Eight ciclosporin products were included in this study, tested capsules to (n 
= 5), peak area measurement adjustment of HPLC system, area calculated as (mV.s) instead 
of (mV.min), and the sampling times increased up to 120 min to included two additional 
points. 
The results from the dissolution test showed that the rupture times for ciclosporin capsules 
of generic (Col), brand (Egy), generic (Ir), brand (Jor), generic (M), brand (Pak), brand 
(Sa) and brand (TK), showed that they all met the USP requirements, rupturing within 15 
min. 
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4.3.1 Standard curve and linearity  
Figure 4.4 shows a typical standard curve for ciclosporin. Coefficient of correlation 
ranged between 0.997 and 1. The mean slope was 55.5  0.4 mV/mg for ciclosporin (n = 
8). 
Figure 4.4: Standard curve for ciclosporin standards in mobile phase showing linear 
calibration line r2 = 1 (Test B) 
4.3.2 Sensitivity 
On eight different days, the mean concentration measured of the lower standard (25 mg/L) 
was 22.3 ± 0.97 mg/L with a CV of 4.4%., and for the highest standard (500 mg/L) it was 
500.4 ± 2.6 mg/L with a CV of 0.5% (Table 4.5). 
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Table 4.5: Sensitivity test of ciclosporin standard showing the concentration of low and 
high standards on different days (Test B) 
Days Measured concentration of lowest 
standard (25 mg/L) 
Measured concentration of highest 
standard (500 mg/L) 
1 23.8 496.8 
2 21.6 503.0 
3 23.0 498.1 
4 21.4 501.2 
5 23.3 499.2 
6 22.3 499.2 
7 22.0 501.3 
8 21.0 504.6 
Average 22.3 500.4 
±SD 1.0 2.6 
4.3.3 Specificity 
The method was specific. There were no significant interfering peaks before, between and 
after each run. 
4.3.4 Precision 
4.3.4.1 Intra-day variability 
Ciclosporin standards at 25, 50, 100, 200, 400, and 500 mg/L were injected into the HPLC 
system on the same day. Table 4.6 shows the actual and measured concentration for these 
samples, average, standard deviation, and the correlation of variation percentage. 
Table 4.6: The average, standard deviation (±SD) and the coefficient of variation (CV) 
for the intra-day variability for ciclosporin assay standard at 25, 50, 100, 200, 400, and 
500 mg/L 
Concentration 
(mg/L) 
Concentration 
(mg/L) 
Concentration 
(mg/L) 
Mean ±SD CV% intra-
day 
25 21.4 21.0 21.2 0.3 1.4 
50 49.3 48.9 49.1 0.3 0.6 
100 93.5 93.8 93.6 0.2 0.2 
200 202.6 203.2 202.9 0.4 0.2 
400 399.1 394.6 396.9 3.2 0.8 
500 501.2 504.6 502.9 2.4 0.5 
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Intra-day variability was acceptable for ciclosporin across the standard range (<2%) 
4.3.4.2 Inter-day variability 
Ciclosporin standards at 25, 50, 100, 200, 400 and 500 mg/L were injected into the HPLC 
system. Table 4.7 shows the hypothetical and measured concentration by HPLC analysis 
for these samples over eight different days along with the average, standard deviation, and 
the coefficient of variation percentage. 
Table 4.7: The average, standard deviation (±SD) and the coefficient of variation (CV) 
for the inter-day variability for ciclosporin assay standards at 25, 50, 100, 200, 400, and 
500 mg/L 
Conc. 
(mg/L) 
Day1 
 
Day2 
 
Day3 
 
Day4 
 
Day5 
 
Day6 
 
Day7 
 
Day8 
 
Mean ±SD CV% 
25 23.8 21.6 23.0 21.4 23.3 22.3 22.0 21.0 22.3 1.0 4.4 
50 52.4 49.2 50.9 49.3 49.7 49.9 49.8 48.9 50.0 1.2 2.3 
100 119.9 120.6 119.6 93.5 119.4 118.2 119.1 93.8 113.0 12.0 10.6 
200 198.7 199.0 198.1 202.6 198.3 199.7 200.8 203.2 200.0 1.9 1.0 
400 399.5 391.9 398.4 399.1 397.1 396.8 393.4 394.6 396.3 2.8 0.7 
500 496.8 503.0 498.1 501.2 499.2 499.2 501.3 504.6 500.4 2.6 0.5 
Inter-day variability was acceptable for ciclosporin across the standard range (<11%) 
4.3.5 Inaccuracy 
The inaccuracy of the method was measured by calculating the difference between the 
actual and measured concentration of each ciclosporin calibration standard (Table 4.8) 
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Table 4.8: Inaccuracy of the assay was < 13% of the true value at standard curve 
concentrations ranging from 25 to 500 mg/L of ciclosporin 
Conc. 
(mg/L) 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Average ±SD 
25 -4.94 -13.65 -8.05 -14.32 -6.91 -10.67 -12.18 -16.00 -10.84 4 
50 4.87 -1.64 1.86 -1.39 -0.59 -0.24 -0.46 -2.22 0.02 2 
100 19.95 20.60 19.58 -6.54 19.40 18.22 19.14 -6.21 13.02 12 
200 -0.67 -0.48 -0.94 1.30 -0.83 -0.16 0.39 1.59 0.02 1 
400 -0.13 -2.02 -0.41 -0.21 -0.73 -0.81 -1.66 -1.36 -0.92 1 
500 -0.64 0.59 -0.37 0.24 -0.15 -0.16 0.27 0.93 0.09 1 
4.3.6 Drug recovery from capsules 
This was done in order to confirm that the dissolution test successfully recovered all the 
capsule content after 90 and 120 min. Maximal recovery (100 ± 0.03%) was after 90 min. 
Recovery after 120 min was 100 ± 0.01% (Table 4.9). 
Table 4.9: The average recovery percentage of ciclosporin mass amount after 90 and 120 
min of the dissolution test (n = 5) 
Recovery Average 
Ciclosporin 90 min 120 min 
Brand TK 100 ± 0.03 % 100 ± 0.01 % 
Brand Pak 94 ± 0.08 % 93 ± 0.09 % 
Brand Sa 99 ± 0.02 % 99 ± 0.01 % 
Generic Col 85 ± 0.02 % 83 ± 0.01 % 
Brand Jor 84 ± 0.09 % 84 ± 0.10 % 
Brand Egy 92 ± 0.01 % 91 ± 0.01 % 
Generic Ir 97 ± 0.02 % 95 ± 0.02% 
Generic M 54 ± 0.10 % 56 ± 0.08% 
4.3.7 Stability 
This test was done to check the stability of ciclosporin standards in stock solutions. 
Ciclosporin standards were stable for the whole period of the experiment. Two different 
concentrations of 50 and 200 mg/L from day 2, 4, and 6 were measured (Table 4.10). 
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The ciclosporin standards were stable for freeze-thaw cycles. The average measured 
concentration for 3 cycles of 50 and 200 mg/L of ciclosporin was 49.45 and 200.44 mg/mL, 
respectively. The CV% of 50 and 200 mg/L ciclosporin standards was less than 1%. 
Inaccuracy of the measured concentration was less than ±2%. 
Table 4.10: The average concentration (±SD) and coefficient of variation (CV) 
ciclosporin stability in stock solution for day 2, 4, and 6 
Conc. (mg/L) Day 2 Day 4 Day 6 Average ±SD CV% 
50 49.18 49.30 49.88 49.45 0.37 0.75 
200 199.04 202.60 199.69 200.44 1.90 0.95 
4.3.8 Final results of Test B 
The same method was successfully applied to measure the actual concentration in each 
ciclosporin product using HPLC analysis. Sampling time was done on nine different 
intervals in order to check for ciclosporin release from capsules. All brands (TK, Sa, Egy, 
Jor, Pak) and two generics (Col, Ir) showed more than 80% of labelled amount in 
ciclosporin capsules after 90 min of the dissolution test giving 100 ± 0.03, 99 ± 0.02, 92 ± 
0.01, 84 ± 0.09, 94 ± 0.08, 85 ± 0.02 % and 97 ± 0.02 (±SD), respectively. One generic 
(M), showed less than the minimum percentage of labelled amount 54 ± 0.10% (Figure 
4.5). Table 4.11 shows the average percentage of ciclosporin mass amount at different time 
intervals, reference capsule (Turkey) showed 100% mass amount after 90 min, (n = 5). 
Relative to the brand (TK), statistical analysis showed significant differences (p<0.0001) 
of the mean percentage content between brand and generic, the 95% CI range for the brands 
(Sa, Egy, Jor, Pak) were (97-102), (90-93), (72-95), and (85-103), respectively, and (83-
87), (94-99), (41-67) for the generics (Col, Ir, M) respectively (Table 4.12). 
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Table 4.11: Average percentage content of ciclosporin in capsules (Test B) 
Drug 
name 
Country 
of origin 
Average 
weight 
(g), n = 5 
Sampling time (min) and average content %, n = 5 
5 10 15 20 30 45 60 90 120 
Neoral®* Turkey 1.50 4
% 
60
% 
81
% 
93
% 
97
% 
98
% 
99
% 
100
% 
100
% 
Neoral®* Saudi 1.50 2
% 
53
% 
71
% 
88
% 
92
% 
96
% 
97
% 
99
% 
99
% 
Neoral® Jordan 1.68 6
% 
68
% 
79
% 
80
% 
80
% 
79
% 
83
% 
84
% 
84
% 
Neoral® Egypt 1.68 6
% 
14
% 
67
% 
80
% 
84
% 
88
% 
89
% 
92
% 
91
% 
Neoral®* Pakistan 1.49 2
% 
72
% 
86
% 
89
% 
93
% 
95
% 
95
% 
94
% 
93
% 
Generic 
Col* 
Colombia 1.32 81
% 
87
% 
88
% 
87
% 
88
% 
87
% 
87
% 
85
% 
83
% 
Generic 
Ir* Iran 1.55 
3
% 
44
% 
72
% 
83
% 
93
% 
98
% 
99
% 
97
% 
95
% 
Generic 
M* Morocco 1.61 
0
% 
33
% 
51
% 
55
% 
55
% 
57
% 
58
% 
54
% 
56
% 
*Ciclosporin 100 mg capsules. Jordan and Egypt capsules contain 50 mg 
Figure 4.5: Percentage dissolved ciclosporin in brand and generics (n = 5) 
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Table 4.12: The average percentage of ciclosporin mass amount, standard deviation, 
coefficient of variation and 95% CI based on reference capsule (TK) 100% mass amount, 
(n = 5) 
Drug  N % of mass 
amount at 90 
min (mg/L) 
± SD CV (%) 95% Confidence 
Interval 
Brand Egy 5 92 1.3 1 (90- 93) 
Brand Jor 5 84 9.1 11 (72-95) 
Brand Pak 5 94 7.5 8 (85-103) 
Brand Sa 5 99 1.9 2 (97-102) 
Generic Col 5 85 1.9 2 (83-87) 
Generic Ir 5 97 2.1 2 (94-99) 
Generic M 5 54 10.0 20 (41-67) 
4.4 UHPLC-MS detection of impurities in ciclosporin capsules 
generic (Col) 
The chemical contents of ciclosporin capsules (Generic Col) were studied using an 
untargeted metabolomic UHPLC-MS-based approach. Then, all the chemical contents of 
generic (Col) capsules were compared to a reference capsule, brand (TK), (reference 
product). A representative TIC is shown in figure 4.6 for the reference compund TK. In 
particular, one impurity was detected at 8 min with high ciclosporin/impurity peak ratio 
suggesting a clean product. In contrast, figure 4.7 shows poor prodcut with multiple 
impurities at 2, 3, 4, 9 and 11 min with very small ciclospotin/impurities peak ratios 
indicating a poor quality product. In addition, one of the impurities at 9.8 min had a putative 
identity of N-(8-Aminooctyl)-N5-(diaminomethylene)-L-ornithinamide, an amino acid 
which could be related to ciclosporin polypeptide. 
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Figure 4.6: The LC-MS total ion chromatogram (TIC) of an example of a relatively clean 
product with a clear ciclosporin peak at 12 min and small impurity at 8 min 
 
Figure 4.7: The LC-MS TIC of an example of a poor product with small peak of 
ciclosporin at 12 min and high impurity at 9 min 
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Figure 4.8 shows clear separation between the samples derived from the generic product 
(generic Col) compared to the reference product (TK) using principal component analysis 
(PCA). PCA is an unsupervised multivariate analysis aimed at reducing high-dimensional 
data into fewer dimensions called principal components (PCs). Each dimension is called a 
PC, which represents a linear combination of original variables. The first PC is the 
component that accounts for the highest variability in the data. Then, each subsequent PC 
accounts for the remaining data variability. 
 
Figure 4.8: Principal component analysis (PCA) of brand (TK) and generic (Col) 
showing sample clustering. There was clear separation indicating these capsules have a 
different chemical content 
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In Figure 4.8, generic (Col) was compared to the reference (TK) using PC1 versus PC2. 
The five capsule samples derived from generic (Col) clustered together and circled with 
red line indicating reproducibility between different capsules except for capsule no. 4 
which clustered away from main cluster indicating a difference in chemical content from 
other generic (Col) capsules. On the other hand, the five reference brand (TK) capsules 
clustered in a smaller cluster compared to (Col) cluster indicating a more homogenous 
content and better reproducibility between capsules.  
Figure 4.9, shows a heatmap and hierarchical clustering for the top 200 metabolomic 
features that were variably expressed between brand (TK) and generic (Col). The heatmap 
shows clearly that the top features belong to two different clusters. Some features were 
present in brand (TK) and absent in generic (Col), whereas others were present in generic 
(Col) and absent in brand (TK). This confirms the different chemical contents of the two 
compared drug formulations. 
 
Figure 4.9: Heatmap of brand (TK) and generic (Col) showing hierarchical clustering of 
top metabolomic features that were variably expressed between brand TK and generic 
Col. 
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Table 4.13 shows the preliminary identifications for the impurities found in generic (Col) 
compared to brand (TK). A 261 fold difference in sorbitol concentrations was detected in 
the generic capsules (p<0.0001). 
In addition, contamination with zizyphine A (a plant extract “Ziziphus jujube, Ziziphus 
vulgaris”), delcorine (an alkaloid, derived during amination reaction in cyclosporin A 
synthesis) and 2-Oxooctadecanoic acid (an inactive ingredient derived from an oil source) 
(Kyoto Encyclopedia of Genes and Genomes, 2015) was found. Of note, zizyphine A, is a 
cyclopeptide product of the central Asian plant Ziziphus oenoplia. Although generic (Col) 
is a product from South America, however, it is manufactured in central Asia. This specific 
contaminant confirms the manufacturer origin of the generic (Col) capsules (p<0.001), (see 
appendix 2 for full list of chemical contaminants detected in all generic capsules compared 
to brand TK).  
Table 4.13: Preliminary MS identification of impurities found in generic Col versus 
brand TK in positive and negative mode 
MS-
Mode 
M/Z 
determined 
monoisotopic 
mass 
Theoretical 
mass* 
Putative ID Fold 
change 
P -value Possibilities 
Pos. 612.3741 611.3683 Zizyphine A 3409 6.95E-10 Plant 
contamination 
Pos. 480.2930 479.2883 Delcorine 1077 3.49E-09 Alkaloid 
derived by 
amination 
reaction 
during CycA 
synthesis 
Neg. 181.0699 182.0790 Sorbitol 261 8.88E-07 Inactive 
ingredient 
Neg. 297.2422 298.2508 2-Oxooctadecanoic 
acid 
26 0.00135 Inactive 
ingredient  
*Theoretical mass data obtained from METLIN: Metabolite Search (https://metlin.scripps.edu/metabo_advanced.php). 
Ziziphus is a natural herb used for many aliments and enhancements. Ziziphus produces 
cyclopeptide alkaloids known as ziziphines and has been used in Chinese herbal medicine 
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and Ayurvedic Indian medicine for many years. It is known to help with relieving stress, 
purifying the blood, improving the immune system, treating bronchitis, anaemia, 
irritability, diarrhoea, fatigue, ulcers and even the leaves are used to treat chickenpox, 
smallpox, measles and many more diseases. It is also used as a weight gainer and to 
increase muscular strength and endurance. It is often administered when patients 
experience restless sleeping behaviours, anxiety, reduced memory (forgetfulness) and 
trouble concentrating (Burton, 2008). Some external uses of the bark can be used to make 
an eyewash to reduce inflammation (Chen et al., 2015). 
4.5 Conclusions 
This study represents a simple, rapid, specific and sensitive HPLC method for the 
determination of an immunosuppressive drug ciclosporin. This method was used 
successfully to determine of ciclosporin mass amount in brand versus generic capsules. 
This study showed that some ciclosporin capsules contain less than the labelled amount. 
According to the USP a minimum of 80% of labelled amount of ciclosporin should 
dissolved in 90 min (USP 35, 2012). In this study the ciclosporin capsules from India and 
Morocco failed to achieve this. Even within the same brand, but from different countries, 
there were differences in the average content within the acceptable limits. Some ciclosporin 
products may contain less than the dose required to achieve a therapeutic effect. This may 
be harmful for patients especially those using NTIDs such as ciclosporin. Irreversible 
kidney damage could occur at high doses of this drug (Johnston & Holt, 2001) and acute 
rejection at the lower therapeutic doses. Overall, switching among and between brand and 
generic ciclosporin can lead to undesirable effects. 
Based on the results from the impurity test, we conclude that some of the ciclosporin 
preparations were found to be contaminated with plant products. This indicates problems 
with ciclosporin pharmaceutical production, and these could lead to harmful clinical effect 
on patients. 
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Chapter 5. Development and application of a UHPLC-
MS/MS method for azithromycin 
5.1 Introduction 
Late in 2013, the FDA launched a warning about a possible fatal side effect of 
azithromycin. This medication may cause abnormal changes in the electrical activity of the 
heart. Azithromycin is a macrolide antibiotic belonging to the azalide group. It is used to 
treat some bacterial infections such as pneumonia, gonorrhoea, sinus and skin. Both brand 
and generics of azithromycin are available worldwide in different dosage forms. 
5.2 Azithromycin 
Azithromycin (Sumamed, Zithromax, Zmax) was discovered in 1980 in Croatia by Pliva 
pharmaceutical company. In 2010, it had become one of the most prescribed antibiotics in 
United States clinics (Bach and Žubrinić, 2013). 
Chemically, azithromycin is described as: (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-
[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-
trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-
3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one (Figure 5.1). 
 
Figure 5.1: Azithromycin chemical structure (National Center for Biotechnology 
Information, 2005) 
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5.2.1 Indications 
Azithromycin is a widely used antibiotic for treating bacterial infections, caused by 
bacteria like Streptococcus pneumonia, Haemophilus influenza, Chlamydia pneumonia, 
Streptococcus pyogenes, Staphylococcus aureus, Neisseria gonorrhoea, which cause 
respiratory, sinusitis, pharyngitis/tonsillitis, skin and urethritis infections (UpToDate, 
2015a). 
To ensure effective treatment use of azithromycin, and reduce bacterial resistance, it should 
only be used when there is a clear indication of a susceptible bacteria or organism (Food 
and Drug Administration, 2013c). 
5.2.2 Mechanism of action 
Azithromycin has a bacteriostatic effect. Its inhibits bacterial protein synthesis by binding 
to the 50S subunit of bacterial ribosomes (Rang et al., 2007). 
5.2.3 Absorption 
Azithromycin bioavailability is 38%. In a two-way crossover study where 12 healthy test 
patients were administered a single 500 mg dose of azithromycin (two 250 mg tablets) 
with or without a high fat meal, food consumption indicated an increase in Cmax by 23% 
but had no impact on AUC. With different formulation, azithromycin suspension was 
given (to test patients) under fed conditions to 28 healthy subjects, Cmax increased by 
56% and there was no change to AUC. Azithromycin Cmax decreased by 24% when 
administered with an antacid containing aluminium and magnesium hydroxide, while the 
AUC did not change (Food and Drug Administration, 2013c). 
5.2.4 Distribution 
After oral administration, distribution of azithromycin in the body may reach up to 31.1 
L/kg. It binds to serum protein in a range from 51% at 0.02 µg/mL to 7% at 2 µg/mL. The 
concentration of azithromycin is higher in tissues compared to plasma or serum and 
penetration into the CSF is poor (UpToDate, 2015a). 
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5.2.5 Elimination 
Azithromycin is excreted mainly through the bile as unchanged drug. Approximately 6% 
of the administered dose appears as unchanged drug in urine (UpToDate, 2015a). 
5.2.6 Adverse events (AE) 
The common AE of azithromycin include GI disturbances such as diarrhoea, loose stools, 
abdominal complaints of pain, spasm, flatulence, nausea and vomiting. A reversible 
increase of some liver enzymes (transaminases, alkaline phosphate) may occur. In blood, 
neutropenia was noted in some cases. Hypersensitivity reactions of skin and mucosa were 
rare. 
5.2.7 Precautions 
Azithromycin should be taken with caution by hepatic disease patients because it is mainly 
excreted by the liver. There are limited data for patients with renal impairment and 
azithromycin should be taken with caution. Macrolides have been associated with 
prolonged QT interval and may cause cardiac arrhythmia, azithromycin treatment should 
be closely monitored (Lu et al., 2015). Using azithromycin without indication may increase 
bacterial resistance. There is not enough data about the use of azithromycin and 
carcinogenesis. There are no confirmed data relating to mutagenic risks and infertility by 
using azithromycin. There are not enough studies of the effects of using azithromycin in 
pregnant women. Animal studies showed that there was no direct effect on the foetus and 
azithromycin is classified under pregnancy category B. Azithromycin should only be 
administered for pregnant women if a clear requirement is determined. For lactating 
mothers azithromycin should be used with caution, as it has not been determined whether 
azithromycin is excreted in milk (Food and Drug Administration, 2013c). 
5.2.8 Contraindications 
Azithromycin is contraindicated in those with hypersensitivity to azithromycin, other 
macrolide antibiotics, or any component of the formulation or who have a history of 
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cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use 
(UpToDate, 2015a). 
5.3 QT-interval 
The QT interval is the time between depolarization to repolarization of the heart. The QT 
interval is around 400 ms. Prolongation of the QT interval increases the risk of cardiac 
arrhythmia which can be fatal (Food and Drug Administration, 2013b, Parnham et al., 
2014). The FDA launched a safety announcement about the irregular heart rhythm 
associated with azithromycin treatment, especially with cardiac disease patients (Food and 
Drug Administration, 2013b). 
5.4 Pharmacodynamics and pharmacokinetics 
After oral administration, azithromycin is rapidly absorbed. It distributes in skin, lung, and 
tonsils. Azithromycin is mainly metabolised by the liver. Additional cation should be 
considered when treating patients with impaired liver function (Food and Drug 
Administration, 2013c). The half-life of elimination after oral administration is 68-72 h 
allowing single dose treatment. Azithromycin is excreted mainly through biliary excretion 
(UpToDate, 2015a). 
5.5 Collection of drug samples (azithromycin) 
Nineteen azithromycin products were obtained from hospitals and commercial pharmacies 
in different countries for inclusion in this study. Four brand samples were manufactured 
by Pfizer, U.S.A. (Brands A, B, C, and D). Generics (A, B, C, D, E, F, G, H, I, J, K, L, M, 
N, and O) were manufactured in Africa, Asia, and Europe (Table 5.1). 
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Table 5.1: Doses and sources of azithromycin tablets 
Drug, dose & code Obtained from Origin 
Azithromycin 500 mg (Brand A) Commercial pharmacy, USA 
Same manufacturer with 
different batch numbers 
Azithromycin 500 mg (Brand B) Commercial pharmacy, USA 
Azithromycin 500 mg (Brand C) Commercial pharmacy, USA 
Azithromycin 500 mg (Brand D) Commercial pharmacy, USA 
Azithromycin 500 mg (Generic A) 
Commercial pharmacy, 
Morocco 
Same manufacturer with 
different batch numbers  
Azithromycin 500 mg (Generic B) 
Commercial pharmacy, 
Morocco 
Azithromycin 500 mg (Generic C) 
Commercial pharmacy, 
Morocco 
Azithromycin 500 mg (Generic D) 
Commercial pharmacy, 
Morocco 
Same manufacturer with 
different batch numbers 
 
Azithromycin 500 mg (Generic E) 
Commercial pharmacy, 
Morocco 
Azithromycin 500 mg (Generic F) 
Commercial pharmacy, 
Morocco 
Azithromycin 500 mg (Generic G) Commercial pharmacy, India 
Same manufacturer with 
different batch numbers 
Azithromycin 500 mg (Generic H) Commercial pharmacy, India 
Azithromycin 500 mg (Generic I) Commercial pharmacy, India 
Azithromycin 500 mg (Generic J) Commercial pharmacy, Egypt Same manufacturer with 
different batch numbers Azithromycin 500 mg (Generic K) Commercial pharmacy, Egypt 
Azithromycin 500 mg (Generic L) Commercial pharmacy, Jordan Same manufacturer with 
different batch numbers Azithromycin 500 mg (Generic M) Commercial pharmacy, Jordan 
Azithromycin 500 mg (Generic N) Commercial pharmacy, India - 
Azithromycin 500 mg (Generic O) 
Hospital Pharmacy, United 
Kingdom 
- 
5.6 Extraction by dissolution (for azithromycin) 
A dissolution method to analyse azithromycin tablets was obtained from the FDA and US 
Pharmacopeia. The dissolution test was carried out under the following conditions: Temp: 
37.5°C ± 0.5, 900 mL 0.1 M phosphate buffer (pH 6.0) was used as a medium, the paddle 
apparatus (Apparatus 2): 75 rpm, sampling time at (5, 10, 20, 30, 45, and 60 min), with 5 
mL volume for each sample. The samples were filtered using 20 µm filters. 
There were noticeable differences between brand A and generic A azithromycin tablets 
specifically in shape (Figure 5.2). 
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Figure 5.2: The differences in shape between brand A and generic A azithromycin. 
During the dissolution test of generic products (D, E, F), they showed different dissolution 
behaviours compared to the branded counterpart. There was noticeable un-dissolved 
residue instead of a cloudy solution (Figure 5.3). 
 
Figure 5.3: Differences in dissolution behaviour between brand A and generic E showing 
undissolved residue after 30 min. 
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Moreover, some tablets did not dissolve completely after 30 min (Figure 5.4). 
 
Figure 5.4: Differences in dissolution behaviour, showing undissolved tablet (generic D) 
after 30 min. 
5.7 LC-MS/MS experimental method validation 
5.7.1 Optimisation of flow rate 
Different flow rates were used to obtain the best resolution and peak shape for azithromycin 
and its internal standard (roxithromycin). 
a) 30 µL/min with 0.1% FA, A: 90 - 5% gradient (Figure 5.5) 
b) 30 µL/min without 0.1% FA, A: 90 - 5% gradient (Figure 5.6) 
c) 30 µL/min + isocratic 50% A/50% B and without 0.1 %FA (Figure 5.7) 
d) 40 µL/min with 0.1% FA, A: 90 - 5% gradient (Figure 5.8) 
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Figure 5.5: Chromatogram showing good detection of azithromycin and IS at 30 µL/min 
flow rate, with 0.1% FA, A: 90 -5% gradient 
 
Figure 5.6: Chromatogram showing no detection of azithromycin and IS at 30 µL/min 
flow rate, with 0 % FA, A: 90 -5% gradient  
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Figure 5.7: Chromatogram showing IS detection and no azithromycin detection at 30 
µL/min flow rate, with 0 % FA, isocratic 50% solution A/50% solution B 
 
Figure 5.8: Chromatogram showing detection of azithromycin and IS with peak tailing at 
40 µL/min flow rate, with 0.1% FA, A: 90 - 5% gradient 
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The best resolution was found at 30 µL/min in the presence of 0.1% FA. In absence of FA, 
azithromycin was not detectable indicating that FA is essential for azithromycin ionisation. 
5.7.2 Preparation of stock, calibration solutions and control samples 
Azithromycin and roxithromycin stock solution (10 mg/mL) was prepared in acetonitrile 
and stored at 4ºC. The azithromycin calibration standards were freshly prepared at the time 
of the experiment. Five concentrations of azithromycin (0.01, 0.03 0.1, 0.3, and 1 µg/mL) 
were prepared in dissolution buffer containing 1 µg/mL roxithromycin. 
5.7.3 Calibration and linearity 
Calibration standards (0.001–1 µg/mL) were injected into the LC-MS/MS system. The 
integrated peak areas of azithromycin and internal standard (roxithromycin) were recorded. 
Linear regression of the standards was done using Microsoft Excel 2010, by plotting the 
peak area ratio of azithromycin divided by roxithromycin against the azithromycin 
concentration of the standards. The linearity was checked by calculating r2 value using 
least-square linear regression analysis. 
Figure 5.9 shows a typical standard curve for azithromycin. Coefficient of correlation was 
0.996. The mean slope was 0.2758 ± 0.0044 for azithromycin. 
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Figure 5.9: Standard curve for azithromycin standards in extraction buffer showing linear 
calibration line r2 = 1 using the UHPLC-MS/MS system 
5.7.4 Method sensitivity 
The lower limit of detection (LLOD) of azithromycin is the lowest concentration with a 
peak area ratio three times higher than the baseline noise. The lower limit of quantification 
(LLOQ) was determined as the lowest concentration of azithromycin with a peak area ratio 
five times higher than the baseline noise with imprecision <10% and inaccuracy <15% 
(Table 5.2). 
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Table 5.2: Sensitivity test of azithromycin standard showing the concentration of LLOD 
and LLOQ on different days 
The LLOD was found to be 0.001 µg/mL with a CV% of 24% and inaccuracy of 37%. As 
these values were not acceptable, this calibration level was removed from the standard 
curve. The LLOQ was found to be 0.01 µg/mL with a CV% of 6.2% and inaccuracy of 
10.6%. 
5.7.5 Method specificity 
The method specificity was investigated by injecting blank extraction buffer before the 
start of each run. The blank standards were used to control for any interfering peaks that 
elute at the same retention time as azithromycin and roxithromycin method was specific. 
There were no significant interfering peaks before, between and after each run (Figure 
5.10). 
Days LLOD (0.001 µg/mL) LLOQ (0.01 µg/mL) 
1 0.0007 0.01 
2 0.0013 0.01 
3 0.0013 0.01 
4 0.0016 0.01 
5 0.0013 0.01 
Average 0.0012 0.01 
±SD 0.0004 0.0005 
CV% 24.70% 6.21% 
Inaccuracy 36.8% 10.6% 
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Figure 5.10: Example chromatogram to show there are no interfering peaks before 
running azithromycin samples 
5.7.1 Imprecision 
5.7.1.1 Inter-day variability 
Quality control samples (QC) of 0.05 and 0.5 µg/mL were prepared by dilution of 
azithromycin stock in extraction buffer solution. 
Imprecision was determined by calculating the coefficient of variation (CV %) of the 
quality control (QC) samples using the following equation. 
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100
ionconcentrat QC  theof average
ionconcentrat QC ofdeviation  standard% CV   
Equation 4: Calculation of coefficient of variation to check inter-day variability of 
azithromycin 
Azithromycin known concentration 0.05 µg/mL (low quality control; LQC) and 0.5 µg/mL 
(high quality control; HQC) were injected into the LC-MS/MS system. Table 5.3 shows 
the hypothetical and measured concentration by LC-MS/MS analysis for these samples 
over five different days along with the average, standard deviation, and the coefficient of 
variation percentage in order to determine the interday imprecision. 
Table 5.3: The average, standard deviation (±SD) and the coefficient of variation (CV) 
for the inter-day variability for azithromycin assay standards at 0.05 and 0.5 µg/mL 
Conc. 
(µg/mL)  
Day 1 Day 2 Day 3 Day 4 Day 5 Mean SD CV% 
0.5 0.51 0.48 0.54 0.46 0.45 0.5 0.0343 0.91% 
0.05 0.051 0.049 0.063 0.051 0.055 0.057 0.0043 7.58% 
Interday imprecision for both LQC and HQC were acceptable (< 8%) indicating good 
reproducibility between days. 
5.7.1.2 Intraday variability 
Azithromycin LQC and HQC were injected into the LC-MS/MS system. Table 5.4 shows 
the hypothetical and measured concentration by LC-MS/MS analysis for five different 
samples within the same day along with the average, standard deviation, and the coefficient 
of variation percentage in order to determine the intraday imprecision. 
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Table 5.4: The average, standard deviation (±SD) and the coefficient of variation (CV) 
for the intraday variability for azithromycin assay standards at 0.05 and 0.5 µg/mL 
Conc. 
(µg/mL) 
Sample 
1 
Sample 
2 
Sample 
3 
Sample 
4 
Sample 
5 
Mean SD CV% 
0.5 0.44 0.45 0.52 0.47 0.49 0.47 0.0333 7.05% 
0.05 0.054 0.049 0.061 0.057 0.054 0.055 0.0042 7.58% 
Intraday imprecision was determined by extraction and analysis of 5 replicates of each of 
the two QC samples within the same run. 
Intraday imprecision for both LQC and HQC was acceptable (< 8%) indicating good 
reproducibility within day. 
5.7.2 Inaccuracy 
The inaccuracy of the assay was determined by measuring the difference between actual 
(hypothetical) and measured concentration of each azithromycin calibration standard. The 
concentration difference was then divided by the actual concentration and multiplied by 
100 (Equation 5). 
100
conc. Actual
conc. measured -conc. ActualInaccuracy   
Equation 5: Inaccuracy percentage calculations of hypothetical and measured 
azithromycin concentrations 
Table 5.5: Inaccuracy of the assay was < 13% of the true value at standard curve 
concentrations ranging from 0.01 to 1 µg/mL of azithromycin 
Conc. 
(µg/mL) 
Day 1 Day 2 Day 3 Day 4 Day 5 Average Conc. 
µg/mL 
Inaccuracy 
 
0.01 0.01 0.01 0.01 0.01 0.01 0.01 9.6% 
0.03 0.03 0.03 0.04 0.03 0.03 0.03 12.2% 
0.1 0.09 0.11 0.11 0.10 0.11 0.10 4.1% 
0.3 0.32 0.33 0.30 0.30 0.30 0.31 3.4% 
1 0.88 0.92 0.87 0.84 0.85 0.87 -12.6% 
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The inaccuracy values were acceptable (<15%) for all of the five azithromycin standards 
(Table 5.5). 
5.7.3 LC-MS/MS system carryover 
The LC-MS/MS system carryover was checked by running blank samples between actual 
samples. The blank sample was checked for the presence of any carried over azithromycin 
and roxithromycin. Calibration standards were also randomised and the calibration curve 
linearity was then checked in order to detect any carryover (Figure 5.11). 
 
Figure 5.11: A blank run after actual sample showing no carry over between samples 
5.7.4 Statistical analysis and graphic presentation 
The graphic presentations and the statistical analyses were done using Excel 2010 for 
Windows version, 14.0.6112.500 (32-bit) and Minitab version, 16. 
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5.7.5 Dissolution extraction recovery 
The recovery of the volume was calculated by dividing the actual volume over the total 
volume then multiplied by the concentration (Table 5.6). 
Conc.
 volumeTotal
 volumeActualRecovery 
 
Equation 6: Recovery calculation of azithromycin standards 
Table 5.6: The average recovery percentage of azithromycin mass amount after 30 and 60 
min and standard error of the dissolution test (n = 3) 
Recovery average 
Azithromycin Av. Content% 30 min Av. Content% 60 min 
Brand A 91% ±9.9 100% ±6.3 
Brand B 94% ±4.8 88% ±2.2 
Brand C 90% ±1.4 96% ±5.3 
Brand D 99% ±6.4 91% ±3 
Generic A 82% ±4.3 77% ±3.6 
Generic B 87% ±13.8 80% ±6.7 
Generic C 86% ±6.2 87% ±5.5 
Generic D 32% ±17.5 58% ±19.6 
Generic E 71% ±8.4 106% ±4.1 
Generic F 71% ±9.3 118% ±11.3 
Generic G 107% ±14.6 104% ±5.8 
Generic H 62% ±10.7 61% ±7.8 
Generic I 88% ±13.1 118% ±5.1 
Generic J 96% ±1.3 84% ±6.2 
Generic K 115% ±5.8 97% ±7.1 
Generic L 94% ±4.5 84% ±2.5 
Generic M 106% ±0.97 99% ±10.3 
Generic N 45% ±19.1 63% ±6.8 
Generic O 86% ±5.7 62% ±3.4 
This test was done in order to confirm that the dissolution test successfully recovered all 
the tablet content after 30 and 60 min. 
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5.7.6 Stability  
Freeze thaw stability was done for three azithromycin calibration standards stored at -20C, 
thawed and re-frozen every week for three weeks. 
This test was done to check azithromycin standards stability in stock solutions. 
Azithromycin standards were stable for the whole period of the experiment. Two different 
concentrations of 0.03 and 0.3 µg/mL from week 1, 2, and 3 were measured (Table 5.7). 
The azithromycin standards were stable for freeze thaw cycles. Average measured 
concentration for 3 cycles of 0.03 and 0.3 µg/mL of azithromycin was 0.033 and 0.32, 
respectively. The CV% of 0.03 and 0.3 µg/mL of azithromycin standards were less than 
6%. Inaccuracy of the measured concentration was less than ±12%. 
Table 5.7: The average concentration (±SD) and coefficient of variation (CV) and 
inaccuracy of azithromycin stability in stock solution for week 1, 2, and 3 
Conc. 
µg/mL 
Week 1 Week 2 Week 3 Average ±SD CV Diff. Inaccuracy 
0.03 0.03 0.03 0.03 0.03 0.001 3.66% 0.003 11.6% 
0.3 0.3 0.3 0.3 0.3 0.019 5.76% 0.022 7.5% 
5.7.7 Final results  
The method was successfully applied to measure the actual concentration in each 
azithromycin product using LC-MS/MS analysis. Sampling time was done at six different 
intervals in order to check for azithromycin release from tablets. All branded products from 
Pfizer (A, B, C, D) and ten generics from different manufacturers (A, B, C, G, I, J, K, L, 
M, O) showed more than 80% of labelled amount in azithromycin capsules after 30 min of 
the dissolution test giving 91 ± 9.9, 94 ± 4.8, 90 ± 1.4, 99 ± 6.4, 82 ± 4.3, 87 ± 13.8, 115 ± 
5.8, 86 ± 6.2, 107 ± 14.6, 88 ± 13.1, 96 ± 1.3, 94 ± 4.5, 106 ± 0.97 and 86 ± 5.7% (±SD), 
respectively. Five generics (D, E, F, H, N), showed less than the minimum percentage of 
labelled amount (80% after 30 min) 32 ± 17.5, 71 ± 8.4, 71 ± 9.3, 62 ± 10.7 and 45 ± 19.1% 
respectively, (Figure 5.12). Relative to brand (A), statistical analysis showed significant 
differences (p<0.0001) of the mean percentage content between brand and generic, the 95% 
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CI range for the brands (B, C, D) were (74-115), (84-96) (71-127), respectively, and (63-
100), (27-146), (60-113), (43-107), (35-107), (31-111), (44-170), (16-108), (32-144), (90-
101), (90-140), (74-114), (102-110), (37-127), (62-110) for the generics (A, B, C, D, E, F, 
G, H, I, J, K, L, M, N, O), respectively (Table 5.8). 
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Figure 5.12: Percentage dissolved azithromycin in brand and generics (n = 3) 
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Table 5.8: The average percentage of azithromycin mass amount, standard deviation, 
coefficient of variation and 95% CI based on reference capsule (Brand A), (n = 3) 
Drug  N % of mass amount at 
30 min (mg/mL) 
± SD CV (%) 95% confidence 
interval 
Brand B 3 94 4.8 9 (74-115) 
Brand C 3 90 1.4 3 (84-96) 
Brand D 3 99 6.4 11 (71-127) 
Generic A 3 82 4.3 9 (63-100) 
Generic B 3 87 13.8 28 (27-146) 
Generic C 3 86 6.2 13 (60-113) 
Generic D 3 32 17.5 95 (43-107) 
Generic E 3 71 8.4 21 (35-107) 
Generic F 3 71 9.3 23 (31-111) 
Generic G 3 107 14.6 24 (44-170) 
Generic H 3 62 10.7 30 (16-108) 
Generic I 3 88 13.1 26 (32-144) 
Generic J 3 96 1.3 2 (90-101) 
Generic K 3 115 5.8 9 (90-140) 
Generic L 3 94 4.5 8 (74-114) 
Generic M 3 106 0.97 2 (102-110) 
Generic N 3 45 19.1 74 (37-127) 
Generic O 3 86 5.7 11 (62-110) 
5.8 Conclusions 
All branded products from Pfizer (A, B, C and D) met the USP requirement. Some generic 
products made by one manufacturer from different batch numbers met the USP 
requirement, generic (A, B and C). Another generic manufacturer with different batch 
numbers, generic (D, E and F), failed to meet the USP requirement. However, after 60 min, 
for two products (generic E and F) more than 80% of azithromycin dissolved. This 
highlights differences in dissolution behaviours between branded and generic copies, 
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which is a delay in the dissolution rate. For generic (G, H and I), an interesting observation 
occurred. Two out of three products (G and I) met the USP requirement and one (generic 
H) failed. Generic products (J, K, L, M and O) met the USP requirement and generic 
product (N) failed. The causes for dissolution test failure are not clear, but it could be due 
to bad storage conditions, lack of GMP and/or GLP, resulting in substandard products. 
As shown in the dissolution test, some generic products (Generic D, E and F) had different 
dissolution behaviours compared to the branded counterpart. There was noticeable 
undissolved residue instead of a cloudy solution and some tablets did not dissolve 
completely (Figure 5.3 and figure 5.4). Therefore, it could be the main reason why they 
failed to meet the USP requirements and showed poor dissolution profiles (average content 
32, 71, and 71% after 30 min). 
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Chapter 6. Bioequivalence study of two azithromycin 
products after oral administration in healthy adults 
under fasting conditions  
6.1 Introduction 
This study was performed to investigate the bioequivalence of azithromycin between test 
product Mazit capsules 250 mg (250 mg azithromycin per capsule: Neopharma, UAE), and 
reference product Zithromax™ (250 mg azithromycin per capsule, Pfizer Italia, S.R.L., 
Italy) in fasting healthy subjects. 
The study was conducted in collaboration with Neopharma Pharmaceutical Company in 
United Arab Emirates. The study was a single dose, open label, randomised, two-way 
crossover design. Clinical investigation of the study was conducted in the International 
Pharmaceutical Research Centre (IPRC), Amman, Jordan, according to the International 
Conference on Harmonisation, ICH for Good Clinical Practice (GCP) guidelines, adopted 
by the European Medicines Agency (EMA). The study protocol called for the 24 healthy 
volunteers plus 1 to 4 alternates. Demographic data and all clinical assessment along with 
laboratory evaluation were performed for all enrolled subjects.  
The subjects received two capsules of Mazit Capsules 250 mg (250 mg azithromycin per 
capsule) and two capsules of Zithromax™ (250 mg azithromycin per capsule) in a 
randomised fashion with a washout period of 21 days. Twenty-eight healthy volunteers 
enrolled and completed the crossover. The bioanalysis of clinical plasma samples was 
accomplished by LC/MS/MS detection, which was developed, and validated in accordance 
with international guidelines at the IPRC. Pharmacokinetic parameters were determined by 
standard non-compartmental methods, and ANOVA statistics were calculated using 
Microsoft Excel 2013 and Minitab-17 Statistical Software. The 90% confidence intervals 
for the ratio (or difference) between the test and reference product pharmacokinetic 
parameters of Cmax, tmax and AUC0-72 were calculated. 
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6.2 Aims and Objectives 
The aim of this study was to investigate the bioequivalence between the test product, Mazit 
capsules 250 mg, Neopharma, UAE, and its reference product Zithromax™, 250 mg, Pfizer 
Italia, S.R.L., Italy, in fasting healthy subjects. 
6.3 Subjects 
Test subjects were recruited from Amman, Jordan and the surrounding areas. Table 6.1, 
showing the demographic data and sequence of participating test subjects. For participation 
in the study, test subjects had to meet the selection criteria outlined in the study protocol. 
Volunteers were informed, by the IPRC representatives, about the aim of the study and any 
potential risks. Volunteers signed written informed consent (IC) statements, and they were 
free to withdraw at any time during the course of the study. The investigators had the right 
to exclude or discontinue any test subjects if they felt that for any reason it would be better 
to do so, such as risks to their health or signs of side effects or failure to abide by the study 
protocol and its requirements. 
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Table 6.1: Demographic data and individual values for the eligible 24 male subjects for 
the bioequivalence study between Mazit Capsules 250 mg (Neopharma, UAE) and 
Zithromax™ manufactured by (Pfizer Italia S.R.L., Italy) 
Subject No. Sequence Height (cm) Weight (kg) Age (years) 
1 BA* 165 80 31 
2 AB 171 60 26 
3 AB 170 66 22 
4 BA 178 60 24 
5 AB 188 90 32 
6 BA 178 65 31 
7 BA 160 65 34 
8 BA 172 70 28 
9 BA 187 88 30 
10 AB 182 85 24 
11 AB 170 65 22 
12 AB 177 60 23 
13 AB 162 60 37 
14 AB 172 70 28 
15 AB 167 70 25 
16 AB 171 70 36 
17 BA 181 85 24 
18 BA 170 82 26 
19 BA 175 60 30 
20 AB 175 65 25 
21 BA 176 75 20 
22 BA 181 70 28 
23 AB 174 80 25 
24 BA 180 80 22 
N  24 24 24 
Mean  174 72 27 
SD  7.08 9.76 4.61 
CV%  4.06 13.60 16.93 
SEM  1.44 1.99 0.94 
Minimum  160 60 20 
Median  175 70 26 
Maximum  188 90 37 
*A: Test product, (Mazit), B: Reference product (Zithromax™). 
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The subjects age ranged between 20 - 37 years (27 ± 4.61 years). Weight at screening was 
between 60-90 kg (72 ± 9.76 kg). Height was between 160 - 188 cm (174 ± 7.08 cm). 
Each subject received a thorough physical assessment, vital signs evaluation (blood 
pressure, pulse, respiratory rate and temperature) and ECG on screening examination. The 
subjects received the same physical assessment and vital signs evaluation and ECG plus 
liver function test on follow up examination, which was within at least 24 h from collecting 
the last sample in period 2. 
6.3.1 Inclusion criteria 
To be eligible for participation in the study, subjects were examined according to following 
criteria before their enrolment in the study. 
 Age 18 – 45 years, inclusive. 
 Subject does not having known allergy to the drug under investigation (azithromycin) 
or any of its other ingredients or any related drug (erythromycin, any macrolide or 
ketolide antibiotic). 
 Medical demographics are within the normal range performed not longer than two 
weeks before the initiation of the clinical study. 
 Results of laboratory tests are within the normal range. (Laboratory tests are performed 
not longer than two weeks before the initiation of the clinical study). 
 Body weight within 15% of ideal weight for height (Table of “Desirable Weights of 
Adults”, Metropolitan Life Insurance Company Statistical Bulletin, 1983). 
6.3.2 Exclusion criteria 
 History of drug or alcohol abuse. 
 Acute infection within one week preceding first study drug administration. 
 Medical demographics with deviations from reference ranges. 
 Subject does not agree not to consume any beverage or food containing methyl-
xanthines e.g. caffeine (coffee, tea, energy drinks, chocolate etc.) 24 h prior to the 
study drug administration of either study period until the end of confinement. 
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 Subject is a heavy smoker (more than 10 cigarettes per day). 
 Subject does not agree not to take any prescription or non-prescription drugs within 
two weeks before first study drug administration and until the end of the study. 
 Subject does not agree not to take any vitamins taken for nutritional purposes within 
two days before first study drug administration and until the end of the study. 
 Results of laboratory tests, which are outside the reference ranges. 
 Subject is on a special diet (for example subject is vegetarian). 
 Subject consumes large quantities of alcohol or beverages containing methyl-
xanthines e.g. coffee, tea, energy drinks, chocolate etc.). 
 Subject does not agree not to consume any beverages of food containing alcohol 48 h 
prior to study drug administration until donating the last sample in each respective 
period. 
 Subject does not agree not to consume any beverages or food containing grapefruit 
seven days prior to first study drug administration until the end of the study. 
 Subject has a history of severe diseases, which have direct impact on the study. 
 Participation in a bioequivalence study or any clinical study within the last two 
months before first study drug administration. 
 Subject intends to be hospitalized within three months after the first study drug 
administration. 
 Subjects who through completion of the study would have donated more than 500 mL 
of blood in 14 days or 750 mL of blood in 30 days, 1000 mL in 90 days, 1250 mL in 
120 days, 1500 mL in 180 days, 2000 mL in 270 days, 2500 mL of blood in 1 year. 
 The subject is a pregnant female (positive urine or blood pregnancy test) or a 
lactating female in case there were female participants (no applicable as only men 
were used in this particular study but still an applicable exclusion criteria if women 
were included as part of any other current or future study). 
 Subject has a history or presence of significant asthma, peptic or gastric ulcer, 
sinusitis, pharyngitis, renal disorder, hepatic disorder, cardiovascular disorder, 
neurological disease, haematological disorders or diabetes, psychiatric, dermatologic 
or immunological disorders. 
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 Subject who has been engaged in strenuous exercise at least one day prior to dosing 
till the last sample of each respective period. 
 Subject is taking one or more of the following medications, nelfinavir, warfarin, 
atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, 
midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, 
trimethoprim/sulfamethoxazole or zidovudine, digoxin, ergotamine or 
dihydroergotamine, terfanadine, ciclosporin, hexobarbital and phenytoin, antacids 
containing aluminium and magnesium hydroxide, cimetidine. 
 Subjects who have been diagnosed with liver disease, kidney disease, certain heart 
problems (abnormalities ECG, slow heartbeat, heart failure), family history of certain 
heart problems, pneumonia, colitis, fungal infection. 
 Subject has a history of difficulties in swallowing or any gastrointestinal disease, 
which could affect the drug absorption. 
Forty eight healthy subjects were recruited according to the selection criteria described in 
the study protocol and volunteered for participation in the study (Figure 6.1). All 
participating subjects were treated as a single group. Each subject was examined 
thoroughly during the screening procedure as described in the study protocol (the screening 
time been set to be not more than two weeks prior to the first study drug administration of 
study period 1). 
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Figure 6.1: Disposition of subjects 
6.3.3 Subject identification 
During the screening process only their initials identified all test subjects. Each test subject 
on admission for period 1 was assigned numbers in sequential order. Test subjects 
throughout the duration of the study retained their represented identification numbers. For 
data processing and reporting, their assigned identification numbers and initials only 
identified test subjects. 
6.3.4 Withdrawal and exclusions 
During this study, 48 subjects were screened. six subjects withdrew for abnormal 
laboratory results, 12 subjects withdrew for personal reasons and 2 subjects withdrew for 
medical conditions. A total of 28 subjects were enrolled and completed the crossover. 
Four subjects experienced vomiting during the bioequivalence study for unknown 
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reasons and were excluded from statistical analysis. Subject withdrawal can be divided 
into 3 groups (Table 6.2). For more details, see (Appendix 5). 
Table 6.2: Types of subjects withdraw from the study 
Types of Withdrawal Definition 
Withdrawal Group 1 Withdrawal after screening procedures have been performed 
but before study drug administration in study period 1 
Withdrawal Group 2 Withdrawal after study drug administration in study period 1 
but before study drug administration in study period 2 
Withdrawal Group 3 Withdrawal after study drug administration in study period 2 
6.4 Randomisation 
The study was a randomised two-way, two sequence crossover design. The order in which 
the test and reference medicines were received by each test subject was determined by the 
randomisation plan (Table 6.3). Test subjects were assigned a number in sequential order 
as per the arrival sequence numbers provided on the test subjects arrival at the centre, by 
check in for period one and based on adherence of the determined protocol requirements. 
All clinical data from this study were collated in case report forms (CRF’s) by members of 
staff in the IPRC. The principal investigators, to ensure correct and accurate completion, 
evaluated all case report forms. The randomisation codes were withheld from the study 
personal (see Appendix 7). 
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Table 6.3: Randomisation plan for the bioequivalence study between Mazit capsules 250 
mg, (250 mg azithromycin per capsule) and Zithromax™, (250 mg azithromycin per 
capsule) 
Subject number 
  
Treatment 
Study period 1 Study period 2 
1 B A 
2 A B 
3 A B 
4 B A 
5 A B 
6 B A 
7 B A 
8 B A 
9 B A 
10 A B 
11 A B 
12 A B 
13 A B 
14 A B 
15 A B 
16 A B 
17 B A 
18 B A 
19 B A 
20 A B 
21 B A 
22 B A 
23 A B 
24 B A 
25 A B 
26 A B 
27 B A 
28 B A 
A: The test product, Mazit, Neopharma, 250 mg azithromycin per capsule 
B: The reference product, Zithromax™, Pfizer Italia, S.R.L., Italy., 250 mg azithromycin per capsule. 
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6.5 Study drug administration 
Study drugs were administered by the clinical staff of the IPRC as follows: 
- Treatment A: Two capsules of Mazit capsules 250 mg, test product, 250 mg 
azithromycin per capsule were given with 240 ml of water. Water was at room 
temperature and was measured with a 250 ml cylinder. 
- Treatment B: Two capsules of Zithromax™, reference product, 250 mg azithromycin 
per capsule were given with 240 ml of water. Water was at room temperature and was 
measured with a 250 ml cylinder (Table 6.4). 
Table 6.4: Identity of the study medications involved in the bioequivalence study 
between Mazit capsules 250 mg (Neopharma, UAE) and Zithromax™ (Manufactured by 
Pfizer Italia S.R.L., Italy). 
Identification Test product- Treatment A Reference product-Treatment B 
Brand name Mazit Capsules 250 mg Zithromax™ 
Dosage form Hard Gelatine Capsule Hard Gelatine Capsule 
Strength 250 mg azithromycin 250 mg azithromycin 
Manufacturer Neopharma, UAE Pfizer Italia S.R.L. Italy 
Batch No. AZA8002 86408002 
Expiry Date 09/2010 03/2013 
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Figure 6.2: Study design and plan 
Adequate quantities of the study formulation were provided. A pre-planned scheme was 
followed as detailed in (Figure 6.2) and the study schematic in (Table 6.5). 
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Table 6.5: The pre planned scheme, which was conducted for the bioequivalence study  
Procedure Study period*  
 Screening Period 1 Period 2 Follow Up# 
Subject identification ✓ ✓ ✓ ✓ 
Informed consent♣ ✓    
Demographic data ✓    
Medical History ✓    
Physical Examination ✓   ✓ 
Vital signs ✓ ✓ ✓  
Hepatitis B ✓    
Hepatitis C ✓    
HIV ✓    
ECG ✓    
Haematology ✓    
Biochemistry ✓   ✓** 
Urinalysis ✓    
Drugs of Abuse  ✓ ✓  
Alcohol screening  ✓ ✓  
Selection Criteria◦ ✓    
Study drug administration  ✓ ✓  
Check for other medications ✓ ✓ ✓ ✓ 
Blood Sampling for pharmacokinetics  ✓ ✓  
Check for adverse events  ✓ ✓ ✓ 
* There was a washout period of at least 21 days between the two administrations of study drugs 
Between 14 days and approximately one day before first study drug administration in study period 1 
◦ To be eligible for participation in the study, test subjects must meet all selection criteria before the first study drug administration in 
study period 1 was established. 
♣ Before screening examination, the subject has to sign the informed consent form. 
# Follow-up was done within at least 24 h of last blood sample 
** liver function test 
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6.6 Adverse events during the study 
Test subjects were monitored throughout the confinement period for AE to the study 
formulation and/or procedures. From the start till the end of the confinement period, a study 
physician or a medically qualified person were on site and on call. At the beginning of the 
second period, test subjects were asked concerning unusual symptoms, which may have 
occurred during the previous administration of the study drug. The qualified medical 
person or study physician evaluated all drug related symptoms of clinical significance 
before the next dose administration. Some adverse events occurred during the study but 
were minimal (Table 6.6). Five out of the twenty-four test subjects experienced AE, with 
headache, abdominal pain and heartburn being the main adverse effects. All adverse effects 
occurred during study period 2 and were classified as mild. 
Table 6.6: Adverse events that occurred during the bioequivalence study 
Subject 
No. 
Adverse event Study 
period 
Severity Onset from 
drug 
administration 
(h) 
Relationship 
to study drug 
Treatment 
given 
Action 
taken 
Outcome 
4 Headache 2 Mild < 24 h Possible A None Complete 
recovery 
7 Abdominal pain 2 Mild < 24 h Possible A None Complete 
recovery 
8 Heart pain 2 Mild < 24 h Possible A None Complete 
recovery 
9 Headache, 
abdominal pain 
2 Mild < 24 h Possible A None Complete 
recovery 
14 Abdominal pain 2 Mild < 24 h Possible B None Complete 
recovery 
6.7 Dietary restriction 
From 48 h prior to the study drug administration, no consumption of alcohol was permitted 
until the collection of the last sample of the respective study period. Any beverages or foods 
containing methyl-xanthines such as caffeine (coffee, tea, cola, cocoa, chocolate, etc.) were 
prohibited for the subjects, 24 h prior to the study drug administration until the end of the 
confinement in each study period. In addition, any foods or beverages containing grapefruit 
were prohibited one week before the first study drug administration up until the end of the 
study. Food and fluid intake were kept identical in both study periods, commencing with 
dinner served 10 h before study drug administration on study day one until the end of 
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confinement. Test subjects were only allowed to consume foods provided within the period 
of confinement. All test subjects received meals in the following time frame intervals, as 
shown in (Table 6.7). 
Table 6.7: Standardised meals served during the bioequivalence study 
Study day Standardized diet Time received 
−1 Dinner Finished at least 10 h before the scheduled time of study drug 
administration in the morning of study day 1 
1 Lunch 4 h after study drug administration 
1 Snack 8 h after study drug administration 
1 Dinner 12 h after study drug administration 
6.8 Blood sample collection and analysis 
In the morning of study day 1 of each study period and before study drug administration, 
a cannula was inserted into the subjects’ forearm vein and remained there until the 24 hour 
blood sample was collected and then the subject returned to donate the rest of samples. The 
volume of blood taken for determination of azithromycin in plasma was 8 mL per sample. 
The following blood samples for the analysis of azithromycin in plasma were collected 
immediately before (2 x 8 mL) at 0.00 (pre-dose) and 0.33, 0.66, 1.00, 1.33, 1.66, 2.00, 
2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 
h, (1 x 8 mL) after administration of study drugs (Appendix 5). The number of blood 
collections for drug analysis was 22 samples in each study period. After centrifugation, 
plasma samples were transferred directly into a 5 mL tube. These samples were 
immediately stored at the study site in a freezer at a nominal temperature of −20 °C. The 
label of collecting tubes had the study’s code, subject number, study period and the 
designated sample number. They did not contain information that would allow 
identification of the given treatment. This assured that the analysis at IPRC analysed the 
samples blindly. A validation with LC/MS/MS detector for the determination of 
azithromycin in human plasma which was developed and validated in accordance with 
international guidelines at the IPRC was used (ICH Harmonised Tripartite Guideline, 1996, 
EURACHEM Guide, 1998, Food and Drug Administration, 2001). 
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6.9 Results 
Demographic data and all clinical assessments along with laboratory evaluation were 
performed for all enrolled subjects. However, for pharmacokinetic evaluations the data 
from 24 subjects were included in the calculation (Table 6.8 and Table 6.9). Drug plasma 
levels were designated as surrogate parameters to indicate clinical activity. Primary 
pharmacokinetic parameters were set to be Cmax and truncated AUC0-72 and were also 
considered to be the bioequivalence determinants. Finally, tmax, AUC0-∞ and t1/2 were set as 
the secondary pharmacokinetic parameters. 
The details of azithromycin results for this bioequivalence study are shown in Tables 6.10, 
6.11, 6.12, 6.13 and 6.14. Bioequivalence could be demonstrated for azithromycin within 
the prescribed 90% confidence interval of 80.00-125.00% for Cmax and truncated AUC0-72. 
The test product, Mazit capsules 250 mg (Neopharma, UAE; 250 mg azithromycin per 
capsule), investigated in this study was shown to be bioequivalent with the reference 
product Zithromax™ (Pfizer Italia S.R.L., Italy, 250 mg azithromycin per capsule) 
following an oral dosage of 500 mg (two capsules). Plasma levels may be used as surrogate 
parameters for clinical activity. Therefore, the data obtained in this study prove, by 
appropriate statistical methods, the essential similarity of plasma levels of azithromycin 
from the test product Zithromax™ (Pfizer Italia, S.R.L., Italy) suggesting equal clinical 
efficacy of these two products.
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Table 6.8: Individual plasma concentration of azithromycin versus time after single dose administration of 500 mg azithromycin 
Treatment A test product: Mazit capsules 250 mg, 250 mg azithromycin per capsule 
 
                  
Subject
No.  0.00 0.33 0.66 1.00 1.33 1.66 2.00 2.50 3.00 3.50 4.00 4.50 5.00 6.00 8.00 10.00 12.00 16.00 24.00 48.00 72.00
1 < 53 10 23 19 221 80 141 155 66 62 77 74 62 18 23 29 23 29 < <
2 < 71 335 651 253 205 250 311 180 130 174 149 121 89 67 37 40 37 25 11 <
3 < < 31 < < < < 100 234 87 205 140 98 80 47 35 30 20 14 16 12
4 < < < < < < < < 40 154 102 103 93 81 67 49 50 25 13 *** <
5 < < 36 43 54 22 18 183 430 317 144 136 118 123 78 62 49 45 32 17 12
6 < < 71 89 68 72 142 264 219 126 151 197 158 66 57 58 38 34 20 11 <
7 < 30 19 15 106 101 337 161 190 127 128 145 109 77 66 68 54 25 44 13 18
8 < < 86 78 32 87 17 159 307 113 88 181 124 73 62 66 37 24 26 12 12
9 < < 12 13 10 12 11 10 20 121 58 37 258 134 62 60 40 30 19 10 <
10 < < 76 25 40 144 188 221 115 136 102 185 124 89 72 47 44 37 32 *** ***
11 < 28 33 33 146 192 287 224 130 130 115 94 68 71 42 31 32 30 24 *** <
12 < < 40 123 292 337 304 268 281 185 144 179 127 121 64 56 48 42 30 15 14
13 < 11 32 45 76 124 272 223 161 149 227 161 151 120 79 53 47 43 26 19 14
14 < 63 37 16 11 12 200 227 93 95 67 76 59 97 56 38 46 31 25 19 15
15 < 13 11 132 293 242 188 127 176 153 118 156 97 66 62 47 36 24 20 < <
16 < < < 21 28 171 154 96 88 114 135 129 70 69 47 30 28 23 20 < <
17 < < 16 23 39 118 97 48 53 37 43 39 56 40 25 15 22 21 18 < <
18 < < 20 < < < 131 209 131 81 72 79 82 61 41 32 33 31 18 < <
Azithromycin Plasma Concentration (ng/mL)
 Time (Hours)                                                
<: below lower limit of quantification. (LLOQ), were considered zero in the calculation of the statistics. 
***: the subject did not give the sample.
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Table 6.8 Continued… 
 
Subject
No.  0.00 0.33 0.66 1.00 1.33 1.66 2.00 2.50 3.00 3.50 4.00 4.50 5.00 6.00 8.00 10.00 12.00 16.00 24.00 48.00 72.00
19 < < 31 13 79 213 281 126 119 89 71 60 81 81 61 44 34 42 28 14 13
20 < 23 28 19 29 335 371 239 200 158 153 135 204 155 98 69 58 54 43 *** ***
21 < < 63 36 57 178 194 208 126 120 86 81 79 63 45 36 30 39 32 18 12
22 < < 14 17 19 15 54 133 88 97 97 406 199 123 53 51 45 34 18 19 11
23 < 14 20 91 126 187 156 61 83 246 104 94 76 73 51 37 31 24 20 13 <
24 < < 19 23 17 56 91 81 103 73 82 73 62 50 39 34 25 26 15 < <
N 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 20 22
Mean 0 13 43 64 75 127 159 159 155 129 114 130 112 86 57 45 39 32 25 10 6
SD 0.00 21.48 66.19 130.49 88.28 103.08 113.04 83.60 92.50 58.50 46.56 75.24 51.18 28.96 17.44 14.64 9.59 8.95 8.16 7.45 6.91
CV% # 168.51 152.74 204.82 118.10 81.27 70.97 52.52 59.65 45.23 40.96 58.03 45.69 33.67 30.80 32.59 24.86 28.12 33.12 71.98 114.31
SEM 0.00 4.39 13.51 26.64 18.02 21.04 23.07 17.06 18.88 11.94 9.50 15.36 10.45 5.91 3.56 2.99 1.96 1.83 1.66 1.67 1.47
Minimum 0 11 10 13 10 12 11 10 20 37 43 37 56 40 18 15 22 20 13 10 11
Medium # 28 31 25 54 144 172 161 131 124 103 132 98 79 59 46 38 31 25 15 13
Maximum 0 71 335 651 293 337 371 311 430 317 227 406 258 155 98 69 58 54 44 19 18
 Time (Hours)                                                
<: below lower limit of quantification. (LLOQ), were considered zero in the calculation of the statistics. 
***: the subject did not give the sample.
#: value cannot be calculated
Azithromycin Plasma Concentration (ng/mL)
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Table 6.9: Individual plasma concentration of azithromycin versus time after single dose administration of 500 mg azithromycin 
Treatment B reference product: Zithromax™, 250 mg of azithromycin per capsule 
 
Subject
No.  0.00 0.33 0.66 1.00 1.33 1.66 2.00 2.50 3.00 3.50 4.00 4.50 5.00 6.00 8.00 10.00 12.00 16.00 24.00 48.00 72.00
1 < < < 27 10 64 115 110 94 116 64 50 110 57 38 27 24 21 < < <
2 < < 20 31 87 203 239 279 210 126 138 123 104 66 40 40 27 18 13 < <
3 < < 15 < < < < < 173 384 246 174 106 106 75 65 47 34 14 11 <
4 < 10 87 25 14 72 37 72 219 257 138 106 104 126 77 64 47 24 26 < ***
5 < < 41 34 50 127 316 389 239 122 111 134 134 95 64 49 34 38 33 15 12
6 < < 55 48 130 255 194 121 113 114 96 106 86 60 43 37 30 19 17 10 <
7 < < 17 17 195 424 186 222 178 220 58 172 114 118 66 71 53 19 36 12 27
8 < 12 112 38 106 329 265 308 163 101 95 96 80 59 46 59 27 22 27 11 14
9 < < 37 42 27 18 15 140 135 159 92 157 162 140 74 60 47 31 25 *** 10
10 < 12 168 88 196 237 199 109 94 113 95 105 91 78 46 44 41 41 29 19 14
11 < 16 11 < < 77 286 290 126 122 120 104 91 67 42 35 39 33 20 *** <
12 < < 37 16 21 322 528 387 294 307 187 181 114 105 97 72 49 44 31 18 13
13 < < 29 22 26 27 235 272 106 147 167 147 114 78 84 55 40 36 27 20 15
14 < < 59 22 11 10 12 182 254 196 182 199 146 112 83 73 61 48 29 22 20
15 < 40 15 165 346 295 406 158 190 206 112 95 88 49 43 46 43 38 25 11 <
16 < < < 33 27 18 14 129 150 129 46 122 111 59 46 39 37 24 19 < <
17 < < < < 11 142 156 76 70 68 62 86 78 106 39 23 31 23 19 13 <
18 < 15 22 11 14 124 162 128 88 68 93 75 92 50 30 31 21 18 18 16 <
<: below lower limit of quantification. (LLOQ), were considered zero in the calculation of the statistics. 
***: the subject did not give the sample.
Azithromycin Plasma Concentration (ng/mL)
 Time (Hours)                                                
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Table 6.9 continued… 
Subject
No.  0.00 0.33 0.66 1.00 1.33 1.66 2.00 2.50 3.00 3.50 4.00 4.50 5.00 6.00 8.00 10.00 12.00 16.00 24.00 48.00 72.00
19 < < 12 < 24 272 434 189 135 * 150 146 177 223 115 88 58 58 33 *** ***
20 < < 38 11 < 15 177 407 222 153 145 151 156 95 101 87 72 72 50 21 18
21 < 23 53 169 125 203 325 174 154 148 91 101 100 63 45 33 31 24 27 22 10
22 < < 29 42 28 14 35 62 122 150 230 185 173 131 68 46 50 38 25 12 <
23 < < < 13 14 11 16 168 48 57 167 99 57 58 30 34 29 23 11 < <
24 < < 14 20 26 88 238 142 135 71 52 75 60 66 36 32 29 21 18 11 <
N 24 24 24 24 24 24 24 24 24 23 24 24 24 24 24 24 24 24 24 21 22
Mean 0 5 36 36 62 139 191 188 155 154 122 125 110 90 60 50 40 32 24 12 7
SD 0.00 10.03 39.38 44.65 84.25 126.18 146.11 109.61 61.80 79.19 54.19 39.69 32.79 39.64 24.15 18.72 12.85 13.69 9.93 7.68 8.50
CV% # 188.12 108.51 122.62 135.89 90.48 76.40 58.28 39.96 51.54 44.28 31.87 29.72 43.90 40.59 37.13 31.90 42.85 41.66 66.13 122.29
SEM 0.00 2.05 8.04 9.11 17.20 25.76 29.82 22.37 12.62 16.51 11.06 8.10 6.69 8.09 4.93 3.82 2.62 2.80 2.03 1.68 1.81
Minimum 0 10 11 11 10 10 12 62 48 57 46 50 57 49 30 23 21 18 11 10 10
Medium # 15 33 29 27 124 194 168 143 129 112 114 105 78 46 46 40 28 25 14 14
Maximum 0 40 168 169 346 424 528 407 294 384 246 199 177 223 115 88 72 72 50 22 27
#: value cannot be calculated
*: broken in clinical site
Azithromycin Plasma Concentration (ng/mL)
 Time (Hours)                                                
<: below lower limit of quantification. (LLOQ), were considered zero in the calculation of the statistics. 
***: the subject did not give the sample.
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Table 6.10: Individual pharmacokinetics of azithromycin after single dose administration 
of 500 mg azithromycin Treatment A test product: Mazit capsules 250 mg, 250 mg of 
azithromycin per capsule 
Subject 
No. 
Cmax (ng/mL) Tmax (h) AUC 0-72 (ng.h/mL) AUC 0-∞ (ng.h/mL) t1/2 (h) 
1 221 2.00 990.5 --- --- 
2 651 1.00 2389.2 2708.2 20.10 
3 234 3.00 1712.9 --- --- 
4 154 3.50 974.8 1100.6 6.71 
5 430 3.00 2698.2 3196.9 28.80 
6 264 2.50 1855.8 2175.1 20.12 
7 337 2.00 2651.8 3405.6 29.03 
8 307 3.00 2087.3 2751.5 38.37 
9 258 5.00 1505.8 1812.8 21.27 
10 221 2.50 1500.2 2666.2 25.26 
11 287 2.00 1286.4 2264.7 28.25 
12 337 1.66 2840.8 3448.3 30.08 
13 272 2.00 2667.00 3752.6 53.75 
14 227 2.50 2146.9 3556.4 65.13 
15 293 1.33 1395.7 1674.5 9.66 
16 171 1.66 1031.2 1720.3 23.88 
17 118 1.66 662.2 1715.7 40.57 
18 209 2.50 1003.7 1343.3 13.08 
19 281 2.00 2148.9 2779.2 33.60 
20 371 2.00 2133.00 3823.1 27.24 
21 208 2.50 2242.6 2828.7 33.85 
22 406 4.50 2211.6 2686.2 29.90 
23 246 3.50 1543.4 2206.9 35.38 
24 103 3.00 841.2 1110.00 12.42 
N 24 24 24 22 22 
Mean 275 2.51 1771.7 2487.6 28.48 
SD 114.32 0.94 657.78 840.75 13.60 
CV% 41.53 37.55 37.13 33.80 47.75 
SEM 23.34 0.19 134.27 179.25 2.90 
Median 261 2.5 1784.35 2676.2 28.53 
Min 103 1.00 662.2 1100.6 6.71 
Max 651 5.00 2840.8 3823.1 65.13 
---No clear elimination 
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Table 6.11: Individual pharmacokinetics of azithromycin after single dose administration 
of 500 mg azithromycin treatment B reference product: Zithromax™, 250 mg of 
azithromycin per capsule 
Subject No. Cmax (ng/mL) Tmax (h) AUC 0-72 (ng.h/mL) AUC 0-∞ (ng.h/mL) t1/2 (h) 
1 116 4 700.1 1216.4 17.04 
2 279 2.5 1230.2 1402.8 9.2 
3 384 3.5 1713 1921.8 13.16 
4 257 3.5 1419.1 1701.4 7.53 
5 389 2.5 2545.4 3093.1 31.64 
6 255 1.66 1429.8 1916.9 33.76 
7 424 2 2807.6 3213.5 31.71 
8 329 1.66 2127.7 2762.7 31.44 
9 162 5 2255.7 2760.4 34.98 
10 237 1.66 2397.6 3320.4 45.69 
11 290 2.5 1253.6 1606.7 12.24 
12 528 2 3092.4 3793.8 37.4 
13 272 2.5 2441.6 3637.8 55.27 
14 254 3 2815.7 5332.9 87.24 
15 406 2 2044 2332.6 18.18 
16 150 3 992.6 1298.2 11.15 
17 156 2 1330.2 2078.9 39.92 
18 162 2 1273.2 5309.7 174.87 
19 434 2 2193.8 2729.4 11.25 
20 407 2.5 3438.3 4081.5 24.77 
21 325 2 2304.2 2787.5 33.5 
22 230 4 1903.2 2248.3 19.94 
23 168 2.5 815.6 949.1 8.41 
24 238 2 1299.9 1842.3 34.18 
N 24 24 24 24 24 
Mean 286 2.58 1909.4 2639.1 34.35 
SD 108.75 0.86 743.82 1184.01 34.93 
CV% 38.09 33.49 38.96 44.86 101.69 
SEM 22.20 0.18 151.83 241.69 7.13 
Median 265 2.50 1973.6 2531 31.54 
Min 116 1.66 700.1 949.1 7.53 
Max 528 5.00 3438.3 5332.9 174.87 
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Table 6.12: Ratio analysis of untransformed Cmax data of azithromycin after an oral dose 
administration of 500 mg azithromycin of Treatment A test product Mazit capsules, 250 
mg of azithromycin per capsule and Treatment B reference product Zithromax™, 250 mg 
of azithromycin per capsule 
Cmax 
Subject No. TEST REFERENCE TEST/REFERENCE 
Data Data Data 
1 221 116 190.52 
2 651 279 233.33 
3 234 384 60.94 
4 154 257 59.92 
5 430 389 110.54 
6 264 255 103.53 
7 337 424 79.48 
8 307 329 93.31 
9 258 162 159.26 
10 221 237 93.25 
11 287 290 98.97 
12 337 528 63.83 
13 272 272 100.00 
14 227 254 89.37 
15 293 406 72.17 
16 171 150 114.00 
17 118 156 75.64 
18 209 162 129.01 
19 281 434 64.75 
20 371 407 91.15 
21 208 325 64.00 
22 406 230 176.52 
23 246 168 146.43 
24 103 238 43.28 
N 24 24 24 
Mean 275 286 104.72 
GM 255 265 96.17 
SD 114.32 108.75 46.81 
CV% 41.53 38.09 44.70 
SEM 23.34 22.20 9.55 
90% CI of 
Geometric 
Means 
Point estimate % 96.16 
Lower limit % 82.95 
Upper limit % 111.51 
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Table 6.13: Ratio analysis of untransformed AUC0-72 data of azithromycin after an oral 
dose administration of 500 mg azithromycin of Treatment A test product Mazit capsules, 
250 mg of azithromycin per capsule and Treatment B reference product Zithromax™, 
250 mg of azithromycin per capsule 
AUC0-72 
Subject 
No. 
TEST REFERENCE TEST/REFERENCE 
Data Data Data 
1 990.5 700.1 141.48 
2 2389.2 1230.2 194.21 
3 1712.9 1713 99.99 
4 974.8 1419.1 68.69 
5 2698.2 2545.4 106.00 
6 1855.8 1429.8 129.79 
7 2651.8 2807.6 94.45 
8 2087.3 2127.7 98.10 
9 1505.8 2255.7 66.76 
10 1500.2 2397.6 62.57 
11 1286.4 1253.6 102.62 
12 2840.8 3092.4 91.86 
13 2667.00 2441.6 109.23 
14 2146.9 2815.7 76.25 
15 1395.7 2044 68.28 
16 1031.2 992.6 103.89 
17 662.2 1330.2 49.78 
18 1003.7 1273.2 78.83 
19 2148.9 2193.8 97.95 
20 2133.00 3438.3 62.04 
21 2242.6 2304.2 97.33 
22 2211.6 1903.2 116.20 
23 1543.4 815.6 189.23 
24 841.2 1299.9 64.71 
N 24 24 24 
Mean 1771.7 1909.4 98.76 
GM 1641 1761 93.21 
SD 657.78 743.82 36.50 
CV% 37.13 38.96 36.96 
SEM 134.27 151.83 7.45 
90% CI of 
Geometric 
Means 
Point estimate % 93.22 
Lower limit % 82.64 
Upper limit % 105.12 
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Table 6.14: Ratio analysis of untransformed AUC0-∞ data of azithromycin after an oral 
dose administration of 500 mg azithromycin of Treatment A test product Mazit capsules, 
250 mg of azithromycin per capsule and Treatment B reference product Zithromax™, 
250 mg of azithromycin per capsule 
AUC0-∞ 
Subject No. TEST REFERENCE TEST/REFERENCE 
Data Data Data 
1 --- 1216.4 0.00 
2 2708.2 1402.8 193.06 
3 --- 1921.8 0.00 
4 1100.6 1701.4 64.69 
5 3196.9 3093.1 103.36 
6 2175.1 1916.9 113.47 
7 3405.6 3213.5 105.98 
8 2751.5 2762.7 99.59 
9 1812.8 2760.4 65.67 
10 2666.2 3320.4 80.30 
11 2264.7 1606.7 140.95 
12 3448.3 3793.8 90.89 
13 3752.6 3637.8 103.16 
14 3556.4 5332.9 66.69 
15 1674.5 2332.6 71.79 
16 1720.3 1298.2 132.51 
17 1715.7 2078.9 82.53 
18 1343.3 5309.7 25.30 
19 2779.2 2729.4 101.82 
20 3823.1 4081.5 93.67 
21 2828.7 2787.5 101.48 
22 2686.2 2248.3 119.48 
23 2206.9 949.1 232.53 
24 1110.00 1842.3 60.25 
N 22 24 22 
Mean 2487.6 2639.1 102 
GM 2337 2397 93.56 
SD 840.75 1184.01 44.60 
CV% 33.80 44.86 43.63 
SEM 179.25 241.69 9.51 
90% CI of 
Geometric 
Means 
Point estimate % 93.56 
Lower limit % 80.06 
Upper limit % 109.32  
---No clear elimination 
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6.9.1 The concentration of Mazit versus Zithromax for all subjects 
The concentration and logarithmic concentration of the test product, Mazit capsules 
(Neopharma, UAE; 250 mg azithromycin per capsule), and the reference product 
Zithromax™ (Pfizer Italia S.R.L., Italy, 250 mg azithromycin per capsule) after an oral 
dosage of 500 mg (two capsules) in subject 1 is shown in the figures below. 
 
Figure 6.3: Concentration of Mazit compared to Zithromax™ (Subject 1) 
 
Figure 6.4: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 1)  
Figures for subjects 2-24 are in appendix 6  
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6.10 Conclusions 
This study was a single centre, open label, randomised, single dose study with two-way 
crossover design to compare the bioavailability of azithromycin between two products, in 
healthy, adult volunteers under fasting conditions. The results of this bioequivalence study 
showed the equivalence of the two studied products in terms of the rate of absorption as 
indicated by Cmax and in terms of the extent of absorption as indicated by AUC0-72 and 
AUC0-∞. The parametric 90% confidence intervals of the mean values for the test/reference 
ratio were in each case well within the bioequivalence acceptable boundaries of 80-125% 
for Cmax and truncated AUC0-72 (Appendix 8). 
Since plasma levels are a meaningful surrogate for pharmacodynamic action and adverse 
events, this demonstrates that an equivalent therapeutic activity and tolerance is to be 
expected from Mazit capsules 250 mg (Neopharma, UAE) test product as compared to 
Zithromax™ (Pfizer Italia, S.R.L., Italy), the reference product. 
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Chapter 7. General discussion and conclusion 
Based on current growth trends, by the time this thesis is finished (2015), it is estimated 
that the counterfeit market will be worth over $150 billion a year. In 2000, there was a 
WHO report on Africa and Asia, confirming that between 38% and 53% of antimalarial 
drugs were counterfeit, with no active ingredients in the drug product. An estimated 
700,000 deaths yearly are from substandard antimalarial and anti-TB medications (Mackey 
and Liang, 2011). During 2003 the estimated yearly profits made from substandard and 
counterfeits were more than $32 billion (World Health Organization, 2003). As mentioned 
in chapter 1, as of 2010, this estimate has more than doubled. This is evidence of the ever-
increasing challenges faced by regulatory bodies and why it is such a lucrative industry. 
Counterfeiters find vulnerabilities in the system, as the incentives to abuse the healthcare 
industry, as mentioned previously, are very high. Authorities and regulators are moving far 
too slowly in terms of reacting to vulnerabilities in the current system. 
One of the points of entry for counterfeit or substandard medicines is the high percentage 
of active ingredient’s now imported into the United States, from regions where regulations 
and quality control are not as rigorous (Blackstone et al., 2014). Due to some vulnerabilities 
in the manufacturing and supply chains, counterfeit and substandard manufacturers can 
make their way through the European supply chains via countries such as China, India, 
Pakistan, Spain and Russia, that have low regulation and quality controls, as most European 
countries import their medications from these regions (Bate, 2008). Further regulation and 
monitoring processes should be applied to poorly regulated areas. It is extremely difficult 
to prevent counterfeit drugs entering a country such as United States as nearly 40% of 
drugs are manufactured overseas and approximately 80% of the active ingredients used for 
all pharmaceuticals are imported into the United States (Blackstone et al., 2014). 
In this thesis, approaches to the investigation of counterfeit drugs have been studied and a 
number of example drugs fully investigated using the described techniques. The in-vitro 
dissolution testing was found to be able to identify differences in dissolution performance 
between branded and generic products. Dissolution testing was carried out according to the 
United States Pharmacopeia (USP) guidelines. According to the USP, not less than 80% of 
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the labelled amount of ciclosporin and azithromycin should dissolve in 90 and 30 min, 
respectively. The samples were analysed using liquid chromatography. 
Dissolution testing was useful in determining the difference in dissolution timings of 
different tablets and capsules. In addition, it was useful as a preparatory technique in order 
to prepare samples for further analysis (e.g.: drug analysis using LC or CE). Therefore, the 
dissolution tester should be available in every drug analysis laboratory. 
In this study, the LC systems with simple UV detection were used to determine the drug 
content of capsules and tablets. In addition, the LC system was also found to be useful in 
determining the presence of impurities in ciclosporin capsules. However, to determine the 
nature and the relative quantities of these impurities required more selective detection, so 
a LC-MS is necessary. Thus, it is recommended to use a combination of LC-UV and LC-
MS for identifying content and impurities, respectively. 
In contrast, the LC-MS system used for identifying impurities was unable to provide 
absolute quantities of the impurities. In order to derive absolute quantities using LC-MS, a 
set of external calibrator and labelled internal standards are required. For most of the 
impurities, there were no available external calibrator/internal standards. Therefore, it was 
difficult to perform absolute quantification. However, further studies are required to 
perform such quantitation. 
7.1 Dissolution testing 
Dissolution testing can be used to test the overall drug formulation if there is suspicion of 
it being counterfeit or substandard. A dissolution method is suitable for testing drugs to 
monitor the effective release of the active ingredients. The guidelines for dissolution testing 
can be obtained from sources such as the USP and FDA. Dissolution test could be used 
during the formulation design stage of the drug. It is an important measurement for quality 
control of a drug. This gives an indication of the timing of which the drug is released (in-
vivo) after consumption and could highlight any potential differences and bioavailability. 
The medium used in ciclosporin dissolution test was only water, while in azithromycin 
dissolution test it was aqueous with 0.1 M phosphate buffer (pH 6.0), which met the USP 
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and FDA guidelines for dissolution testing. It is safe to consider that the choice of water as 
an appropriate bio-relevant dissolution medium as its used for quality control testing 
(Qureshi, 2010). Although, further review for the dissolution testing guidelines should be 
considered to make the dissolution testing closer to the GI environment, especially 
important for ionisable drugs. A study of an in-vitro dissolution test on amoxicillin 
concluded that 62.5% of the tested generics were not substitutable for the brand Amoxil™ 
(Kassaye and Genete, 2013). 
7.2 Ciclosporin study 
Since ciclosporin is an important immunosuppressant agent, it requires careful therapeutic 
dosing. In recent years, many studies have questioned the use of generic substitutes, 
especially when considering those that are NTIDs. 
In this test the aim was to develop, validate and apply a dissolution test for ciclosporin in 
capsules using a HPLC method and then to compare brand medications to the generic or 
copy products. Moreover, the detection of contaminates and the source of impurities in 
these products are essential to understand. 
A sensitive and specific HPLC-UV method was developed to detect and subsequently 
quantitate the ciclosporin active base in capsules. Dissolution testing of the capsules was 
done as specified in the USP. Analytes were isocratically eluted at 0.7 mL/min with 
acetonitrile and water (70:30% v/v) and 0.03% v/v trifluroacetic acid over the 25 min 
runtime. Although the USP recommends that the column should be heated to 80°C, there 
is a difference in the temperature researchers choose that fits with their respective system. 
When this method was applied, it did not achieve the required separation, but at 50°C the 
necessary sensitivity and separation was achieved. The HPLC method developed in this 
study is significantly different to that stated in the USP. 
Treating patients orally, using capsules or tablets is still one of the most used routes of 
administration. After oral administration of capsules, the capsule shell should rupture 
within a specific time to allow the release of the drug in the gastrointestinal tract before 
going to the systemic circulation. The rate of dissolution of the capsule is therefore 
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essential. Dissolution profiles revealed that all the ciclosporin capsules used in these 
investigations complied with USP, rupturing within 15 min (The United States 
Pharmacopeia, 2008). There are discrepancies in the dissolution methods between the FDA 
and the USP. The FDA suggest to use a litre of 0.1 N HCl containing 4 mg of N,N-
dimethydodecylamine-N-oxide per mL at 75 rpm. The USP in 2012 recommend the use of 
500 mL water at 50 rpm (Food and Drug Administration, 2008a, USP 35, 2012). 
According to the USP, the guideline for dissolution sampling is at 90 min for ciclosporin 
which requires a minimum of 80% of the active ingredient. As part of the study reported 
here, additional sampling times up to 2 h were required to monitor the dissolution 
behaviours.  
The standard curve, when fitted using least square linear regression, was linear. The LC 
successfully separate the compound of interest. Detection of ciclosporin at low and high 
concentration was reproducible and the method was sensitive. The method was specific, as 
the blank runs did not produce any interfering peaks coinciding with retention time of 
ciclosporin. The within day and between day variability of the standards was within an 
acceptable range. The method was accurate. There was no system carry over for 
ciclosporin. Blank samples were run between the actual samples without detection of any 
carry-over of ciclosporin. 
The application of the assay was successful. The Turkish brand was the best brand in terms 
of content of the active ingredient with 100 ± 0.05% and 100 ± 0.03% for both test 
conditions. Generics from India and Morocco had only 69 ± 0.08% and 54 ± 0.10 %, 
respectively. There were one or more impurities in all capsules. 
It was confirmed in this thesis, that there is a difference in dissolution behaviours between 
generic ciclosporin and its branded counterpart. In Tables 4.3 and 4.11, ciclosporin test A 
and B, there was a noticeable early release of ciclosporin after 5 min sampling time of 
generic C and generic Col. The average percentage content of ciclosporin found, was 85% 
and 81%, respectively. During this sampling time, none of the other tested brands and 
generics had that much release of ciclosporin. The reason for the rapid ciclosporin release 
for the above mentioned generic could be due to the thin transparent capsule shell. These 
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ciclosporin capsules met the USP requirements, rupturing within 15 min but there is no 
clear information about the effects of early release of ciclosporin. It was found in test A, 
that generic I average content was less than the required USP amount (69.3% after 90 min). 
Moreover, in test B, the average content of ciclosporin M, was found to be 54% only after 
90 min. This indicates that these two products could be substandard and/or counterfeit. The 
contents of one of the ciclosporin capsules we reported in this study is in agreement with 
those found by other researchers (Bonifacio et al., 2009), where they detected only 68% of 
the labelled concentration in one of the generic capsules. Using such products with lower 
therapeutic doses in transplant patients could lead to acute rejection (Browne et al., 2001). 
Even within brands of ciclosporin from different countries, there were differences in the 
average content after 90 min within the acceptable limit. In Table 4.11, at 90 min sampling 
times, the average content of ciclosporin for TK, Sa, Jor, Egy and Pak was 100, 99, 84, 92, 
and 94%, respectively. This indicates that even within the same brand, there are differences 
in the average content of ciclosporin. Some small differences in NTIDs such as ciclosporin, 
could lead to harmful side effects. Based on these results, switching between generic and 
branded ciclosporin is not recommended. The tests provided some surprising results. Some 
of the test products had less than 80% requirement and even some of the branded drugs 
which are supposed to have set the benchmark did not have 100% either. This highlights 
potential poor standards in the manufacturing process which need to be reviewed. 
While using the HPLC method to quantify ciclosporin labelled amount, some impurities 
were detected using the UV detector (Figure 4.2). The impurities in ciclosporin capsules 
were then investigated using a UHPLC-MS in order to identify the nature of these 
impurities. Samples were then analysed for the whole chemical content using a Q-TOF 
LC-MS system and compared to each other using univariate (fold change and p values) 
and multivariate (PCA and heatmaps) statistical methods. All generic capsules were found 
to have a different chemical content when compared to the brand product. On identifying 
the nature of impurities in one of the generic compounds (Col), sorbitol was found to be 
higher by 260 fold change. Sorbitol is widely used in the pharmaceutical industry as an 
inactive ingredient, its function being to sweeten medicines such as syrups and chewable 
tablets. It is synthesised by hydrogenation of glucose and is formulated into a liquid or 
Chapter 7 General discussion and conclusion 
    Page 160 of 296 
crystalline preparation. Sorbitol is less sweet than glucose and contains less calories. In 
ciclosporin capsules, sorbitol is used as a plasticizer (Rowe et al., 2009). 
A known side effect of sorbitol is its laxative effect but as it is administered in small 
quantities in pharmaceuticals, this is not a common occurrence. 
Other side effects may include anal irritation, diarrhoea, gas, stomach cramps, and nausea. 
It also has potential serious side effects which require medical intervention such as allergic 
reactions concerning rash, itching, difficulty breathing, swelling of the mouth, face, lips or 
tongue and rectal bleeding (UpToDate, 2015b). 
According to the FDA, the maximum amount of sorbitol in soft gelatine liquid filled 
capsules (such as ciclosporin) should be 97 mg (Food and Drug Administration, 2015c). 
However, there is no listed label quantity of sorbitol as an inactive ingredient in ciclosporin 
capsule products. Even though the amount of sorbitol as an inactive ingredient is not listed 
in the ciclosporin product, a high amount of sorbitol can cause some serious side effects 
(Rowe et al., 2009). 
Other contaminants such as the ciclosporin degradation product delcorine and the plant 
contaminant zizyphine A, were also found in the generic product. Their safety and 
immunosuppressive activity are unknown and need further investigation. 
The results in this study were surprising in that the content was much less than 80% in 
some of the capsules and was not 100 % in all the brand capsules either. This raises 
concerns over the manufacturing standards and the quality control measures employed 
even within the same brand manufactured in different countries. In the literature, the 
Danish medicine agencies suggested that generic substitution should no longer be used for 
ciclosporin following a reassessment (Heisterberg, 2011). Taking together, this data 
highlights the need for more quality control test of generic products and post marketing 
pharmacovigilance. 
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7.3 Azithromycin study 
Azithromycin is a widely used antibiotic. In India alone, there are 40 manufacturers 
producing 54 generic versions (Medindia, 2015). It was selected for this study due to an 
FDA warning about the potential fatality risk. According to Kelesidis and Falagas, as of 
2009, 11% of counterfeit antimicrobial medications worldwide, were macrolides (Kelesidis 
and Falagas, 2015). The purpose of this study was to quantify the percentage labelled 
amount of azithromycin in brand versus generic copies, after in-vitro dissolution testing. 
According to the USP not less than 80% of the labelled amount of azithromycin should 
dissolve in 30 min. 
In this study, azithromycin tablets from different generic preparations were subjected to 
dissolution testing at six sampling times in order to get results that are more adequate. In 
the USP monograph about azithromycin tablets, it mentions that the sampling times for 
dissolution should be done at 30 min, while the FDA provide more sampling times at 10, 
20, 30 and 45 min. Five of the generic products studied failed to meet the USP requirements 
at azithromycin dissolution time of 30 min. On the other hand, after 60 min, only three 
generic products were below the acceptable limit. The results showed that, some generic 
tablets were not fully dissolved after 30 min and needed more time to fully dissolve. This 
indicates a formulation or manufacturing liability with azithromycin tablets. 
In this study, a UHPLC-MS/MS method was modified to quantify azithromycin labelled 
amount in the generic and brand counterpart tablets (Rossmann et al., 2014). 
Roxithromycin was selected as an IS because it has a comparable structure, retention time 
and ionisation to azithromycin (Xu et al., 2008), and the method was validated. In this 
study, the UHPLC-MS/MS azithromycin method was found to be highly sensitive and 
accurate with acceptable precision. In order to get good peak resolution, previous studies 
suggested using either ion-pairing reagents or derivatization of azithromycin (Sharma and 
Mullangi, 2013). The use of ion-pairing agents is associated with unwanted effects such as 
ion suppression, high background noise and shortening of the LC column life. The use of 
derivatization agents is also undesirable as they can be toxic. In this study, azithromycin 
and its internal standard roxithromycin were adequately separated and achieved excellent 
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peak resolution with minimal peak tailing using LC-MS/MS and without using any ion-
pairing agents or derivatization method. Furthermore, the run time was short allowing a 
high sample throughput. 
After validation, the method was applied for the measurement of the actual concentration 
in each azithromycin products. Five generics (D, E, F, H, N) had less than the minimum 
percentage of labelled amount, indicating a presence of substandard and/or counterfeit 
medications for consumers. In this study, only three tablets from each product were 
available for analysis. Results from this study showed that the CV of the analysis of these 
three tablets was less than 15% for ten products, indicating good reproducibility between 
analysed tablets for these products. However, another eight products showed CV higher 
than 15% indicating bad reproducibility and high variability between tablets. Two products 
showed a CV higher than 50% indicating a serious problem in these tablets. These results 
would raise concerns about using low quality antibiotics. 
With an increase in the estimated sales of counterfeit medicines, quality control tests of 
antibiotics are essential to ensure effective treatment (Le Doare et al., 2015). Using poor 
quality antibiotics could result in an increase of bacterial resistance, failure of the treatment 
and/or toxicity (Kelesidis et al., 2007, Johnston and Holt, 2014, Kelesidis and Falagas, 
2015). 
7.4 Bioequivalence testing: brand vs generic 
Over the last 30 years, bioequivalence testing has become an even more integral process 
in the pharmaceutical industry. The FDA has implemented many rules and regulations 
when it comes to bioequivalence testing, from the 1970s until today (Buehler, 2010). 
Bioequivalence testing is necessary in approving generic drugs. They are an essential 
benchmark that drugs need to pass in order to confirm they offer the same properties as the 
branded counterpart. For a generic drug to be approved, the bioavailability should be 
between 80-125% compared to the branded product (European Medicine Agency, 2001). 
In this thesis, a single dose bioequivalence study between Mazit 250 mg and Zithromax™ 
250 mg showed that they were bioequivalent within the acceptable limits 80-125% with no 
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significant safety profile observed. Some bioequivalence studies were done on 
azithromycin and the same conclusion was reached, that the generic was bioequivalent to 
the branded counterpart (Ren et al., 2007). 
In theory, generic drugs can be substituted with their branded counterpart. The fact that the 
cost of branded medications is higher than generics, encourages insurance companies, 
pharmacies, doctors and health care organisations to favour generics as an alternative 
(Silverman, 2015). A Medline search by Meridith, of the data published between 1973-
2003 suggested that generic drug substitution should be approached with caution. 
Bioequivalence tests are done as a single dose study, while multiple doses may be required 
to reach steady state (Meredith, 2003). Another Medline search from 1966-2006 by Al-
Jazairi et al., in 2008, suggested that generic drug substitution is acceptable as long as 
generics have met the bioavailability limits. However, extra caution and monitoring should 
be considered with regards to NTIDs (e.g. ciclosporin, warfarin, carbamezapine, thyroxine) 
and highly variable drugs (e.g. verapamil), where interchangeability is not recommended 
(Al-Jazairi et al., 2008). A PubMed search from 1974-2010, by Desmarais et al., concluded 
that the use of generic substitution may lead to some side effects and/or toxicity resulting 
in more complications and may eliminate cost savings (Desmarais et al., 2011). A 
systematic review was carried out by Goth et al., in 2015 using Medline, Embase and the 
Cochrane Database, on generic substitution based on the effectiveness and cost efficiencies 
compared to its branded counterpart. It suggested that more research is required for generic 
interchangeability, especially for antiepileptic and immunosuppressive drugs (Gothe et al., 
2015). There should be more communication and education about using generic 
substitutions (Heikkila et al., 2007, Keenum et al., 2012). 
However, there is a lot of debate regarding what acceptance limits are required for generic 
drugs and this is even more important for NTIDs as the slightest variation could have 
serious effects. Bioequivalence tests for some generic drugs have confirmed that there are 
bioequivalence variations between a generic and its branded counterpart (Del Tacca et al., 
2009). Other opinions in the pharmaceutical industry say that the current generic drug 
approval system is sufficient to conform to a branded drugs therapeutic equivalence 
(Motola and De Ponti, 2006). 
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The use of NTIDs requires a more detailed patient monitoring process, as small differences 
in bioavailability can have serious effects. The EMA set out new guidelines concerning 
NTIDs specifically highlighting the acceptance limit of AUC to a tighter range of between 
90-111.11% but there is currently no available list confirming all the NTIDs that require 
this new guideline (European Medicine Agency, 2010). The MHRA announced that 
ciclosporin is classified as an NTID and warns that patients should be administered the 
same brand of ciclosporin and if this is not possible to undergo close monitoring 
(Medicines and Healthcare products Regulatory Agency, 2009). The fact that health 
regulation authorities have tightened the acceptance range for NTIDs, confirms that the 
current bioequivalence limit is too wide. This could indicate that, interchanging between 
brand and generics may lead to unwanted effects. 
On the other hand, many systematic reviews and studies suggest that there are no 
significant differences when switching from brand to generic (Kesselheim et al., 2008, 
Moore et al., 2009). 
The results in this thesis confirm that there are some differences between ciclosporin and 
azithromycin products, brand versus generic and brand versus brand. This highlights the 
importance of not using ciclosporin as an interchangeable drug. 
7.5 Future control of generic and counterfeit drugs 
It is advisable that the health care authorities review the guidelines for approving generic 
medications on all levels. Post marketing pharmacovigilance is essential to ensure good 
quality medications are available for patients. Cost savings from using generics may not 
be real if serious side effects and/or toxicity occur. In a nutshell, it is not about brand or 
generic but quality and safety. 
Several recent conferences have addressed the noticeable increase of concern within the 
health regulators and pharmaceutical industry about fake medicines. 
One suggested solution to decrease the spread of counterfeit and substandard medicines is 
to review pricing. Price factors are one, if not the main reason for consumers to search for 
cheaper alternatives. This may incentivise consumers to search for and purchase drugs from 
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online pharmacies, which as mentioned earlier in this thesis, have a much higher chance of 
being counterfeit or substandard. One solution could be to look at the manufacturing costs 
that are imposed on pharmaceuticals such as registration costs (Medicines and Healthcare 
products Regulatory Agency, 2014). If costs associated by regulators are reviewed and 
reduced, this could result in a reduction in consumers looking for alternatives and lowering 
chances of potential adverse effects. In addition, many consumers are unaware of the risks 
from purchasing drugs online from Internet based pharmacies. Further information and 
warnings are needed to inform consumers of the possible dangers and how to proactively 
check the authenticity of vendors and of the drugs purchased. 
As mentioned in the thesis, there are many stages where counterfeits or substandard 
production methods can enter or occur. This could be reduced by refining the stages from 
manufacturing to distribution and by implementing a regular track and trace system where 
you can follow the whole process of a drug, from manufacturing, to distribution and 
dispensing can be followed. Manufacturers may not want to disclose who their suppliers 
are or their business practices, but transparency in the pharmaceutical industry should be 
essential to lower the risk to public health, reduce funding terrorism, better economic 
prosperity and reduce the vulnerabilities of counterfeit and substandard drugs entering the 
supply chain. Pharmaceutical counterfeiting could be the most important criminal activity 
worldwide, as this funds global terrorism and is a great risk to public safety. 
Another solution proposed by the American House Energy & Commerce Sub-committee 
on Oversight and Investigations hearing on counterfeit drugs was to increase state licensure 
supervision of drug wholesalers. In today’s age of technology, there are options that can be 
put in place to help fight the issue of counterfeit drugs entering the supply chain. One 
technology being considered is Radio Frequency Identification (RFID) (Food and Drug 
Administration, 2005). RFID is a chip that stores a serial number and can confirm the 
products identity. It can store much more information than a traditional barcode and can 
add a level of automation and inventory checks that traditional barcodes cannot. RFID has 
already made its way into adding an additional layer of security in passports. This 
highlights their reputation as a reliable form of tracking and data storage. An RFID consists 
of three main components, 1) the transponder, which is the actual radio frequency tag. This 
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is the piece that holds all the information, 2) the antenna, which is the coil that allows 
information to be read off the RFID tag and 3) the receiver, which is the scanner that 
decodes the information stored on the RFID tag. RFID tags are available in many sizes. 
Small RFID tags can be successfully added to individual drug packaging behind labels, 
which are scanned individually in close range and larger RFID tags to monitor and track 
large quantities of drugs in batches, as they move within a factory or logistically. In 
addition, security alerts can be implemented to logistics to monitor where shipments are 
and automatically notify vulnerabilities like shipments not being recorded as reaching their 
destination or not arriving at the desired destination within their expected time frame, 
highlighting possible delays due to counterfeit manipulation or tampering. Another 
advantage of RFID technology is that it is continuously being improved and innovated, 
thus allowing the ability to expand and update without the need to invest in a whole new 
infrastructure from the ground up. Large pharmaceutical companies have already started 
to implement this technology, AstraZeneca being one of the first. We can agree that the 
costs to implement and improve security and regulations are high but it has to be focused 
as a long-term goal. The benefits in reducing counterfeiting and substandard drugs will be 
felt across many sections and will thus free up revenues that would be otherwise used to 
react to the many repercussions. A global effort in implementation should be considered as 
cross border regulations would help reduce counterfeit drugs on a mass scale. 
In this thesis, some of the main vulnerabilities in the current pharmaceutical industries and 
ways in which we can approach to tackle the issues were discussed. The key ones being 
that the biggest flaws are in the legitimate supply chains. Upon further review, some ideas 
on cutting down on the levels of the supply chain and the advantages of introducing 
technologies in the manufacturing and distribution levels using RFID. This is even more 
important as drugs that are highly recognized and are in high demand in the marketplace 
receive less scrutiny. Technologies in large and small scale logistics could aid in faster and 
autonomous verification. “Good counterfeiters” invest a lot of time and effort into 
packaging in order to go undetected or arouse less suspicion. As labelling is the first area 
approached by counterfeiters it is even more important that small scale technologies are 
innovated and implemented into packaging. 
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These are some examples of the types of drugs that are being falsely labelled, Avastin (for 
cancer treatment) in the United States in 2012, made its way onto the market and affected 
19 medical practices. Investigation confirmed that the drugs contained no active ingredient. 
Truvada and Viread (for HIV/AIDS) was seized in the United Kingdom in 2011, again false 
labelling was used and in Kenya in 2011, just under 3,000 patients were affected by 
counterfeit Zidolam-N (for HIV/AIDS). This again highlights the even more importance 
of implementing technologies that can reduce fake labelling and increase the potential to 
verify drugs more easily. 
Further steps and checks should be made to ensure that packaging that is being disposed 
of, is destroyed in a manner, which will make it difficult to reuse. Another aspect of the 
challenge in the first stage is making the entry for counterfeiters even more difficult. As 
some manufacturing plants close, the equipment can be resold at a much lower cost, thus 
providing an opportunity for a much lower capital investment to start a counterfeit 
operation. One method to tackle this could be to require a form of registration for all 
manufacturing equipment that can be used for pharmaceutical manufacturing, similar to 
car registration. We can agree that even in the auto industry it has its vulnerabilities but a 
record keeping system in itself could be a deterrent or aid in future investigations. 
As discussed in this thesis, the Internet has become a big opportunity for fake pharmacies 
to sell counterfeit and substandard drugs. Consumers do not know how to verify if the 
vendors are authentic or if they are reputable. The drugs being delivered could be shipped 
from countries that have a high probability of counterfeit or substandard drug track record 
and low regulation from authorities. Consumers are looking for alternatives to their current 
suppliers, as cost reduction is one of the biggest incentives. They do not care who supplies 
them the drugs as long as they believe them to be authentic and at a cheaper price. 
Criminals are always looking for the most profitable opportunities. Counterfeiters focused 
more on supplying individuals with lifestyle drugs but some are now shifting their focus to 
supplying pharmaceutical wholesalers, prioritizing those that supply aid organizations and 
hospitals. These are the ones that focus heavily on cost reduction. For counterfeiters to 
exploit this is very easy. The lack or no regulation in fake online pharmacies makes it 
extremely difficult for authorities to crack down on these global operations. With the 
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growing popularity of unregulated virtual currencies such as Bitcoin and consumers 
accepting the use of virtual currencies by using intermediary merchants to convert and pay 
for items online, it is becoming more difficult for authorities to track monetary transactions 
online. 
Free trade has opened up international markets for developing countries to export key 
pharmaceuticals. Unfortunately as discussed, due to low regulations and standards, this has 
opened up the risk of counterfeit and substandard production. Local authorities in 
developing countries could choose local economic developments over a global initiative to 
fight drug counterfeiting. Another challenge to tackle is on the border entry points, if 
customs cannot authenticate in the field they must allow drugs to continue on their destined 
route. Improvement in detection and testing at key import zones could increase the quantity 
of counterfeit and substandard drugs being seized. The next stage of detection needs to be 
held at the distribution level, where those who wish to trade pharmaceuticals to smaller 
regional distributors need to accept some form of responsibility and accountability for 
drugs that are being handled. The last phase of verification and detection must be at the 
dispensing stage. We can agree that system updates across many levels will come at a cost, 
especially in a time where healthcare systems are under a lot of financial pressure, but the 
future savings and risk reduction is worth the investment and future savings. 
Additional methods for detecting counterfeit and substandard medicines could be by using 
Physical Chemical Identifiers (PCiDs). According to the FDA, PCiD is a substance or 
combination of substances possessing a unique physical or chemical property that 
unequivocally identifies and authenticates a drug product or dosage form (Food and Drug 
Administration, 2011a). As machinery is more expensive and there are difficulties in 
certain techniques, such as colour matching when layering, this could deter counterfeiters 
to even attempt. As new methods and techniques in the manufacturing process are 
implemented, a new level of intricacy such as compression techniques for embossing and 
layering, to printing logos and bar codes, make it more difficult for counterfeiters. This in 
itself adds a critical element for the end consumer, increasing the chances of detection 
before consumption. Another identifiable PCiD technique is the use of pearlescent colours 
in the film coating process that make it very hard to replicate the colours. These 
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predominantly rely on the consumer being aware of their drug/s, especially with taste as 
some drugs are coated with flavours to mask the taste of the core tablet. However adding 
an element of taste and appearance does have its drawbacks such as higher costs. With the 
added machinery and manufacturing processes, these costs will undoubtedly be passed 
onto the consumer, but these extra costs could be subsidised by regulators or governments. 
There are the additional factors in film coating techniques, such as Micro Taggants, that 
are microscopic particles, etched onto the drug, but this form factor in my opinion is not as 
effective as labelling technology. Because verification requires inspection of an actual 
tablet using a field reader, this would mean that only drugs that have raised suspicion would 
be tested (Zadbuke et al., 2013). 
As mentioned in the thesis here is another example on the slow to react and implement of 
important changes to regulation and anti-counterfeiting measures. The falsified medicines 
directive (FMD) was published back in 2011 with a goal to successfully implement it by 
2018 (European Commission, 2011). Seven years to implement such measures is far too 
long. Especially with the rate of speed that counterfeiters operate and adapt, this is 
unacceptable. Laws need to be tightened to put consumer safety as the first priority and if 
pharmaceutical companies do not comply, heavy fines should be imposed. 
One of the solutions to assist in detecting counterfeit and substandard medications could 
be to install testing facilities within hospitals staffed with trained personnel. Another 
solution could be independent analytical units within a region or a city as is the case in the 
U.K. with food safety testing. These units could random test those medications that 
routinely raise suspicion about their quality or effectiveness. This could provide an 
additional layer of safety before reaching patients. Additionally, it can indicate when 
counterfeits have entered the supply chain. The costs to implement such analytical units 
could be high but at least it would protect patients and reduce further complications. These 
units would be independent from regulators and drug companies removing any conflict of 
interest. 
With the evidence from the USA of former government employees taking senior positions 
in large pharmaceutical companies, it is clear that a conflict of interest is present. This 
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could be a reason why regulations have never been put in place or are too relaxed, and are 
not challenged. This is despite the benefits of regulation outweighing the risks. One 
example is the link between the former U.S. Secretary of Defence and the approval of the 
sugar substitute “Aspartame”. When a suspicion of a conflict of interest is raised, this needs 
to be investigated and addressed. You can always follow the money and there is no smoke 
without fire. With big pharmaceutical companies donating millions of dollars to political 
campaigns, these serve as an IOU for later years and consumers may no longer be a priority 
(Gennet, 2011). 
7.6 Possible further studies 
7.6.1 Ciclosporin 
1. Analyse more capsules from a wider range of countries so adding to the existing list 
of generics. 
2. Improve the method to investigate more impurities in both the generic and brand 
capsules. 
3. Investigation of possible toxic effect from impurities in all capsules. 
7.6.2 Other drugs 
1. Set up a new study to measure the active ingredients of lisinopril in brand versus 
generic tablets obtained from different countries.  
2. This will involve development of a nonspecific capillary electrophoresis method and 
a HPLC method for determination of active ingredients of lisinopril in tablets. 
3. Development of a methodology that will enable us to accurately identify the 
impurities in both ciclosporin and lisinopril. This will involve development of either 
LC-MS or NMR methodology for identification of impurities 
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4. Set up a pharmacokinetic study in patients receiving brand versus generic ciclosporin 
and lisinopril formulations in order to accurately measure the efficacy/toxicity profile 
and the bioequivalence of the generic formulations 
Alfazema & Perrett (1997) developed, using chemometrics, a generic MECC method to 
analyse complex urines and other unknowns (Alfazema et al., 1997). Cyclodextrins (CDs) 
are powerful modifiers of CE separations. With low-wavelength UV, sulphated-ß-CD-
MECC can separate and detect both charged and uncharged species simultaneously 
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Appendices 
Appendix 1: Raw Data for ciclosporin HPLC test A and B 
Table A1.1: Peak areas for ciclosporin brand S 
Sample Peak Area Ciclosporin mg/mL 
S1 5 min 0 0.00 
S1 10 min 68.3 0.15 
S1 15 min 85.1 0.19 
S1 30 min 87.2 0.19 
S1 60 min 83.9 0.18 
S1 90 min 82.2 0.18 
S2 5 min 0 0.00 
S2 10 min 36.1 0.08 
S2 15 min 72.5 0.16 
S2 30 min 85.7 0.19 
S2 60 min 88.1 0.19 
S2 90 min 85 0.19 
S3 5 min 0 0.00 
S3 10 min 46.8 0.10 
S3 15 min 73.5 0.16 
S3 30 min 84.8 0.19 
S3 60 min 80.5 0.18 
S3 90 min 86.2 0.19 
S4 5 min 1.4 0.00 
S4 10 min 63.8 0.14 
S4 15 min 88.4 0.19 
S4 30 min 91.4 0.20 
S4 60 min 87 0.19 
S4 90 min 97.4 0.21 
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Table A1.2: Peak areas for ciclosporin brand T 
Sample Peak Area Ciclosporin mg/mL 
T1 5 min 17.3 0.04 
T1 10 min 54.6 0.13 
T1 15 min 73.8 0.18 
T1 30 min 85.8 0.21 
T1 60 min 86 0.21 
T1 90 min 91.5 0.22 
T2 5 min 0 0.00 
T2 10 min 62.1 0.15 
T2 15 min 95.3 0.23 
T2 30 min 86.6 0.21 
T2 60 min 88.5 0.22 
T2 90 min 87.6 0.21 
T3 5 min 4.8 0.01 
T3 10min 70.4 0.17 
T3 15 min 77.2 0.19 
T3 30 min 81.9 0.20 
T3 60 min 80 0.20 
T3 90 min 88.4 0.22 
T4 5 min 0 0.00 
T4 10 min 0 0.00 
T4 15 min 86.5 0.21 
T4 30 min 83.2 0.20 
T4 60 min 87.1 0.21 
T4 90 min 81.9 0.20 
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Table A1.3: Peak areas for ciclosporin brand P 
Sample Peak Area Ciclosporin mg/mL 
P1 5 min 0 0.00 
P1 10 min 73.5 0.16 
P1 15 min 80.8 0.18 
P1 30 min 84 0.19 
P1 60 min 87 0.19 
P1 90 min 82.5 0.18 
P2 5 min 0 0.00 
P2 10 min 67.5 0.15 
P2 15 min 96.2 0.21 
P2 30 min 72.8 0.16 
P2 60 min 90.2 0.20 
P2 90 min 88.3 0.20 
P3 5 min 0 0.00 
P3 10 min 71.6 0.16 
P3 15 min 85.3 0.19 
P3 30 min 82.2 0.18 
P3 60 min 82.9 0.18 
P3 90 min 89.6 0.20 
P4 5 min 25.2 0.06 
P4 10 min 80.4 0.18 
P4 15 min 86.4 0.19 
P4 30 min 98.2 0.22 
P4 60 min 88.3 0.20 
P4 90 min 88.1 0.19 
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Table A1.4: Peak areas for ciclosporin brand J 
Sample Peak Area Ciclosporin mg/mL 
J1 5 min 2.3 0.00 
J1 10 min 28.4 0.06 
J1 15 min 32.6 0.07 
J1 30 min 39.9 0.09 
J1 60 min 42.3 0.09 
J1 90 min 41.7 0.09 
J2 5 min 0 0.00 
J2 10 min 30.8 0.07 
J2 15 min 38.5 0.08 
J2 30 min 38.7 0.08 
J2 60 min 39.6 0.09 
J2 90 min 37.3 0.08 
J3 5 min 1.8 0.00 
J3 10 min 34.2 0.07 
J3 15 min 37.6 0.08 
J3 30 min 38.9 0.08 
J3 60 min 40.4 0.09 
J3 90 min 41 0.09 
J4 5 min 1.8 0.00 
J4 10 min 29.6 0.06 
J4 15 min 39.1 0.08 
J4 30 min 37.4 0.08 
J4 60 min 41.3 0.09 
J4 90 min 42.5 0.09 
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Table A1.5: Peak areas for ciclosporin brand E 
Sample Peak Area Ciclosporin mg/mL 
E1 5 min 0 0.00 
E1 10 min 3.3 0.01 
E1 15 min 18.9 0.04 
E1 30 min 32 0.07 
E1 60 min 35.7 0.08 
E1 90 min 40.5 0.09 
E2 5 min 1.9 0.00 
E2 10 min 0 0.00 
E2 15 min 18.2 0.04 
E2 30 min 34.3 0.07 
E2 60 min 35.2 0.08 
E2 90 min 37.5 0.08 
E3 5 min 1.9 0.00 
E3 10 min 8.8 0.02 
E3 15 min 35.5 0.08 
E3 30 min 37.6 0.08 
E3 60 min 37.1 0.08 
E3 90 min 40.2 0.09 
E4 5 min 1.9 0.00 
E4 10 min 13.3 0.03 
E4 15 min 33.5 0.07 
E4 30 min 40 0.09 
E4 60 min 40.1 0.09 
E4 90 min 41.7 0.09 
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Table A1.6: Peak areas for ciclosporin generic C 
Sample Peak Area Ciclosporin mg/mL 
C1 5 min 68.8 0.15 
C1 10 min 82.5 0.18 
C1 15 min 80.8 0.18 
C1 30 min 85 0.19 
C1 60 min 86.1 0.19 
C1 90 min 88.5 0.19 
C2 5 min 79.7 0.18 
C2 10 min 82.6 0.18 
C2 15 min 84.6 0.19 
C2 30 min 83.8 0.18 
C2 60 min 76.2 0.17 
C2 90 min 86.1 0.19 
C3 5 min 75.6 0.17 
C3 10 min 96.7 0.21 
C3 15 min 81.9 0.18 
C3 30 min 87.6 0.19 
C3 60 min 86.8 0.19 
C3 90 min 87.7 0.19 
C4 5 min 89.2 0.20 
C4 10 min 90.8 0.20 
C4 15 min 83.5 0.18 
C4 30 min 83.8 0.18 
C4 60 min 81.5 0.18 
C4 90 min 88.8 0.20 
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Table A1.7: Peak areas for ciclosporin generic I 
Sample Peak Area Ciclosporin mg/mL 
I1 5 min 16.9 0.04 
I1 10 min 60 0.13 
I1 15 min 68 0.15 
I1 30 min 69.7 0.15 
I1 60 min 71.1 0.16 
I1 90 min 61.8 0.14 
I2 5 min 0 0.00 
I2 10 min 46.9 0.10 
I2 15 min 67.4 0.15 
I2 30 min 60.2 0.13 
I2 60 min 66.1 0.15 
I2 90 min 66.9 0.15 
I3 5 min 0 0.00 
I3 10 min 54.1 0.12 
I3 15 min 65.2 0.14 
I3 30 min 59.7 0.13 
I3 60 min 63.4 0.14 
I3 90 min 61.4 0.14 
I4 5 min 0.1 0.00 
I4 10 min 15.9 0.04 
I4 15 min 68.6 0.15 
I4 30 min 58.4 0.13 
I4 60 min 62.2 0.14 
I4 90 min 77.2 0.17 
Table A1.8: Ciclosporin capsules rupture times test A 
Ciclosporin Rupture time (min) Average 
(min) Run 1 Run 2 Run 3 Run 4 
Brand S 05:30 05:49 06:20 05:13 05:43:00 
Brand T 05:00 05:16 04:30 05:42 05:07:00 
Brand P 06:00 06:00 05:30 04:59 05:37:15 
Brand J 05:10 04:54 05:23 05:19 05:11:30 
Brand E 06:00 05:27 05:31 05:01 05:29:45 
Generic C 02:20 01:10 02:15 02:00 01:56:15 
Generic I 04:40 05:50 06:22 05:27 05:34:45 
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Table A1.9: Peak areas for ciclosporin brand Sa 
Sample Peak Area Ciclosporin mg/L 
Sa1 5 min 217.6 4 
Sa1 10 min 5557.5 100 
Sa1 15 min 8385.6 151 
Sa1 20 min 9144.8 164 
Sa1 30 min 9187.7 165 
Sa1 45 min 9739.5 175 
Sa1 60 min 9595.2 172 
Sa1 90 min 9756.6 175 
Sa1 120 min 10061.6 181 
Sa2 5 min 252.1 5 
Sa2 10 min 4906 88 
Sa2 15 min 6541.1 118 
Sa2 20 min 7204.2 129 
Sa2 30 min 8350.5 150 
Sa2 45 min 9647.7 173 
Sa2 60 min 9576.8 172 
Sa2 90 min 10217.7 184 
Sa2 120 min 10228.7 184 
Sa3 5 min 226 4 
Sa3 10 min 7248.4 130 
Sa3 15 min 8442.8 152 
Sa3 20 min 8625.6 155 
Sa3 30 min 9047.7 163 
Sa3 45 min 8785.9 158 
Sa3 60 min 9534.1 171 
Sa3 90 min 9932 179 
Sa3 120 min 9875.3 177 
Sa4 5 min 251.7 5 
Sa4 10 min 5574.8 100 
Sa4 15 min 7615.3 137 
Sa4 20 min 9181 165 
Sa4 30 min 9368.6 168 
Sa4 45 min 9849 177 
Sa4 60 min 10076.4 181 
Sa4 90 min 9840.4 177 
Sa4 120 min 10043 181 
Sa5 5 min 0 0 
Sa5 10 min 1723.3 31 
Sa5 15 min 2692.6 48 
Sa5 20 min 7984.8 144 
Sa5 30 min 8507.3 153 
Sa5 45 min 8917 160 
Sa5 60 min 9483.9 170 
Sa5 90 min 10119.6 182 
Sa5 120 min 10235.8 184 
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Table A1.10: Peak areas for ciclosporin brand TK 
Sample Peak Area Ciclosporin mg/L 
TK1 5 min 0.6 0 
TK1 10 min 1969.1 36 
TK1 15 min 4396.6 80 
TK1 20 min 7627.4 138 
TK1 30 min 8528 154 
TK1 45 min 9132.4 165 
TK1 60 min 9711.4 176 
TK1 90 min 9919.2 180 
TK1 120 min 10105.5 183 
TK2 5 min 1503.4 27 
TK2 10 min 6155.8 111 
TK2 15 min 7105.1 129 
TK2 20 min 7966.5 144 
TK2 30 min 8651.7 157 
TK2 45 min 8866.2 161 
TK2 60 min 8675.2 157 
TK2 90 min 9448.3 171 
TK2 120 min 10041.6 182 
TK3 5 min 7.4 0 
TK3 10 min 7552.9 137 
TK3 15 min 8819.3 160 
TK3 20 min 9494.5 172 
TK3 30 min 9709.2 176 
TK3 45 min 9910.6 179 
TK3 60 min 10097 183 
TK3 90 min 10144.5 184 
TK3 120 min 10204.6 185 
TK4 5 min 174.1 3 
TK4 10 min 7876.7 143 
TK4 15 min 9586.8 174 
TK4 20 min 9628.5 174 
TK4 30 min 9801 178 
TK4 45 min 9860.8 179 
TK4 60 min 9960 180 
TK4 90 min 10069.5 182 
TK4 120 min 9955 180 
TK5 5 min 217.3 4 
TK5 10 min 5395.6 98 
TK5 15 min 7129.8 129 
TK5 20 min 8662.3 157 
TK5 30 min 9498.5 172 
TK5 45 min 9680.1 175 
TK5 60 min 9885.6 179 
TK5 90 min 9954.2 180 
TK5 120 min 9969.9 181 
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Table A1.11: Peak areas for ciclosporin brand Pak 
Sample Peak Area Ciclosporin mg/L 
Pak1 5 min 0 0 
Pak1 10 min 6561.1 117 
Pak1 15 min 8749.6 156 
Pak1 20 min 9065.9 161 
Pak1 30 min 9318.2 166 
Pak1 45 min 9707.6 173 
Pak1 60 min 9896.9 176 
Pak1 90 min 10044.5 179 
Pak1 120 min 10122.4 180 
Pak2 5 min 164.5 3 
Pak2 10 min 7312.5 130 
Pak2 15 min 8994 160 
Pak2 20 min 9208.7 164 
Pak2 30 min 9536.7 170 
Pak2 45 min 9861 176 
Pak2 60 min 9910.1 176 
Pak2 90 min 10106.8 180 
Pak2 120 min 9997.7 178 
Pak3 5 min 180.6 3 
Pak3 10 min 7092.6 126 
Pak3 15 min 7830.3 139 
Pak3 20 min 8264.7 147 
Pak3 30 min 8843.8 157 
Pak3 45 min 9107.6 162 
Pak3 60 min 9264.1 165 
Pak3 90 min 9722.9 173 
Pak3 120 min 9731.5 173 
Pak4 5 min 208.4 4 
Pak4 10 min 6731.3 120 
Pak4 15 min 8319.9 148 
Pak4 20 min 8704.6 155 
Pak4 30 min 9226.3 164 
Pak4 45 min 9594.9 171 
Pak4 60 min 9666.3 172 
Pak4 90 min 9536.8 170 
Pak4 120 min 9728.6 173 
Pak5 5 min 338.3 6 
Pak5 10 min 6420 114 
Pak5 15 min 7553.7 134 
Pak5 20 min 8110 144 
Pak5 30 min 8554.1 152 
Pak5 45 min 9007.2 160 
Pak5 60 min 9078 162 
Pak5 90 min 9350.4 166 
Pak5 120 min 8782.3 156 
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Table A1.12: Peak areas for ciclosporin brand Jor 
Sample Peak Area Ciclosporin mg/L 
Jor1 5 min 289.1 5 
Jor1 10 min 3550.2 64 
Jor1 15 min 4312.4 78 
Jor1 20 min 3976.1 72 
Jor1 30 min 3902.6 70 
Jor1 45 min 3512.4 63 
Jor1 60 min 3431.5 62 
Jor1 90 min 3448.9 62 
Jor1 120 min 3372.5 61 
Jor2 5 min 283.5 5 
Jor2 10 min 4128.2 74 
Jor2 15 min 3604.8 65 
Jor2 20 min 3603.3 65 
Jor2 30 min 3455.9 62 
Jor2 45 min 3483.5 63 
Jor2 60 min 4437 80 
Jor2 90 min 4516.1 81 
Jor2 120 min 4592.7 83 
Jor3 5 min 289.3 5 
Jor3 10 min 3241.7 58 
Jor3 15 min 3867.6 70 
Jor3 20 min 4238.5 76 
Jor3 30 min 4461.4 80 
Jor3 45 min 4508.9 81 
Jor3 60 min 4438.3 80 
Jor3 90 min 4560.5 82 
Jor3 120 min 4600.5 83 
Jor4 5 min 303.6 5 
Jor4 10 min 3286.7 59 
Jor4 15 min 3783.9 68 
Jor4 20 min 3971.9 72 
Jor4 30 min 3966.2 71 
Jor4 45 min 3814 69 
Jor4 60 min 3879.5 70 
Jor4 90 min 4054.3 73 
Jor4 120 min 4353.7 78 
Jor5 5 min 292.2 5 
Jor5 10 min 1685.5 30 
Jor5 15 min 3125.2 56 
Jor5 20 min 3436.1 62 
Jor5 30 min 3605.9 65 
Jor5 45 min 3920.4 71 
Jor5 60 min 4316.8 78 
Jor5 90 min 4324.6 78 
Jor5 120 min 4457.1 80 
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Table A1.13: Peak areas for ciclosporin brand Egy 
Sample Peak Area Ciclosporin mg/L 
Egy1 5 min 258.9 5 
Egy1 10 min 582.1 11 
Egy1 15 min 3431.5 62 
Egy1 20 min 4112.8 75 
Egy1 30 min 4234.9 77 
Egy1 45 min 4347.8 79 
Egy1 60 min 4477.4 81 
Egy1 90 min 4602.6 84 
Egy1 120 min 4577 83 
Egy2 5 min 254.1 5 
Egy2 10 min 326.6 6 
Egy2 15 min 3195.1 58 
Egy2 20 min 3512.8 64 
Egy2 30 min 3922.8 71 
Egy2 45 min 4189.7 76 
Egy2 60 min 4205.9 76 
Egy2 90 min 4541.2 82 
Egy2 120 min 4593.2 83 
Egy3 5 min 258.2 5 
Egy3 10 min 1539.8 28 
Egy3 15 min 3770.2 68 
Egy3 20 min 4177.4 76 
Egy3 30 min 4196.3 76 
Egy3 45 min 4459.9 81 
Egy3 60 min 4398.4 80 
Egy3 90 min 4526.8 82 
Egy3 120 min 4628.4 84 
Egy4 5 min 265 5 
Egy4 10 min 329.2 6 
Egy4 15 min 2349.5 43 
Egy4 20 min 3579.9 65 
Egy4 30 min 4000.1 73 
Egy4 45 min 4233.7 77 
Egy4 60 min 4454.7 81 
Egy4 90 min 4633.7 84 
Egy4 120 min 4569.9 83 
Egy5 5 min 266.8 5 
Egy5 10 min 569.5 10 
Egy5 15 min 3135.3 57 
Egy5 20 min 3674.9 67 
Egy5 30 min 3921.4 71 
Egy5 45 min 4256.9 77 
Egy5 60 min 4304.2 78 
Egy5 90 min 4465.7 81 
Egy5 120 min 4435.4 81 
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Table A1.14: Peak areas for ciclosporin generic Col 
Sample Peak Area Ciclosporin mg/L 
Col1 5 min 7958.6 143 
Col1 10 min 8410.6 151 
Col1 15 min 8333.4 150 
Col1 20 min 8283.9 149 
Col1 30 min 8635.8 155 
Col1 45 min 8642.3 155 
Col1 60 min 8660.9 156 
Col1 90 min 8741.8 157 
Col1 120 min 8456.9 152 
Col2 5 min 6094.7 109 
Col2 10 min 8103 145 
Col2 15 min 8429 151 
Col2 20 min 8669.9 156 
Col2 30 min 8668.8 156 
Col2 45 min 8603.8 154 
Col2 60 min 8799 158 
Col2 90 min 8616.9 155 
Col2 120 min 8513.7 153 
Col3 5 min 7872.5 141 
Col3 10 min 8245.2 148 
Col3 15 min 8450.5 152 
Col3 20 min 8195.4 147 
Col3 30 min 8460.3 152 
Col3 45 min 8570 154 
Col3 60 min 8545.8 153 
Col3 90 min 8453.9 152 
Col3 120 min 8332.2 150 
Col4 5 min 8056.1 145 
Col4 10 min 8208.9 147 
Col4 15 min 8353.5 150 
Col4 20 min 8330.8 150 
Col4 30 min 8409 151 
Col4 45 min 8275.1 149 
Col4 60 min 8304.9 149 
Col4 90 min 8277.2 149 
Col4 120 min 8224 148 
Col5 5 min 7674.8 138 
Col5 10 min 8218 148 
Col5 15 min 8219.8 148 
Col5 20 min 8298.6 149 
Col5 30 min 8413.4 151 
Col5 45 min 8434.5 151 
Col5 60 min 8755.1 157 
Col5 90 min 8667.1 156 
Col5 120 min 8534.7 153 
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Table A1.15: Peak areas for ciclosporin generic Ir 
Sample Peak Area Ciclosporin mg/L 
Ir1 5 min 366.8 7 
Ir1 10 min 3152.5 56 
Ir115 min 6124.8 109 
Ir1 20 min 7878.4 141 
Ir1 30 min 9249.7 165 
Ir1 45 min 9853.5 176 
Ir1 60 min 10151.9 181 
Ir1 90 min 9747.7 174 
Ir1 120 min 9751.2 174 
Ir2 5 min 10.3 0 
Ir2 10 min 3313.6 59 
Ir2 15 min 6149.1 110 
Ir2 20 min 7818.6 140 
Ir2 30 min 8939.5 160 
Ir2 45 min 9807.8 175 
Ir2 60 min 10078.5 180 
Ir2 90 min 9943.3 178 
Ir2 120 min 9973.5 178 
Ir3 5 min 390.1 7 
Ir3 10 min 4886.9 87 
Ir3 15 min 7500 134 
Ir3 20 min 8265.8 148 
Ir3 30 min 8755.5 156 
Ir3 45 min 9388.4 168 
Ir3 60 min 9828 176 
Ir3 90 min 9991.8 179 
Ir3 120 min 9750.5 174 
Ir4 5 min 340.1 6 
Ir4 10 min 3608.5 64 
Ir4 15 min 6027.6 108 
Ir4 20 min 7239.7 129 
Ir4 30 min 9026 161 
Ir4 45 min 9723.4 174 
Ir4 60 min 9665 173 
Ir4 90 min 9557.8 171 
Ir4 120 min 9597.9 172 
Ir5 5 min 277.3 5 
Ir5 10 min 5983.9 107 
Ir5 15 min 8403.2 150 
Ir5 20 min 9115.3 163 
Ir5 30 min 9429.6 169 
Ir5 45 min 9529.1 170 
Ir5 60 min 9652.4 173 
Ir5 90 min 9521.7 170 
Ir5 120 min 9601.7 172 
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Table A1.16: Peak areas for ciclosporin generic M 
Sample Peak Area Ciclosporin mg/L 
M1 5 min 5.4 0 
M1 10 min 5687.5 103 
M1 15 min 5660.8 103 
M1 20 min 6160.2 112 
M1 30 min 5998.1 109 
M1 45 min 7397.4 135 
M1 60 min 7680.4 140 
M1 90 min 6545.9 119 
M1 120 min 6745.4 123 
M2 5 min 4 0 
M2 10 min 3015.6 55 
M2 15 min 5786.5 105 
M2 20 min 7081.1 129 
M2 30 min 6574.3 120 
M2 45 min 6780.6 123 
M2 60 min 6411.5 117 
M2 90 min 5214.6 95 
M2 120 min 5783.2 105 
M3 5 min 0.3 0 
M3 10 min 4289.5 78 
M3 15 min 5204.2 95 
M3 20 min 4915.1 89 
M3 30 min 5579 102 
M3 45 min 4679.4 85 
M3 60 min 5302 96 
M3 90 min 4831.1 88 
M3 120 min 4972.6 90 
M4 5 min 2.8 0 
M4 10 min 2095 38 
M4 15 min 3592.7 65 
M4 20 min 3640.4 66 
M4 30 min 3306.8 60 
M4 45 min 3387.4 62 
M4 60 min 3862.3 70 
M4 90 min 3890.3 71 
M4 120 min 4652 85 
M5 5 min 3.5 0 
M5 10 min 382.3 7 
M5 15 min 3658.6 67 
M5 20 min 4561.8 83 
M5 30 min 4992.9 91 
M5 45 min 5239 95 
M5 60 min 5150.5 94 
M5 90 min 6040.4 110 
M5 120 min 5699.7 104 
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Table A1.17: Ciclosporin capsules rupture times test B 
Ciclosporin Rupture time (min) 
Run 1 Run 2 Run 3 Run 4 Run 5 
Brand Sa All capsules ruptured within 15 min 
Brand TK All capsules ruptured within 15 min 
Brand Pak All capsules ruptured within 15 min 
Brand Jor All capsules ruptured within 15 min 
Brand Egy All capsules ruptured within 15 min 
Generic Col All capsules ruptured within 15 min 
Generic Ir All capsules ruptured within 15 min 
Generic M All capsules ruptured within 15 min 
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Appendix 2: UHPLC-MS results of the impurities detection in 
ciclosporin capsules 
Table A2.18: Impurities in ciclosporin capsules from Colombia (Col), in negative and 
positive modes 
 
Table A2.19: Impurities in ciclosporin capsules from Egypt (Egy), in negative and 
positive modes 
 
  
Col Neg
Molecular formula Name Fold ChangeTtest
C6H14O6 Sorbitol 261.17481 8.9E-07
C18H34O3 2-Oxooctadecanoic acid 26.9869983 0.00135
C7H13O6P Mevinphos 2.08953018 0.46759
C10H6N2O2S2 Oxidized Photinus luciferin 1.97221459 0.00238
C5H10O6 D-Xylonate 1.57202829 0.40148
Col Pos
Molecular formula Name Fold ChangeTtest
C33H49N5O6 Zizyphine A 3409.64127 6.95E-10
C26H41NO7 Delcorine 1077.2487 3.5E-09
Br3GaH3N gallium;azane;tribromide 952.8728 3.4E-09
C24H51NO7P 1-Palmitoylglycerophosphocholine 841.99466 1E-09
C26H45N7O7 seryl-HYPE(transpropyl)-octahydroindole-2-carbonyl-arginine 618.967749 1.3E-06
Eg Neg
Molecular formulaName Fold Change Ttest
I4In- tetraiodoindiganuide 1688.45986 0.34626
C17H35NO3 AC1L4KW4 54.0655596 0.33662
C17H35NO3 AC1L4KW4 52.4486712 0.33574
C20H40O3 L-2-Hydroxyphytanate 29.7710108 0.3363
C18H32O3 (9Z,12Z)-(8R)-Hydroxyoctadeca-9,12-dienoic acid 17.6520245 0.32446
Eg Pos
Molecular formulaName Fold Change Ttest
C20H34O3 2alpha-(Hydroxymethyl)-5alpha-androstane-3beta,17beta-diol 10.0637702 0.34073
C36H74Hg Dioctadecylmercury 8.69145162 0.39697
C7H10O 3-CYCLOHEXENE-1-CARBOXALDEHYDE 8.47751377 0.0001
C20H32O3 (15S)-15-Hydroxy-5,8,11-cis-13-trans-eicosatetraenoate 7.89162577 0.27577
C25H32N2O2 Dextromoramide 5.26814004 0.29427
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Table A2.20: Impurities in ciclosporin capsules from India (I), in negative and positive 
modes 
 
Table A2.21: Impurities in ciclosporin capsules from Iran (Ir), in negative and positive 
modes 
 
  
India Neg
Molecular formula Name Fold Change Ttest
C29H30O8 Piperaduncin B 3506.41425 8.5E-08
C12H24O11 Melibiitol 1341.30713 1.8E-10
C22H21N2S+ AC1L2KWH 1224.92981 7.1E-10
C21H21ClN4OS Ziprasidone 606.023622 1.6E-08
C6H14O6 Sorbitol 90.784177 3.3E-09
India Pos
Molecular formula Name Fold Change Ttest
Cl6H2Pt chloroplatinic acid 2593.85547 2.6E-10
C12H24O2 lauric acid 2069.97359 1.7E-08
C15H25Cl3N4 N-ethyl-4-nonyl-6-(trichloromethyl)-1,3,5-triazin-2-amine 1436.77562 1.7E-10
C10H23N3O N,N-Dibutylglycine hydrazide 1418.85452 1E-06
Ir Neg
Molecular formula Name Fold Change Ttest
C6H14O6 Sorbitol 497.818238 1.1E-11
C12H24O11 Melibiitol 262.2803 2E-08
C9H12N2O5 Deoxyuridine 100.136193 2.5E-14
C7H13O6P Mevinphos 3.41571746 0.21911
C10H6N2O2S2 Oxidized Photinus luciferin 1.73012836 0.06219
Ir Pos
Molecular formula Name Fold Change Ttest
C38H63NO10 alpha-(3-hydroxysialyl)cholesterol 9887.12843 3.1E-07
C37H63NO6S AC1L5827 5180.27028 1.2E-06
C31H62NO8P PC(10:0/13:0)[U] 5179.92812 0.00051
C35H60O7P2 all-trans-Heptaprenyl diphosphate 4168.99115 4E-07
C26H41NO7 Delcorine 3007.32626 2.3E-05
C40H63NO6 NSC679741 2297.89493 0.00387
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Table A2.22: Impurities in ciclosporin capsules from Jordan (Jor), in negative and 
positive modes 
 
Table A2.23: Impurities in ciclosporin capsules from Morocco (M), in negative and 
positive modes 
 
Jor Neg
Molecular formula Name Fold Change Ttest
C18H36O3 (R)-2-Hydroxystearate 3.06488194 0.04801
C18H36O3 (R)-2-Hydroxystearate 2.00790836 0.17774
C10H6N2O2S2 Oxidized Photinus luciferin 1.82755613 0.05196
C10H6N2O2S2 Oxidized Photinus luciferin 1.42473336 1E-05
C19H24N2O2 Praziquantel 1.27067976 0.55117
Jor Pos
Molecular formula Name Fold Change Ttest
C6H9N3 3,3'-iminodipropionitrile 3.3215266 0.01494
C4H5NO allyl isocyanate 2.65591664 0.00167
C20H36O3 15-hydroxyicosa-11,13-dienoic acid 2.63146847 3.9E-05
C20H36O3 15-hydroxyicosa-11,13-dienoic acid 2.37246828 0.00049
FO3P-2 fluorophosphate 1.70247524 0.00037
M Neg
Molecular formula Name Fold Change Ttest
C41H54O2 Okenone 11839.3048 5.5E-06
C42H56O4 2,2'-Diketospirilloxanthin 5986.36865 3.1E-05
C11H20O10 Vicianose 5552.06902 0.34668
C34H50N2O4+2 AC1L1RH6 4665.35719 7.3E-05
H2O7P2-2 pyrophosphate 2- 2250.24899 0.3468
C26H52N2O5S 61741-09-1 1515.07028 7.8E-07
Tc Technetium-101 840.783931 0.34646
M Pos
Molecular formula Name Fold Change Ttest
C30H46N4O4 AC1L1G95 1522.08278 0.00032
C38H52N2O4+2 AC1L46ED 1303.11028 0.00018
C44H87NO8P+ AC1MHWLG 1256.02653 0.10026
C29H48O7 Contignasterol 793.070597 0.00054
C40H46N4 BRN 0466832 743.569797 0.00027
C42H83NO7P 1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphonocholine 638.292384 0.11432
C41H54O2 Okenone 630.807688 0.00031
C27H25Br5N2O9 CHEMBL454956 570.038657 0.23225
C31H70O18 AC1L1WNS 449.927854 0.00025
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Table A2.24: Impurities in ciclosporin capsules from Pakistan (Pak), in negative and 
positive modes 
 
Table A2.25: Impurities in ciclosporin capsules from Saudi (Sa), in negative and positive 
modes 
 
  
Pak Neg
Molecular formula Name Fold Change Ttest
C10H6N2O2S2 Oxidized Photinus luciferin 1.07840377 0.22804
C18H36N6O4 Ile Arg Ile 1.06317935 0.47937
C10H6N2O2S2 Oxidized Photinus luciferin 1.02430833 0.86963
C20H24O3 Acitretin Ro 12-7310 1.01927338 0.87279
C21H26O3 Acitretin 0.99859995 0.98356
C18H38N6O4 Lys Lys Lys 0.99355099 0.93072
C14H22N2O3 Atenolol 0.98993979 0.91512
C18H22N2S Trimeprazine 0.97062822 0.44611
C4H2O4 Acetylenedicarboxylate 0.96777327 0.55454
Pak
Molecular formula Name Fold Change Ttest
C22H43NO erucyl amide 320.773752 0.13787
C20H40N2. C2H4O2 Glyodin 110.947191 0.06791
C32H64N4O2 AC1NMO0A 97.9016981 0.09702
C19H36O3 methyl ricinoleate 30.2515164 0.03053
C20H36O3 15-hydroxyicosa-11,13-dienoic acid 4.60343945 1.9E-09
C20H36O3 15-hydroxyicosa-11,13-dienoic acid 4.01295774 1.7E-09
C27H22F4N4O3S Losulazine 1.75328667 0.31099
C5H8O3S 4-Methylthio-2-oxobutanoic acid 1.72723948 0.08443
Sa Neg
Molecular formula Name Fold Change Ttest
C20H36O3 (&plusmn;)11-HEDE 2.90547033 1.6E-05
C6H9N3 3,3'-iminodipropionitrile 2.64516157 0.08245
C18H28O 6-[5]-ladderane-1-hexanol 1.86989155 0.00018
C21H34O4 Tetrahydrocorticosterone 1.70920777 0.00086
Sa Pos Fold Change Ttest
C18H22O8P2 Diethylstilbestrol diphosphate 1.67917944 0.58649
C18H30O 4-Dodecylphenol 1.6715494 4.5E-07
C24H22O12 Malonyldaidzin 1.60361504 0.61524
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Appendix 3: Metabolomic data analysis for ciclosporin 
capsules from Colombia (Col) 
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Figure A3.1: Score plot between the selected PCs  
 
Figure A3.2: 3D score plot between the selected PCs 
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Appendix 4: The protocol of the bioequivalence study 
between Mazit 250 mg (test product) and Zithromax™ 250 mg in 
healthy subjects 
Bioequivalence study of Neopharma, UAE Mazit capsules 250 mg (250 mg azithromycin 
per capsule) relative to Zithromax™ manufactured by Pfizer Italia S.R.L., Italy under 
authority of Pfizer Inc., USA. (250 mg azithromycin per capsule), after oral 
administration of 500 mg to healthy adults under fasting conditions 
 
International Pharmaceutical Research Centre (IPRC), Jordan 
Sponsor: Neopharma, UAE 
Drug Identification: Azithromycin 
Drug Class: Macrolides Antibiotic 
Protocol Code: AZI-C017 
Study Code: AZI-NEO-C0409/685 
 
Date: August 17, 2009 
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Appendix 5: The Research Ethics Committee approval for the 
bioequivalence study of Mazit 250 mg (test product) and 
Zithromax™ 250 mg (reference product) 
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Appendix 6: Raw data for all subjects who participated in the 
bioequivalence study of Mazit 250 mg (test product) and 
Zithromax™ 250 mg (reference product) 
Table A6.26: Schedule of vital signs, physical assessment and other clinical observations 
during the bioequivalence study 
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Table A6.27: Subjects and reasons of withdrawal from the bioequivalence study 
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Table A6.28: Demographic data and individual values for eligible subjects included in 
the bioequivalence study 
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Table A6.29: Drug administration times for all subjects in period 1 and 2 
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Table A6.30: Adverse events for all subjects during the study 
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Figure A6.3: Concentration of Mazit compared to Zithromax™ (Subject 2) 
 
Figure A6.4: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 2) 
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Figure A6.5: Concentration of Mazit compared to Zithromax™ (Subject 3) 
 
Figure A6.6: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 3) 
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Figure A6.7: Concentration of Mazit compared to Zithromax™ (Subject 4) 
 
Figure A6.8: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 4) 
       Appendices 
    Page 245 of 296 
 
Figure A6.9: Concentration of Mazit compared to Zithromax™ (Subject 5) 
 
Figure A6.10: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 5) 
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Figure A6.11: Concentration of Mazit compared to Zithromax™ (Subject 6) 
 
Figure A6.12: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 6) 
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Figure A6.13: Concentration of Mazit compared to Zithromax™ (Subject 7) 
 
Figure A6.14: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 7) 
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Figure A6.15: Concentration of Mazit compared to Zithromax™ (Subject 8) 
 
Figure A6.16: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 8) 
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Figure A6.17: Concentration of Mazit compared to Zithromax™ (Subject 9) 
 
Figure A6.18: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 9) 
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Figure A6.19: Concentration of Mazit compared to Zithromax™ (Subject 10) 
 
Figure A6.20: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
10) 
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Figure A6.21: Concentration of Mazit compared to Zithromax™ (Subject 11) 
 
Figure A6.22: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
11) 
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Figure A6.23: Concentration of Mazit compared to Zithromax™ (Subject 12) 
 
Figure A6.24: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
12) 
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Figure A6.25: Concentration of Mazit compared to Zithromax™ (Subject 13) 
 
Figure A6.26: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
13) 
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Figure A6.27: Concentration of Mazit compared to Zithromax™ (Subject 14) 
 
Figure A6.28: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
14) 
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Figure A6.29: Concentration of Mazit compared to Zithromax™ (Subject 15) 
 
Figure A6.30: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
15) 
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Figure A6.31: Concentration of Mazit compared to Zithromax™ (Subject 16) 
 
Figure A6.32: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
16) 
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Figure A6.33: Concentration of Mazit compared to Zithromax™ (Subject 17) 
 
Figure A6.34: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
17) 
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Figure A6.35: Concentration of Mazit compared to Zithromax™ (Subject 18) 
 
Figure A6.36: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
18) 
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Figure A6.37: Concentration of Mazit compared to Zithromax™ (Subject 19) 
 
Figure A6.38: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
19) 
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Figure A6.39: Concentration of Mazit compared to Zithromax™ (Subject 20) 
 
Figure A6.40: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
20) 
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Figure A6.41: Concentration of Mazit compared to Zithromax™ (Subject 21) 
 
Figure A6.42: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
21) 
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Figure A6.43: Concentration of Mazit compared to Zithromax™ (Subject 22) 
 
Figure A6.44: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
22) 
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Figure A6.45: Concentration of Mazit compared to Zithromax™ (Subject 23) 
 
Figure A6.46: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
23) 
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Figure A6.47: Concentration of Mazit compared to Zithromax™ (Subject 24) 
 
Figure A6.48: Logarithmic concentration of Mazit compared to Zithromax™ (Subject 
24)  
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Appendix 7: Variation from the study protocol for the 
bioequivalence study between Mazit 250 mg (test product) and 
Zithromax™ 250 mg (reference product) 
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Appendix 8: The informed consent and other forms used in 
the bioequivalence study between Mazit 250 mg (test product) 
and Zithromax™ (reference product) 
 
       Appendices 
    Page 268 of 296 
 
       Appendices 
    Page 269 of 296 
 
  
       Appendices 
    Page 270 of 296 
 
       Appendices 
    Page 271 of 296 
 
       Appendices 
    Page 272 of 296 
 
  
       Appendices 
    Page 273 of 296 
 
  
       Appendices 
    Page 274 of 296 
 
       Appendices 
    Page 275 of 296 
 
       Appendices 
    Page 276 of 296 
 
       Appendices 
    Page 277 of 296 
 
       Appendices 
    Page 278 of 296 
 
       Appendices 
    Page 279 of 296 
 
       Appendices 
    Page 280 of 296 
 
       Appendices 
    Page 281 of 296 
Appendix 9: Statistical analysis for the bioequivalence study 
of Mazit 250 mg (test product) and Zithromax™ 250 mg 
(reference product) 
Minitab Project Report 
 
General Linear Model: LogCmax versus Treatment, Sequence, Period, 
Subject  
 
Method 
 
Factor coding  (-1, 0, +1) 
 
 
Factor Information 
 
Factor             Type    Levels  Values 
Treatment          Fixed        2  Mazit, Zithromax 
Sequence           Fixed        2  AB, BA 
Period             Fixed        2  1, 2 
Subject(Sequence)  Random      24  2(AB), 3(AB), 5(AB), 10(AB), 11(AB), 12(AB), 
13(AB), 
                                   14(AB), 15(AB), 16(AB), 20(AB), 23(AB), 
1(BA), 4(BA), 
                                   6(BA), 7(BA), 8(BA), 9(BA), 17(BA), 18(BA), 
19(BA), 
                                   21(BA), 22(BA), 24(BA) 
 
 
Analysis of Variance 
 
Source               DF   Adj SS    Adj MS  F-Value  P-Value 
  Treatment           1  0.00345  0.003450     0.21    0.655 
  Sequence            1  0.13548  0.135483     3.33    0.082 
  Period              1  0.00218  0.002182     0.13    0.722 
  Subject(Sequence)  22  0.89572  0.040714     2.42    0.022 
Error                22  0.36957  0.016798 
Total                47  1.40640 
 
 
Model Summary 
 
       S    R-sq  R-sq(adj)  R-sq(pred) 
0.129609  73.72%     43.86%       0.00% 
 
 
Coefficients 
 
Term                  Coef  SE Coef  T-Value  P-Value   VIF 
Constant            2.4150   0.0187   129.09    0.000 
Treatment 
  Mazit            -0.0085   0.0187    -0.45    0.655  1.00 
Sequence 
  AB                0.0531   0.0187     2.84    0.010  1.00 
Period 
  1                 0.0067   0.0187     0.36    0.722  1.00 
Subject(Sequence) 
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  2(AB)             0.1614   0.0877     1.84    0.079     * 
  3(AB)             0.0086   0.0877     0.10    0.923     * 
  5(AB)             0.1436   0.0877     1.64    0.116     * 
  10(AB)           -0.1086   0.0877    -1.24    0.229     * 
  11(AB)           -0.0080   0.0877    -0.09    0.928     * 
  12(AB)            0.1570   0.0877     1.79    0.087     * 
  13(AB)           -0.0336   0.0877    -0.38    0.706     * 
  14(AB)           -0.0877   0.0877    -1.00    0.328     * 
  15(AB)            0.0695   0.0877     0.79    0.436     * 
  16(AB)           -0.2636   0.0877    -3.00    0.007     * 
  20(AB)            0.1213   0.0877     1.38    0.181     * 
  1(BA)            -0.1575   0.0877    -1.79    0.086     * 
  4(BA)            -0.0632   0.0877    -0.72    0.479     * 
  6(BA)             0.0522   0.0877     0.59    0.558     * 
  7(BA)             0.2156   0.0877     2.46    0.022     * 
  8(BA)             0.1403   0.0877     1.60    0.124     * 
  9(BA)            -0.0513   0.0877    -0.58    0.565     * 
  17(BA)           -0.2294   0.0877    -2.61    0.016     * 
  18(BA)           -0.0971   0.0877    -1.11    0.281     * 
  19(BA)            0.1812   0.0877     2.07    0.051     * 
  21(BA)            0.0531   0.0877     0.60    0.551     * 
  22(BA)            0.1232   0.0877     1.40    0.174     * 
 
 
Regression Equation 
 
LogCmax = 2.4150 - 0.0085 Treatment_Mazit + 0.0085 Treatment_Zithromax 
+ 0.0531 Sequence_AB 
          - 0.0531 Sequence_BA + 0.0067 Period_1 - 0.0067 Period_2 
          + 0.1614 Subject(Sequence)_2(AB) + 0.0086 Subject(Sequence)_3(AB) 
          + 0.1436 Subject(Sequence)_5(AB) - 0.1086 Subject(Sequence)_10(AB) 
          - 0.0080 Subject(Sequence)_11(AB) + 0.1570 Subject(Sequence)_12(AB) 
          - 0.0336 Subject(Sequence)_13(AB) - 0.0877 Subject(Sequence)_14(AB) 
          + 0.0695 Subject(Sequence)_15(AB) - 0.2636 Subject(Sequence)_16(AB) 
          + 0.1213 Subject(Sequence)_20(AB) - 0.1600 Subject(Sequence)_23(AB) 
          - 0.1575 Subject(Sequence)_1(BA) - 0.0632 Subject(Sequence)_4(BA) 
          + 0.0522 Subject(Sequence)_6(BA) + 0.2156 Subject(Sequence)_7(BA) 
          + 0.1403 Subject(Sequence)_8(BA) - 0.0513 Subject(Sequence)_9(BA) 
          - 0.2294 Subject(Sequence)_17(BA) - 0.0971 Subject(Sequence)_18(BA) 
          + 0.1812 Subject(Sequence)_19(BA) + 0.0531 Subject(Sequence)_21(BA) 
          + 0.1232 Subject(Sequence)_22(BA) - 0.1672 Subject(Sequence)_24(BA) 
 
Equation treats random terms as though they are fixed. 
 
 
Fits and Diagnostics for Unusual Observations 
 
Obs  LogCmax     Fit    Resid  Std Resid 
  2   2.8136  2.6279   0.1857       2.12  R 
 26   2.4456  2.6313  -0.1857      -2.12  R 
 
R  Large residual 
 
 
Expected Mean Squares, using Adjusted SS 
 
                      Expected Mean Square 
   Source             for Each Term 
1  Treatment          (5) + Q[1] 
2  Sequence           (5) + 2.0000 (4) + Q[2] 
3  Period             (5) + Q[3] 
4  Subject(Sequence)  (5) + 2.0000 (4) 
5  Error              (5) 
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Error Terms for Tests, using Adjusted SS 
 
                                          Synthesis 
   Source             Error DF  Error MS  of Error MS 
1  Treatment             22.00    0.0168  (5) 
2  Sequence              22.00    0.0407  (4) 
3  Period                22.00    0.0168  (5) 
4  Subject(Sequence)     22.00    0.0168  (5) 
 
 
Variance Components, using Adjusted SS 
 
Source              Variance  % of Total     StDev  % of Total 
Subject(Sequence)  0.0119580      41.58%  0.109353      64.49% 
Error              0.0167985      58.42%  0.129609      76.43% 
Total              0.0287565              0.169577 
 
  
Comparisons for LogCmax  
  
Dunnett Multiple Comparisons with a Control: Response = LogCmax, Term 
= Treatment  
 
Grouping Information Using the Dunnett Method and 90% Confidence 
 
Treatment             N     Mean  Grouping 
Zithromax (Control)  24  2.42350  A 
Mazit                24  2.40654  A 
 
Means not labeled with the letter A are significantly different from the 
control level mean. 
 
 
Dunnett Simultaneous Tests for Level Mean - Control Mean 
 
Difference of      Difference       SE of     Simultaneous             Adjusted 
Treatment Levels     of Means  Difference        90% CI       T-Value   P-Value 
Mazit - Zithromax     -0.0170      0.0374  (-0.0812, 0.0473)    -0.45     0.655 
 
Individual confidence level = 90.00% 
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General Linear Model: LogAUC0-t versus Treatment, Sequence, Period, 
Subject  
 
Method 
 
Factor coding  (-1, 0, +1) 
 
 
Factor Information 
 
Factor             Type    Levels  Values 
Treatment          Fixed        2  Mazit, Zithromax 
Sequence           Fixed        2  AB, BA 
Period             Fixed        2  1, 2 
Subject(Sequence)  Random      24  2(AB), 3(AB), 5(AB), 10(AB), 11(AB), 12(AB), 
13(AB), 
                                   14(AB), 15(AB), 16(AB), 20(AB), 23(AB), 
1(BA), 4(BA), 
                                   6(BA), 7(BA), 8(BA), 9(BA), 17(BA), 18(BA), 
19(BA), 
                                   21(BA), 22(BA), 24(BA) 
 
 
Analysis of Variance 
 
Source               DF   Adj SS    Adj MS  F-Value  P-Value 
  Treatment           1  0.01120  0.011198     1.01    0.326 
  Sequence            1  0.07908  0.079077     1.44    0.243 
  Period              1  0.00710  0.007104     0.64    0.433 
  Subject(Sequence)  22  1.20804  0.054911     4.94    0.000 
Error                22  0.24457  0.011117 
Total                47  1.54999 
 
 
Model Summary 
 
       S    R-sq  R-sq(adj)  R-sq(pred) 
0.105437  84.22%     66.29%      24.89% 
 
 
Coefficients 
 
Term                  Coef  SE Coef  T-Value  P-Value   VIF 
Constant            3.2305   0.0152   212.27    0.000 
Treatment 
  Mazit            -0.0153   0.0152    -1.00    0.326  1.00 
Sequence 
  AB                0.0406   0.0152     2.67    0.014  1.00 
Period 
  1                 0.0122   0.0152     0.80    0.433  1.00 
Subject(Sequence) 
  2(AB)            -0.0369   0.0714    -0.52    0.610     * 
  3(AB)            -0.0373   0.0714    -0.52    0.606     * 
  5(AB)             0.1474   0.0714     2.06    0.051     * 
  10(AB)            0.0069   0.0714     0.10    0.924     * 
  11(AB)           -0.1673   0.0714    -2.34    0.029     * 
  12(AB)            0.2008   0.0714     2.81    0.010     * 
  13(AB)            0.1358   0.0714     1.90    0.070     * 
  14(AB)            0.1196   0.0714     1.68    0.108     * 
  15(AB)           -0.0434   0.0714    -0.61    0.549     * 
  16(AB)           -0.2660   0.0714    -3.73    0.001     * 
  20(AB)            0.1616   0.0714     2.26    0.034     * 
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  1(BA)            -0.2694   0.0714    -3.77    0.001     * 
  4(BA)            -0.1194   0.0714    -1.67    0.108     * 
  6(BA)             0.0220   0.0714     0.31    0.761     * 
  7(BA)             0.2461   0.0714     3.45    0.002     * 
  8(BA)             0.1339   0.0714     1.88    0.074     * 
  9(BA)             0.0756   0.0714     1.06    0.301     * 
  17(BA)           -0.2174   0.0714    -3.05    0.006     * 
  18(BA)           -0.1366   0.0714    -1.91    0.069     * 
  19(BA)            0.1468   0.0714     2.06    0.052     * 
  21(BA)            0.1668   0.0714     2.34    0.029     * 
  22(BA)            0.1222   0.0714     1.71    0.101     * 
 
 
Regression Equation 
 
LogAUC0-t = 3.2305 - 0.0153 Treatment_Mazit + 0.0153 Treatment_Zithromax 
+ 0.0406 Sequence_AB 
            - 0.0406 Sequence_BA + 0.0122 Period_1 - 0.0122 Period_2 
            - 0.0369 Subject(Sequence)_2(AB) - 0.0373 Subject(Sequence)_3(AB) 
            + 0.1474 Subject(Sequence)_5(AB) + 0.0069 Subject(Sequence)_10(AB) 
            - 0.1673 Subject(Sequence)_11(AB) + 0.2008 Subject(Sequence)_12(AB) 
            + 0.1358 Subject(Sequence)_13(AB) + 0.1196 Subject(Sequence)_14(AB) 
            - 0.0434 Subject(Sequence)_15(AB) - 0.2660 Subject(Sequence)_16(AB) 
            + 0.1616 Subject(Sequence)_20(AB) - 0.2211 Subject(Sequence)_23(AB) 
            - 0.2694 Subject(Sequence)_1(BA) - 0.1194 Subject(Sequence)_4(BA) 
            + 0.0220 Subject(Sequence)_6(BA) + 0.2461 Subject(Sequence)_7(BA) 
            + 0.1339 Subject(Sequence)_8(BA) + 0.0756 Subject(Sequence)_9(BA) 
            - 0.2174 Subject(Sequence)_17(BA) - 0.1366 Subject(Sequence)_18(BA) 
            + 0.1468 Subject(Sequence)_19(BA) + 0.1668 Subject(Sequence)_21(BA) 
            + 0.1222 Subject(Sequence)_22(BA) - 0.1705 Subject(Sequence)_24(BA) 
 
Equation treats random terms as though they are fixed. 
 
 
Fits and Diagnostics for Unusual Observations 
 
Obs  LogAUC0-t     Fit    Resid  Std Resid 
  2     3.3783  3.2310   0.1472       2.06  R 
 26     3.0900  3.2372  -0.1472      -2.06  R 
 
R  Large residual 
 
 
Expected Mean Squares, using Adjusted SS 
 
                      Expected Mean Square 
   Source             for Each Term 
1  Treatment          (5) + Q[1] 
2  Sequence           (5) + 2.0000 (4) + Q[2] 
3  Period             (5) + Q[3] 
4  Subject(Sequence)  (5) + 2.0000 (4) 
5  Error              (5) 
 
 
Error Terms for Tests, using Adjusted SS 
 
                                          Synthesis 
   Source             Error DF  Error MS  of Error MS 
1  Treatment             22.00    0.0111  (5) 
2  Sequence              22.00    0.0549  (4) 
3  Period                22.00    0.0111  (5) 
4  Subject(Sequence)     22.00    0.0111  (5) 
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Variance Components, using Adjusted SS 
 
Source              Variance  % of Total     StDev  % of Total 
Subject(Sequence)  0.0218969      66.33%  0.147976      81.44% 
Error              0.0111169      33.67%  0.105437      58.03% 
Total              0.0330138              0.181697 
 
  
Comparisons for LogAUC0-t  
  
Dunnett Multiple Comparisons with a Control: Response = LogAUC0-t, Term 
= Treatment  
 
Grouping Information Using the Dunnett Method and 90% Confidence 
 
Treatment             N     Mean  Grouping 
Zithromax (Control)  24  3.24575  A 
Mazit                24  3.21520  A 
 
Means not labeled with the letter A are significantly different from the 
control level mean. 
 
 
Dunnett Simultaneous Tests for Level Mean - Control Mean 
 
Difference of      Difference       SE of     Simultaneous             Adjusted 
Treatment Levels     of Means  Difference        90% CI       T-Value   P-Value 
Mazit - Zithromax     -0.0305      0.0304  (-0.0828, 0.0217)    -1.00     0.326 
 
Individual confidence level = 90.00% 
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General Linear Model: LogAUC0inf versus Treatment, Sequence, Period, 
Subject  
 
Method 
 
Factor coding  (-1, 0, +1) 
Rows unused    2 
 
 
Factor Information 
 
Factor             Type    Levels  Values 
Treatment          Fixed        2  Mazit, Zithromax 
Sequence           Fixed        2  AB, BA 
Period             Fixed        2  1, 2 
Subject(Sequence)  Random      24  2(AB), 3(AB), 5(AB), 10(AB), 11(AB), 12(AB), 
13(AB), 
                                   14(AB), 15(AB), 16(AB), 20(AB), 23(AB), 
1(BA), 4(BA), 
                                   6(BA), 7(BA), 8(BA), 9(BA), 17(BA), 18(BA), 
19(BA), 
                                   21(BA), 22(BA), 24(BA) 
 
 
Analysis of Variance 
 
Source               DF   Adj SS    Adj MS  F-Value  P-Value 
  Treatment           1  0.00919  0.009194     0.54    0.470 
  Sequence            1  0.06337  0.063370     1.40    0.250  x 
  Period              1  0.05592  0.055915     3.30    0.084 
  Subject(Sequence)  22  1.02460  0.046573     2.75    0.013 
Error                20  0.33853  0.016927 
Total                45  1.45701 
 
x Not an exact F-test. 
 
 
Model Summary 
 
       S    R-sq  R-sq(adj)  R-sq(pred) 
0.130103  76.77%     47.72%           * 
 
 
Coefficients 
 
Term                  Coef  SE Coef  T-Value  P-Value   VIF 
Constant            3.3653   0.0196   171.58    0.000 
Treatment 
  Mazit            -0.0145   0.0196    -0.74    0.470  1.04 
Sequence 
  AB                0.0380   0.0196     1.93    0.067  1.05 
Period 
  1                 0.0356   0.0196     1.82    0.084  1.05 
Subject(Sequence) 
  2(AB)            -0.1134   0.0884    -1.28    0.214     * 
  3(AB)             -0.098    0.125    -0.79    0.439     * 
  5(AB)             0.0943   0.0884     1.07    0.299     * 
  10(AB)            0.0703   0.0884     0.80    0.436     * 
  11(AB)           -0.1228   0.0884    -1.39    0.180     * 
  12(AB)            0.1551   0.0884     1.75    0.095     * 
  13(AB)            0.1644   0.0884     1.86    0.078     * 
  14(AB)            0.2358   0.0884     2.67    0.015     * 
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  15(AB)           -0.1074   0.0884    -1.21    0.239     * 
  16(AB)           -0.2288   0.0884    -2.59    0.018     * 
  20(AB)            0.1934   0.0884     2.19    0.041     * 
  1(BA)             -0.292    0.125    -2.35    0.029     * 
  4(BA)            -0.1911   0.0884    -2.16    0.043     * 
  6(BA)            -0.0173   0.0884    -0.20    0.847     * 
  7(BA)             0.1923   0.0884     2.17    0.042     * 
  8(BA)             0.1131   0.0884     1.28    0.216     * 
  9(BA)             0.0223   0.0884     0.25    0.803     * 
  17(BA)           -0.0512   0.0884    -0.58    0.569     * 
  18(BA)            0.0993   0.0884     1.12    0.275     * 
  19(BA)            0.1127   0.0884     1.27    0.217     * 
  21(BA)            0.1211   0.0884     1.37    0.186     * 
  22(BA)            0.0632   0.0884     0.71    0.483     * 
 
 
Regression Equation 
 
LogAUC0inf = 3.3653 - 0.0145 Treatment_Mazit + 0.0145 Treatment_Zithromax 
             + 0.0380 Sequence_AB - 0.0380 Sequence_BA + 0.0356 Period_1 
- 0.0356 Period_2 
             - 0.1134 Subject(Sequence)_2(AB) - 0.098 Subject(Sequence)_3(AB) 
             + 0.0943 Subject(Sequence)_5(AB) + 0.0703 Subject(Sequence)_10(AB) 
             - 0.1228 Subject(Sequence)_11(AB) 
+ 0.1551 Subject(Sequence)_12(AB) 
             + 0.1644 Subject(Sequence)_13(AB) 
+ 0.2358 Subject(Sequence)_14(AB) 
             - 0.1074 Subject(Sequence)_15(AB) 
- 0.2288 Subject(Sequence)_16(AB) 
             + 0.1934 Subject(Sequence)_20(AB) 
- 0.2427 Subject(Sequence)_23(AB) 
             - 0.292 Subject(Sequence)_1(BA) - 0.1911 Subject(Sequence)_4(BA) 
             - 0.0173 Subject(Sequence)_6(BA) + 0.1923 Subject(Sequence)_7(BA) 
             + 0.1131 Subject(Sequence)_8(BA) + 0.0223 Subject(Sequence)_9(BA) 
             - 0.0512 Subject(Sequence)_17(BA) 
+ 0.0993 Subject(Sequence)_18(BA) 
             + 0.1127 Subject(Sequence)_19(BA) 
+ 0.1211 Subject(Sequence)_21(BA) 
             + 0.0632 Subject(Sequence)_22(BA) 
- 0.1720 Subject(Sequence)_24(BA) 
 
Equation treats random terms as though they are fixed. 
 
 
Fits and Diagnostics for Unusual Observations 
 
Obs  LogAUC0inf    Fit   Resid  Std Resid 
 18       3.128  3.377  -0.248      -2.83  R 
 25       3.085  3.085   0.000          *     X 
 27       3.284  3.284   0.000          *     X 
 42       3.725  3.477   0.248       2.83  R 
 
R  Large residual 
X  Unusual X 
 
 
Expected Mean Squares, using Adjusted SS 
 
                      Expected Mean Square 
   Source             for Each Term 
1  Treatment          (5) + Q[1] 
2  Sequence           (5) + 1.8333 (4) + Q[2] 
3  Period             (5) + Q[3] 
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4  Subject(Sequence)  (5) + 1.9091 (4) 
5  Error              (5) 
 
 
Error Terms for Tests, using Adjusted SS 
 
   Source             Error DF  Error MS  Synthesis of Error MS 
1  Treatment             20.00    0.0169  (5) 
2  Sequence              22.66    0.0454  0.9603 (4) + 0.0397 (5) 
3  Period                20.00    0.0169  (5) 
4  Subject(Sequence)     20.00    0.0169  (5) 
 
 
Variance Components, using Adjusted SS 
 
Source              Variance  % of Total     StDev  % of Total 
Subject(Sequence)  0.0155289      47.85%  0.124615      69.17% 
Error              0.0169267      52.15%  0.130103      72.22% 
Total              0.0324556              0.180154 
 
  
Comparisons for LogAUC0inf  
  
Dunnett Multiple Comparisons with a Control: Response = LogAUC0inf, 
Term = Treatment  
 
Grouping Information Using the Dunnett Method and 90% Confidence 
 
Treatment             N     Mean  Grouping 
Zithromax (Control)  24  3.37973  A 
Mazit                22  3.35082  A 
 
Means not labeled with the letter A are significantly different from the 
control level mean. 
 
 
Dunnett Simultaneous Tests for Level Mean - Control Mean 
 
Difference of      Difference       SE of     Simultaneous             Adjusted 
Treatment Levels     of Means  Difference        90% CI       T-Value   P-Value 
Mazit - Zithromax     -0.0289      0.0392  (-0.0966, 0.0387)    -0.74     0.470 
 
Individual confidence level = 90.00% 
 
  
       Appendices 
    Page 290 of 296 
General Linear Model: Logt½ versus Treatment, Sequence, Period, Subject  
 
Method 
 
Factor coding  (-1, 0, +1) 
Rows unused    2 
 
 
Factor Information 
 
Factor             Type    Levels  Values 
Treatment          Fixed        2  Mazit, Zithromax 
Sequence           Fixed        2  AB, BA 
Period             Fixed        2  1, 2 
Subject(Sequence)  Random      24  2(AB), 3(AB), 5(AB), 10(AB), 11(AB), 12(AB), 
13(AB), 
                                   14(AB), 15(AB), 16(AB), 20(AB), 23(AB), 
1(BA), 4(BA), 
                                   6(BA), 7(BA), 8(BA), 9(BA), 17(BA), 18(BA), 
19(BA), 
                                   21(BA), 22(BA), 24(BA) 
 
 
Analysis of Variance 
 
Source               DF   Adj SS    Adj MS  F-Value  P-Value 
  Treatment           1  0.00468  0.004677     0.07    0.787 
  Sequence            1  0.00000  0.000000     0.00    1.000  x 
  Period              1  0.11383  0.113830     1.82    0.193 
  Subject(Sequence)  22  2.29016  0.104098     1.66    0.129 
Error                20  1.25300  0.062650 
Total                45  3.66324 
 
x Not an exact F-test. 
 
 
Model Summary 
 
       S    R-sq  R-sq(adj)  R-sq(pred) 
0.250300  65.80%     23.04%           * 
 
 
Coefficients 
 
Term                  Coef  SE Coef  T-Value  P-Value   VIF 
Constant            1.3916   0.0377    36.88    0.000 
Treatment 
  Mazit            -0.0103   0.0377    -0.27    0.787  1.04 
Sequence 
  AB                0.0000   0.0377     0.00    1.000  1.05 
Period 
  1                 0.0509   0.0377     1.35    0.193  1.05 
Subject(Sequence) 
  2(AB)             -0.258    0.170    -1.52    0.145     * 
  3(AB)             -0.232    0.240    -0.97    0.345     * 
  5(AB)              0.088    0.170     0.52    0.610     * 
  10(AB)             0.140    0.170     0.82    0.422     * 
  11(AB)            -0.122    0.170    -0.72    0.481     * 
  12(AB)             0.134    0.170     0.79    0.440     * 
  13(AB)             0.345    0.170     2.03    0.056     * 
  14(AB)             0.486    0.170     2.85    0.010     * 
  15(AB)            -0.269    0.170    -1.58    0.129     * 
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  16(AB)            -0.179    0.170    -1.05    0.305     * 
  20(AB)             0.023    0.170     0.13    0.894     * 
  1(BA)             -0.221    0.240    -0.92    0.367     * 
  4(BA)             -0.540    0.170    -3.17    0.005     * 
  6(BA)              0.024    0.170     0.14    0.887     * 
  7(BA)              0.090    0.170     0.53    0.601     * 
  8(BA)              0.149    0.170     0.88    0.391     * 
  9(BA)              0.044    0.170     0.26    0.798     * 
  17(BA)             0.213    0.170     1.25    0.225     * 
  18(BA)             0.288    0.170     1.69    0.106     * 
  19(BA)            -0.103    0.170    -0.60    0.552     * 
  21(BA)             0.136    0.170     0.80    0.434     * 
  22(BA)            -0.004    0.170    -0.02    0.982     * 
 
 
Regression Equation 
 
Logt½ = 1.3916 - 0.0103 Treatment_Mazit + 0.0103 Treatment_Zithromax 
+ 0.0000 Sequence_AB 
        - 0.0000 Sequence_BA + 0.0509 Period_1 - 0.0509 Period_2 
        - 0.258 Subject(Sequence)_2(AB) - 0.232 Subject(Sequence)_3(AB) 
        + 0.088 Subject(Sequence)_5(AB) + 0.140 Subject(Sequence)_10(AB) 
        - 0.122 Subject(Sequence)_11(AB) + 0.134 Subject(Sequence)_12(AB) 
        + 0.345 Subject(Sequence)_13(AB) + 0.486 Subject(Sequence)_14(AB) 
        - 0.269 Subject(Sequence)_15(AB) - 0.179 Subject(Sequence)_16(AB) 
        + 0.023 Subject(Sequence)_20(AB) - 0.155 Subject(Sequence)_23(AB) 
        - 0.221 Subject(Sequence)_1(BA) - 0.540 Subject(Sequence)_4(BA) 
        + 0.024 Subject(Sequence)_6(BA) + 0.090 Subject(Sequence)_7(BA) 
        + 0.149 Subject(Sequence)_8(BA) + 0.044 Subject(Sequence)_9(BA) 
        + 0.213 Subject(Sequence)_17(BA) + 0.288 Subject(Sequence)_18(BA) 
        - 0.103 Subject(Sequence)_19(BA) + 0.136 Subject(Sequence)_21(BA) 
        - 0.004 Subject(Sequence)_22(BA) - 0.078 Subject(Sequence)_24(BA) 
 
Equation treats random terms as though they are fixed. 
 
 
Fits and Diagnostics for Unusual Observations 
 
Obs  Logt½    Fit   Resid  Std Resid 
 18  1.117  1.618  -0.502      -2.97  R 
 25  1.231  1.231  -0.000          *     X 
 27  1.119  1.119  -0.000          *     X 
 42  2.243  1.741   0.502       2.97  R 
 
R  Large residual 
X  Unusual X 
 
 
Expected Mean Squares, using Adjusted SS 
 
                      Expected Mean Square 
   Source             for Each Term 
1  Treatment          (5) + Q[1] 
2  Sequence           (5) + 1.8333 (4) + Q[2] 
3  Period             (5) + Q[3] 
4  Subject(Sequence)  (5) + 1.9091 (4) 
5  Error              (5) 
 
 
Error Terms for Tests, using Adjusted SS 
 
   Source             Error DF  Error MS  Synthesis of Error MS 
1  Treatment             20.00    0.0626  (5) 
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2  Sequence              23.09    0.1025  0.9603 (4) + 0.0397 (5) 
3  Period                20.00    0.0626  (5) 
4  Subject(Sequence)     20.00    0.0626  (5) 
 
 
Variance Components, using Adjusted SS 
 
Source              Variance  % of Total     StDev  % of Total 
Subject(Sequence)  0.0217111      25.74%  0.147347      50.73% 
Error              0.0626500      74.26%  0.250300      86.18% 
Total              0.0843611              0.290450 
 
  
Comparisons for Logt½  
  
Dunnett Multiple Comparisons with a Control: Response = Logt½, Term = 
Treatment  
 
Grouping Information Using the Dunnett Method and 90% Confidence 
 
Treatment             N     Mean  Grouping 
Zithromax (Control)  24  1.40189  A 
Mazit                22  1.38127  A 
 
Means not labeled with the letter A are significantly different from the 
control level mean. 
 
 
Dunnett Simultaneous Tests for Level Mean - Control Mean 
 
Difference of      Difference       SE of     Simultaneous             Adjusted 
Treatment Levels     of Means  Difference        90% CI       T-Value   P-Value 
Mazit - Zithromax     -0.0206      0.0755  (-0.1508, 0.1095)    -0.27     0.787 
 
Individual confidence level = 90.00% 
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General Linear Model: t1/2 versus Treatment, Sequence, Period, Subject  
 
Method 
 
Factor coding  (-1, 0, +1) 
Rows unused    2 
 
 
Factor Information 
 
Factor             Type    Levels  Values 
Treatment          Fixed        2  Mazit, Zithromax 
Sequence           Fixed        2  AB, BA 
Period             Fixed        2  1, 2 
Subject(Sequence)  Random      24  2(AB), 3(AB), 5(AB), 10(AB), 11(AB), 12(AB), 
13(AB), 
                                   14(AB), 15(AB), 16(AB), 20(AB), 23(AB), 
1(BA), 4(BA), 
                                   6(BA), 7(BA), 8(BA), 9(BA), 17(BA), 18(BA), 
19(BA), 
                                   21(BA), 22(BA), 24(BA) 
 
 
Analysis of Variance 
 
Source               DF   Adj SS  Adj MS  F-Value  P-Value 
  Treatment           1    640.1  640.07     0.94    0.344 
  Sequence            1     22.9   22.90     0.03    0.867  x 
  Period              1    740.4  740.44     1.09    0.309 
  Subject(Sequence)  22  17563.0  798.32     1.17    0.362 
Error                20  13615.5  680.78 
Total                45  32347.5 
 
x Not an exact F-test. 
 
 
Model Summary 
 
      S    R-sq  R-sq(adj)  R-sq(pred) 
26.0917  57.91%      5.29%           * 
 
 
Coefficients 
 
Term                Coef  SE Coef  T-Value  P-Value   VIF 
Constant           30.54     3.93     7.76    0.000 
Treatment 
  Mazit            -3.81     3.93    -0.97    0.344  1.04 
Sequence 
  AB               -0.72     3.93    -0.18    0.856  1.05 
Period 
  1                 4.10     3.93     1.04    0.309  1.05 
Subject(Sequence) 
  2(AB)            -15.2     17.7    -0.86    0.403     * 
  3(AB)            -16.4     25.0    -0.66    0.520     * 
  5(AB)              0.4     17.7     0.02    0.982     * 
  10(AB)             5.7     17.7     0.32    0.753     * 
  11(AB)            -9.6     17.7    -0.54    0.595     * 
  12(AB)             3.9     17.7     0.22    0.827     * 
  13(AB)            24.7     17.7     1.39    0.179     * 
  14(AB)            46.4     17.7     2.61    0.017     * 
  15(AB)           -15.9     17.7    -0.90    0.381     * 
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  16(AB)           -12.3     17.7    -0.69    0.496     * 
  20(AB)            -3.8     17.7    -0.21    0.832     * 
  1(BA)            -22.1     25.0    -0.89    0.386     * 
  4(BA)            -24.1     17.7    -1.36    0.189     * 
  6(BA)             -4.3     17.7    -0.24    0.810     * 
  7(BA)             -0.9     17.7    -0.05    0.960     * 
  8(BA)              3.6     17.7     0.21    0.839     * 
  9(BA)             -3.1     17.7    -0.18    0.861     * 
  17(BA)             9.0     17.7     0.51    0.618     * 
  18(BA)            62.7     17.7     3.54    0.002     * 
  19(BA)            -8.8     17.7    -0.50    0.624     * 
  21(BA)             2.4     17.7     0.14    0.893     * 
  22(BA)            -6.3     17.7    -0.36    0.724     * 
 
 
Regression Equation 
 
t1/2 = 30.54 - 3.81 Treatment_Mazit + 3.81 Treatment_Zithromax 
- 0.72 Sequence_AB 
       + 0.72 Sequence_BA + 4.10 Period_1 - 4.10 Period_2 
- 15.2 Subject(Sequence)_2(AB) 
       - 16.4 Subject(Sequence)_3(AB) + 0.4 Subject(Sequence)_5(AB) 
       + 5.7 Subject(Sequence)_10(AB) - 9.6 Subject(Sequence)_11(AB) 
       + 3.9 Subject(Sequence)_12(AB) + 24.7 Subject(Sequence)_13(AB) 
       + 46.4 Subject(Sequence)_14(AB) - 15.9 Subject(Sequence)_15(AB) 
       - 12.3 Subject(Sequence)_16(AB) - 3.8 Subject(Sequence)_20(AB) 
       - 7.9 Subject(Sequence)_23(AB) - 22.1 Subject(Sequence)_1(BA) 
       - 24.1 Subject(Sequence)_4(BA) - 4.3 Subject(Sequence)_6(BA) 
       - 0.9 Subject(Sequence)_7(BA) + 3.6 Subject(Sequence)_8(BA) 
       - 3.1 Subject(Sequence)_9(BA) + 9.0 Subject(Sequence)_17(BA) 
       + 62.7 Subject(Sequence)_18(BA) - 8.8 Subject(Sequence)_19(BA) 
       + 2.4 Subject(Sequence)_21(BA) - 6.3 Subject(Sequence)_22(BA) 
       - 8.0 Subject(Sequence)_24(BA) 
 
Equation treats random terms as though they are fixed. 
 
 
Fits and Diagnostics for Unusual Observations 
 
Obs   t1/2    Fit  Resid  Std Resid 
 18   13.1   86.1  -73.0      -4.15  R 
 25   17.0   17.0   -0.0          *     X 
 27   13.2   13.2   -0.0          *     X 
 42  174.9  101.9   73.0       4.15  R 
 
R  Large residual 
X  Unusual X 
 
 
Expected Mean Squares, using Adjusted SS 
 
                      Expected Mean Square 
   Source             for Each Term 
1  Treatment          (5) + Q[1] 
2  Sequence           (5) + 1.8333 (4) + Q[2] 
3  Period             (5) + Q[3] 
4  Subject(Sequence)  (5) + 1.9091 (4) 
5  Error              (5) 
 
 
Error Terms for Tests, using Adjusted SS 
 
   Source             Error DF  Error MS  Synthesis of Error MS 
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1  Treatment             20.00  680.7771  (5) 
2  Sequence              23.55  793.6517  0.9603 (4) + 0.0397 (5) 
3  Period                20.00  680.7771  (5) 
4  Subject(Sequence)     20.00  680.7771  (5) 
 
 
Variance Components, using Adjusted SS 
 
Source             Variance  % of Total    StDev  % of Total 
Subject(Sequence)   61.5680       8.29%   7.8465      28.80% 
Error               680.777      91.71%  26.0917      95.76% 
Total               742.345              27.2460 
 
  
Wilcoxon Signed Rank CI: DiffT-R  
 
                                      Confidence 
             Estimated    Achieved     Interval 
          N     Median  Confidence   Lower  Upper 
DiffT-R  24      0.000        90.0  -0.340  0.250 
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Appendix 10: Additional work undertaken using Capillary 
Electrophoresis (CE) method 
 
